Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
  • A61K31/415—1,2-Diazoles
  • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
• • A—HUMAN NECESSITIES
  • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
  • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
  • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
  • A01K67/027—New or modified breeds of vertebrates
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
  • A61K31/19—Carboxylic acids, e.g. valproic acid
  • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
  • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
  • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
  • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
  • A61K31/7088—Compounds having three or more nucleosides or nucleotides
  • A61K31/713—Double-stranded nucleic acids or oligonucleotides
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
  • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
  • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
  • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
  • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K49/00—Preparations for testing in vivo
  • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
  • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0043—Nose
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0048—Eye, e.g. artificial tears
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0085—Brain, e.g. brain implants; Spinal cord
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
  • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
  • A61K9/1605—Excipients; Inactive ingredients
  • A61K9/1629—Organic macromolecular compounds
  • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
  • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/2004—Excipients; Inactive ingredients
  • A61K9/2013—Organic compounds, e.g. phospholipids, fats
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
  • A61K9/4841—Filling excipients; Inactive ingredients
  • A61K9/4858—Organic compounds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
  • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
  • A61K9/51—Nanocapsules; Nanoparticles
  • A61K9/5107—Excipients; Inactive ingredients
  • A61K9/5123—Organic compounds, e.g. fats, sugars
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/06—Antimigraine agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/08—Antiepileptics; Anticonvulsants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
  • A61P25/16—Anti-Parkinson drugs
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
  • C12N15/09—Recombinant DNA-technology
  • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
  • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
  • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
• • A—HUMAN NECESSITIES
  • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
  • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
  • A01K2207/00—Modified animals
  • A01K2207/20—Animals treated with compounds which are neither proteins nor nucleic acids
• • A—HUMAN NECESSITIES
  • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
  • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
  • A01K2267/00—Animals characterised by purpose
  • A01K2267/03—Animal model, e.g. for test or diseases
  • A01K2267/035—Animal model for multifactorial diseases
  • A01K2267/0356—Animal model for processes and diseases of the central nervous system, e.g. stress, learning, schizophrenia, pain, epilepsy
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2310/00—Structure or type of the nucleic acid
  • C12N2310/10—Type of nucleic acid
  • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2320/00—Applications; Uses
  • C12N2320/30—Special therapeutic applications

Definitions

• the present invention in some embodiments thereof, relates to therapy, and, more particularly, but not explicitly, to pharmaceutical compositions and methods for treating neurological conditions associated with abnormal activity of neuronal nitric oxide synthase (nNOS) such as, but not limited to, autistic spectrum disorders (ASDs) and neural-derived cancer.
• nNOS neuronal nitric oxide synthase
• ASDs autistic spectrum disorders
• neural-derived cancer neural-derived cancer.
• NO Nitric oxide
• SNO S-nitrosylation
• ASD autism spectrum disorders
• NO serves as a signaling molecule, which takes part in the regulation of synaptic activity, synaptic plasticity, and vesicle trafficking.
• NO might be toxic, possibly leading to modified phenotypes and cell death. It reacts with superoxide radical (O 2 ) and forms peroxyni trite (ONOO ) which ultimately induces damage to DNA, lipids, and proteins during oxidative stress.
• NO may affect cellular signaling through proteins S-nitrosylation (SNO), tyrosine nitration, and S-nitrosogluthanione (GSNO) formation.
• SNO S-nitrosylation
• GSNO S-nitrosogluthanione
• Protein tyrosine nitration under stress conditions has been considered as a potential marker for nitrosative stress.
• 3-nitrotyrosine (Ntyr) is a product of tyrosine nitration mediated by peroxynitrite, which acts as nitrating agent.
• SNO is a reversible NO-mediated post-translational modification of cysteine thiols in which cysteine is converted to nitrosothiol.
• SNO plays a major role in the localization and activity of a wide range of key enzymes and receptors leading to modulation of many signaling pathways, axonal transport, synaptic plasticity, and protein assembly.
• aberrant SNO signaling and increase in Ntyr may contribute to the progression of many neurodegenerativ e , neurodevelopmental , and neuropsychiatric disorders as well as neural tumors, as summarized below.
• NO is produced by the three types of NO synthases, nNOS, iNOS and eNOS.
• nNOS which stands for neuronal nitric oxide synthase, is found in neuronal tissues.
• NOSs Nitric oxide synthases
• nNOS or NOS- 1 neuronal
• iNOS or NOS-2 cytokine- inducible
• eNOS or NOS-3 endothelial
• iNOS and nNOS are soluble and found predominantly in the cytosol, while eNOS is membrane associated.
• nNOS Neuronal nitric oxide synthase
• CNS central nervous system
• CNS central nervous system
• Aberrant signaling that leads to multiple neurological disorders nNOS also performs a role in cell communication and is associated with plasma membranes.
• nNOS The subcellular localization of nNOS in skeletal muscle is mediated by anchoring of nNOS to dystrophin.
• nNOS contains an additional N-terminal domain, the PDZ domain.
• the gene coding for nNOS is located on Chromosome 12.
• nNOS has been found in neurons, astrocytes, the adventitia of brain blood vessels and cardiac myocytes. Besides brain tissue, nNOS has been found by immunohistochemistry in other tissues. nNOS is known to be specifically inhibited by 7-nitroindazole, which acts as a non- competitive substrate inhibitor.
• Neuroblastoma is referred to a spectrum of neuroblastic tumors that originate from the neural crest cells during fetal development.
• Pediatric cancers like NB, account for 97 % of all neuroblastic tumors.
• NB is the most common tumor among children less than one year of age worldwide.
• NB nitric oxide
• SNO nitric oxide
• PTM post-translational modification
• mTOR mechanistic target of rapamycin
• Nitric oxide protects neuroblastoma cells from apoptosis induced by serum deprivation through cAMP- response element-binding protein (CREB) activation.
• CREB cAMP- response element-binding protein
• a method of treating a disease or condition in which a beneficial clinical effect is achieved by reduction in neuronal nitric oxide synthase (nNOS) activity comprising administering to a subject in need thereof an effective amount of a composition comprising an active agent which reduces nNOS activity, as describe herein in any of the respective embodiments, thereby treating the disease or condition in which a beneficial clinical effect is achieved by reduction in nNOS activity.
• nNOS neuronal nitric oxide synthase
• a pharmaceutical composition comprising an active agent which reduces nNOS activity, as describe herein in any of the respective embodiments, and optionally a pharmaceutically acceptable carrier, for use treating the disease or condition in which a beneficial clinical effect is achieved by reduction in nNOS activity.
• the reduction in nNOS activity is in the central nervous system (CNS).
• the reduction in nNOS activity is selectively or preferentially in the CNS of the subject as compared to other tissues.
• the reduction is a reduction in nNOS activity in the brain.
• the composition comprises an active agent which is nNOS specific.
• the administering mode achieves a reduction of nNOS activity selectively and preferentially in the CNS.
• the administering mode comprises local administration.
• the composition comprises a carrier which carries the agent to the CNS of the subject.
• the carrier comprises an adeno- associated virus.
• the agent decreases nNOS expression. According to some of any of the embodiments described herein, the agent decreases nNOS translation.
• the agent inhibits nNOS enzymatic activity.
• the agent is selected from the group consisting of a small molecule, a competing peptide and an antibody or a fragment thereof.
• the agent binds to an active site of nNOS and blocks substrate binding.
• the agent is N ⁇ - Nitroarginine, or any small molecule agent as described herein.
• the agent is represented by the Formula I: or a pharmaceutically acceptable salt thereof, wherein:
• R 1 is selected from hydrogen, alkyl and cycloalkyl and is preferably hydrogen; and R 2 -R 5 are each independently selected from hydrogen, alkyl, cycloalkyl, aryl, heteroalicyclic, heteroaryl, halo, haloalkyl, hydroxy, alkoxy, aryloxy, thiol, amine, carboxylate, thiocarboxylate, and a poly(alkylene glycol) moiety.
• R 1 is hydrogen
• each of R 2 -R 5 is hydrogen.
• the compound of Formula I is in a form of an anionic salt thereof.
• the compound of Formula I is in a form of a cationic salt thereof.
• the agent is an amino acid based inhibitor.
• the agent is PIN or nitric oxide synthase interacting protein (NOSIP).
• the agent is a selective nNOS inhibitor.
• the agent reduces a level of an NO precursor.
• the agent increases a level of GSNO reductase level.
• the agent is a nNOS- specific nucleic acid sequence.
• the agent is an antisense or a siRNA.
• the agent is aDNA editing agent.
• the agent is CRISPR/Cas9 for selectively reducing expression of nNOS.
• a carrier for the agent is a viral delivery vector.
• the disease or condition is a neurological disease or condition.
• the disease or condition is a brain disorder.
• the disease or condition is an autism spectrum disorder (ASD).
• ASD autism spectrum disorder
• the disease or condition is ADD or ADHD.
• the disease or condition is selected from the group consisting of Alzheimer’s disease, Parkinson’s disease, Huntington’ s disease, multiple sclerosis, schizophrenia, addiction, amyotrophic lateral sclerosis (ALS), epilepsy, bipolar disease and migraine.
• the disease or condition is a neurodevelopmental disorder, a psychiatric disorder or a neurodegenerative disease.
• the disease or condition is a cancer of a neural origin or a neuroectodermal origin.
• the cancer is selected from the group consisting of neuroblastoma, glioma, ganglioglioma, central neurocytoma, ganglioneuroblastoma, medulloblastoma and a primitive neuroectodermal tumor (PNET).
• neuroblastoma glioma
• ganglioglioma central neurocytoma
• ganglioneuroblastoma medulloblastoma
• medulloblastoma a primitive neuroectodermal tumor (PNET).
• PNET neuroectodermal tumor
• the neuroblastoma comprise a mutation in ALK.
• the administering is to a striatum and/or cortex of the CNS of the subject.
• the composition comprises a CNS (e.g., brain)- selective delivery vehicle.
• CNS e.g., brain
• the brain- selective delivery vehicle comprises nanoparticles, liposomes or exosomes.
• the delivery vehicle comprises a ligand or receptor to enhance uptake across the BBB of the subject.
• the composition is administered along with ultrasound or magnetic stimulation to enhance entry through the BBB of the subject.
• a level of physiologically available nitric oxide in neuronal cells of the subject is reduced by at least 20 % .
• a concentration of nitro-tyrosine in the plasma of the subject is reduced by at least 20
• a pharmaceutical composition comprising a therapeutically active agent which reduces neuronal nitric oxide synthase (nNOS) activity, as described herein in any of the respective embodiments, and a pharmaceutically acceptable carrier, wherein the composition and the therapeutically active agent are selected such that upon administration of the composition to a subject, reduction in the nNOS activity is effected selectively or preferentially in the central nervous system (CNS) or in the brain of the subject as compared to other tissues.
• CNS central nervous system
• reduction in nNOS activity in neuronal cells (e.g., expressing nNOS) or in the CNS (e.g., the brain) of the subject is by at least 20 %, or by at least 30 %, or by at least 40 %.
• a reduction in NOS activity is other tissues or organs is no more than 10 %, or no more than 5 %, or no more than 2 %, or no more than 1 %.
• reduction in nNOS activity in neuronal cells (e.g., expressing nNOS) or in the CNS (e.g., the brain) of the subject is higher by at least 20 %, or by at least 30 %, or by at least 40 % compared to other tissues or organs.
• the composition is configured for local administration to the CNS of the subject.
• the composition is configured for local administration to the brain of the subject.
• the composition is configured to deliver the therapeutically active agent selectively to the central nervous system of the subject.
• the composition is configured to deliver the therapeutically active agent selectively to the brain of the subject.
• the therapeutically active agent is selective to nNOS.
• the composition is configured to deliver the therapeutically active agent selectively to the brain or the central nervous system for an extended time period.
• the composition is configured to deliver an amount of the therapeutically active agent sufficient to reduce nNOS activity in the brain during a time period of at least 1 day, or at least one week, at least 12 days.
• the pharmaceutical composition is formulated for oral, nasal or buccal delivery or administration.
• the carrier comprises an aqueous solution.
• the carrier comprises a mixture of at least one lipid, at least one of a surfactant, and a water-miscible organic solvent, dispersed in an aqueous solution.
• the pharmaceutical composition is in a form of a tablet, a capsule, a syrup, a solution, a spray, an aerosol or a dispersion.
• composition is formulated for administration by injection.
• the carrier comprises an aqueous solution.
• the carrier comprises a mixture of at least one lipid, at least one of a surfactant, and a water-miscible organic solvent, and according tom some embodiments the mixture forms lipid nanoparticles dispersed in an aqueous solution upon contacting an aqueous solution.
• the carrier forms a depot for an extended release of the therapeutically active agent.
• the carrier is a polymeric carrier, preferably comprising at least one biodegradable polymer.
• the polymeric carrier comprises poly(sebacic-co-ricinoleic) acid.
• the polymeric carrier comprises PLGA, PLA, PCL, polycarbonate or a combination thereof.
• the carrier is an aqueous carrier and the therapeutically active agent is dissolvable in the aqueous carrier.
• composition as described herein in any of the respective embodiments, for use in treating a disease or condition in which a beneficial clinical effect is achieved by reduction in nNOS activity, as described herein.
• a pharmaceutical composition comprising an agent that reduces nNOS activity and which is nNOS specific and a pharmaceutically acceptable carrier, the composition being formulated for oral delivery or administration.
• a pharmaceutical composition comprising a compound of Formula I or a pharmaceutically acceptable salt thereof as described herein in any of the respective embodiments, and a pharmaceutically acceptable carrier, the composition being formulated for oral, nasal or buccal delivery or administration.
• the carrier comprises an aqueous solution.
• the compound comprises a pharmaceutically acceptable salt thereof which is water-dissolvable or water-immiscible.
• the carrier further comprises lipid nanoparticles dispersed in the aqueous solution.
• the pharmaceutical composition is for oral administration to a subject in need thereof between one and four times per day.
• a pharmaceutical composition comprising an agent that reduces nNOS activity and which is nNOS specific and a pharmaceutically acceptable carrier, wherein the carrier comprises an aqueous solution and lipid nanoparticles dispersed in the aqueous solution.
• a pharmaceutical composition comprising a compound of Formula I or a pharmaceutically acceptable salt thereof as described herein in any of the respective embodiments and a pharmaceutically acceptable carrier, wherein the carrier comprises an aqueous solution and lipid nanoparticles dispersed in the aqueous solution.
• the carrier is formed upon contacting a PNL formulation as described herein with an aqueous solution.
• a pharmaceutical composition comprising an agent that reduces nNOS activity and which is nNOS specific and a pharmaceutically acceptable carrier, wherein the carrier comprises a mixture of at least one lipid, at least one surfactant (preferably hydrophilic), and a water-miscible organic solvent, and forms, upon contacting an aqueous solution or medium (e.g., physiological medium), a dispersion of lipid nanoparticles in the aqueous solution or medium
• an aqueous solution or medium e.g., physiological medium
• a pharmaceutical composition comprising a compound of Formula I or a pharmaceutically acceptable salt thereof as described herein in any of the respective embodiments and a pharmaceutically acceptable carrier, wherein the carrier comprises a mixture of at least one lipid, at least one surfactant (preferably hydrophilic), and a water-miscible organic solvent, and forms, upon contacting an aqueous solution or medium (e.g., physiological medium), a dispersion of lipid nanoparticles in the aqueous solution or medium
• aqueous solution or medium e.g., physiological medium
• a pharmaceutical composition comprising an agent that reduces nNOS activity as described herein in any of the respective embodiments and a pharmaceutically acceptable carrier, the composition being formulated for releasing the composition of Formula I or the salt thereof during a time period of at least one day, or of at least one week.
• a pharmaceutical composition comprising a compound of Formula I or a pharmaceutically acceptable salt thereof as described herein in any of the respective embodiments and a pharmaceutically acceptable carrier, the composition being formulated for releasing the composition of Formula I or the salt thereof during a time period of at least one day, or of at least one week.
• pharmaceutical composition is formulated for administration by injection.
• the carrier is a polymeric carrier, preferably comprising at least one biodegradable polymer.
• the polymeric carrier comprises poly(sebacic-co-ricinoleic) acid.
• the polymeric carrier comprises PLGA, PLA, PCL, polycarbonate or a combination thereof.
• a pharmaceutical composition as described herein in any of the respective embodiments for use in treating a medical condition in which a beneficial clinical effect is achieved by reduction in neuronal nitric oxide synthase (nNOS) activity.
• nNOS neuronal nitric oxide synthase
• a pharmaceutical composition as described herein in any of the respective embodiments for use in treating a medical condition in which a beneficial effect is achieved by reducing a level of physiologically available nitric oxide in neuronal cells of a subject by at least 20 %.
• a method of treating an autism spectrum disorder in a subject in need thereof comprising administering to the subject an effective amount of a composition comprising an active agent which reduces nNOS activity, as described herein in any of the respective embodiments, wherein reduction in the nNOS activity is selectively or preferentially in the brain of the subject as compared to other tissues, thereby treating the autism spectrum disorder.
• a method of treating an autism spectrum disorder in a subject in need thereof comprising administering to the subject an effective amount of a pharmaceutical composition as described herein in any of the respective embodiments, thereby treating the autism spectrum disorder.
• a pharmaceutical composition as described herein in any of the respective embodiments for use in treating an autism spectrum disorder in a subject in need thereof.
• a method of treating neural cancer in a subject in need thereof comprising administering to the subject an effective amount of a composition comprising an active agent which reduces nNOS activity, as described herein in any of the respective embodiments, wherein reduction in the nNOS activity is selectively or preferentially in a respective nerve tissue of the subject as compared to other tissues, thereby treating the neural cancer.
• a method of treating neural cancer in a subject in need thereof comprising administering to the subject an effective amount of a pharmaceutical composition as described herein in any of the respective embodiments, thereby treating the cancer.
• the neural cancer is neuroblastoma.
• a pharmaceutical composition as described herein in any of the respective embodiments for use in treating neural cancer in a subject in need thereof.
• the agent that reduces nNOS activity is a compound of Formula I or a salt thereof, as described herein in any of the respective embodiments .
• the neural cancer is neuroblastoma.
• the agent that reduces nNOS activity is a compound of Formula I or a salt thereof, as described herein in any of the respective embodiments and the cancer is neuroblastoma.
• the agent is represented by Formula I as described herein in any of the respective embodiments,
• a method of producing a laboratory animal model for autism spectrum disorder comprising administering to the laboratory animal an effective amount of a composition which increases NO levels in a brain of the animal to produce an ASD-like phenotype.
• the composition comprises an NO donor.
• the NO donor comprises S-nitroso-N-acetylpenicillamines (SNAP) .
• the administering is systemic.
• the administering is directly into the brain of the animal.
• the NO donor is selected from the group consisting of SNAP, nitrates, nitrites, N-nitroso, C-nitroso, S-nitroso, heterocyclics, metal/NO complexes, diazeniumdiolates, S-nitrosothiols, sydnonimines and sodium nitroprusside (SNP).
• SNP sodium nitroprusside
• an animal model produced according to the method as described herein in any of the respective embodiments.
• compositions for the delivery of 7-nitroindazole to mammals there is provided a pharmaceutical compositions for the delivery of 7-nitroindazole to mammals
• the pharmaceutical compositions as described herein is for the oral delivery of 7-nitroindazole.
• the pharmaceutical composition as described herein is for delivery of 7-nitroindazole by injections for prolonged periods of time.
• the pharmaceutical composition as described herein is a polymeric microparticles composition.
• the polymer is PLGA.
• the pharmaceutical composition as described herein is a pro-nanodispersion lipid formulation (PNL) or a dispersion of lipid particles in an aqueous solution formed therefrom
• PNL pro-nanodispersion lipid formulation
• the pharmaceutical composition as described herein comprises a solution or a mixture of surfactants, lipids and solvents that upon addition to aqueous media forms nanoparticles.
• the pharmaceutical composition as described herein comprises microspheres composed of a biodegradable polymer.
• the pharmaceutical composition as described herein comprises a composition administered subcutaneously or intramuscularly that possess continued, extended or slow release administration, over prolonged periods of time or targeted slow and regulated delivery.
• the pharmaceutical composition as described herein is loaded in soft gelatin capsule for oral administration.
• the pharmaceutical composition as described herein comprises microspheres dispersed in water for injection.
• the pharmaceutical composition as described herein comprises the active agent (an agent that reduces nNOS activity as described herein) dispersed in a pasty biodegradable polymer carrier for injection.
• a method for treating autism spectrum disorder comprising: administering to the subject in need of such treatment an effective amount of a neuronal NO-reducing composition.
• the NO-reducing composition comprises one or more of a small molecule, an amino acid based molecule, or a nucleic acid based molecule (or a combination of several types of molecules, as described herein
• the reduction in NO may be by one of the following mechanism
• a method for producing an animal model for autism spectrum disorder comprising: administering to a laboratory animal an effective amount of a nitric oxide donor.
• the administration is systemic
• the administration is by a CNS targeted delivery system
• the administration is to the brain.
• the administration is to the brain using nanoparticles delivered to the olfactory tissue.
• FIGs. 2A-B are bar graphs showing the effect of S-nitro-N-acetylpenicillamine (SNAP, an NO donor) treatment on WT mice, as determined in novel object recognition (NOR) test (FIG. 2A) and three-chambered sociability test (FIG. 2B).
• SNAP alters WT behavior.
• WT and SNAP mice were interested significantly in the familiar object (NOR) and empty cage (sociability test) compared to the WT with no treatments.
• FIGs. 3A-B are bar graphs showing the effect of 7-NI treatment on mutant mice, as determined in NOR (FIG. 3A) and three- chambered sociability (FIG. 3B) tests. 7-NI reversed the autistic behavior in mutant mice.
• FIGs. 3C-D present a Western blot (WB) analysis (FIG. 3C) and a quantitative bar graph (FIG. 3D), of cortex tissues prepared from wild-type mice (WT), SHANK3 model mice (Ml) and SHANK3 model mice treated with 7-NI (M1+7-NI).
• WB Western blot
• Ml SHANK3 model mice
• M1+7-NI 7-NI
• FIGs. 3E-F present a Western blot (WB) analysis (FIG. 3E) and a quantitative bar graph (FIG. 3F), of cortex tissues prepared from wild-type mice (WT), CNTNAP2 (-/-) model mice (M2) and CNTNAP2 (-/-) model mice treated with 7-NI (M2+7-NI).
• WB Western blot
• M2 CNTNAP2
• M2+7-NI 7-NI
• FIGs. 3G-H present confocal microscopy images (FIG. 3G) and a quantitative bar graph (FIG. 3H) showing nitro-tyrosine in the cortical region of neurons of wild-type mice (WT), SHANK3 model mice (Ml) and SHANK3 model mice treated with 7-NI (M1+7-NI).
• FIGs. 4A-D present schematic illustrations of a novel object recognition test (NOR; FIG. 4A), a Three-chamber Sociability Test (FIG. 4B), Elevated Plus Maize Test (FIG. 4C), and Marble burying test (FIG. 4D).
• FIGs. 5A-D show that SNAP administration induces ASD-like phenotypes in C57BL/6 mice, as determined in behavioral tests analysis for wild-type (WT) mice and SNAP-treated mice (i.p. injection of 20 mg/kg daily for 10 days). These results validate the results of the experiments shown in Figures 2A-B.
• FIG. 5B is a bar graph presenting data obtained in the Three- chamber sociability test shown in FIG. 4B, showing the (time of interacting with either a familiar mouse (SI) or a novel mouse (S2).
• SI familiar mouse
• S2 novel mouse
• FIG. 5C is a bar graph presenting data obtained in the Elevated plus-maze test shown in FIG. 4C, showing the time spent in the open arms.
• FIGs. 6A-C present bar graphs showing the data obtained in a novel object recognition test (see, FIG. 4A) for wild-type (WT) mice, SHANK3 knockout mice (Ml) and 7-NI-treated mice (M1+7NI) (i.p. injection of 80 mg/kg daily for 10 days) aged 6 weeks (FIG. 6A) and aged 10 months (FIGs. 6B and 6C).
• WT mice wild-type mice
• Ml SHANK3 knockout mice
• M1+7NI 7-NI-treated mice
• the data is presented as mean ⁇ SEM. Two-tailed t-test was conducted. *P ⁇ 0.05, **P ⁇ 0.01, ***P ⁇ 0.001. Similar trends were observed in the aged mice, as can be seen in FIGs. 6B and 6C.
• FIGs. 7A-B show data obtained in A three-chamber sociability test (FIG. 7A) and in an elevated plus maize test (FIG. 7B) for wild-type (WT) mice, the CNTNPA2 mutant mice (M2) and the 7-NI-treated mice (M2+7NI) (i.p. injection of 80 mg/kg daily for 10 days). 7-NI reversed the autistic phenotype in both tests.
• FIGs. 8A-D are graphs showing behavioral test analyses of SHANK3 mutant mice that were treated with 7-NI at 0, 20 ,50, and 80 mg/kg.
• FIG. 8C presents the time of interacting with a stranger mouse in the sociability test, first session.
• FIG. 8D presents the time of interacting with the novel stranger mouse (S2) in the sociability test.
• the 80 mg/kg treated mice spent more time interacting with the novel mouse compared to their counterparts that were treated with lower doses of 7-NI.
• FIGs. 9A-D show a comparative Immunofluorescence analysis of synaptophysin and 3- nitrotyrosine in differentiated SH-SY-5Y cells,SH-SY-5Y+SHANK3 si RNA treatment, and SH- SY-5Y cells with SHANK3 siRNA+ nNOS si-RNA group.
• Rabbit MAP2+ primary mouse monoclonal 3-nitrotyrosine (FIGs. 9A-B).
• Primary rabbit monoclonal synaptophysin+ primary mouse Map2 (FIGs. 9C-D).
• FIGs. 9A and 9C were acquired using a confocal microscope.
• the data presented in the gar graphs in FIGs. 9B and 9D are mean ⁇ SEM.
• One-way ANOVA followed by Fisher’s LSD multiple comparison post hoc test was conducted. *P ⁇ 0.05, **P ⁇ 0.01, ***P ⁇ 0.001.
• FIGs. 10A-C present photographs of vials containing an exemplary pre-nanodispersion lipid (PNL) formulation without (MA-9-61-stock) and with (MA-9-61-A) 2 % w/v 7-NI (FIG. 10A), photographs of vials containing aqueous dispersions of each formulation (FIG. 10B), and DLS particle size data of each formulation (FIG. IOC).
• FIGs. 11A-F present exemplary synthetic pathways for preparing exemplary cationic salts of 7-NI (FIGs. 11A-E) and exemplary anionic salts of 7-NI (FIG. 11F).
• FIGs. 12A-B present a representative UV spectra of 7-NI and a standard curve in methanol at 355 nm generated therefrom (FIG. 12A), and a plot showing the release of 7-NI from the PSARA gel formulation (MA-8-75-A) in phosphate buffer solution (PBS) at 37 °C.
• the drug content in the formulation is 5 % w/w.
• FIGs. 13A-E show behavioral test analyses for wild-type (Control) mice, SHANK3 mutant mice (SHANK3) and the 7-NI-treated SHANK3 mice (Single administration - Treated) (SHANK3 - /- . i.p. injection of 5 % w/w 7-NI PSARA gel formulation described in Example 12 herein). Experiments were initiated on the 4 th day after the injection.
• FIG. 13A presents data obtained in an open field test - motor activity (4 th day after the single administration).
• FIGs. 13B-C present the data obtained in the Three-chamber sociability test, on dayl (9 th day after the single administration) (FIG. 13B) and day2 (10 th day after the single administration) (FIG. 13C).
• the SHANK3 mice didn’t show any significant change in the time interacting with the stranger 1 mouse compared to the control mice.
• the SHANK3 mice spent significantly less time interacting with the stranger 2 mouse compared to the control mice.
• the data obtained in the Marble burying test is presented in FIG. 13D (7 th day after the single administration), showing the number of marbles buried.
• the analysis showed that the SHANK3 mice buried significantly less marbles than the control mice, indicating a lack of novelty seeking and restricted interests.
• the 7-NI-treated mice buried more marbles comparing to SHANK3 mice (n-4,4,4 for the Control , SHANK3 , and treated mice respectively. ***P ⁇ 0.001, ***P ⁇ 0.001).
• the data obtained in the Elevated plus maze test is presented in FIG. 13E (12 th day after the single administration).
• the SHANK3 mice didn’t show any significant change in the time spent in the open arms compared to their control counterparts .
• the data is presented as mean ⁇ SEM. Two-tailed t-test was conducted. *P ⁇ 0.05.
• FIGs. 14A-E shows an optimal concentration of 7-NI (FIG. 14A), and successful knockdown of nNOS by siRNA (FIGs. 14B-E).
• FIG. 14A presents comparative plots showing the cell viability of SH-SY5Y as measured by MTT (the dose-response curve). The concentration of 7-NI for the cell treatment was 100 mM. Data were presented in percentage of 100.
• FIG. 14B is a representative blot of nNOS. 1, SH-SY5Y; 2, SH-SY5Y+negative control (NC); and 3, SH- SY5Y+si-nNos.
• FIG. 14C presents representative fluorescence images of nNOS immunofluorescence.
• Blue color represents DAPI (a marker of nucleus), green color shows NeuN (a marker of neuron) and red color represents nNOS.
• FIG. 14D is a bar graph showing the relative abundance of nNOS.
• FIG. 14E is a bar graph showing the relative fluorescence intensity of nNOS.
• FIGs. 15A-B are bar graphs showing the effects of 7-NI and nNOS silencing on the nNOS activity and NO levels in SH-SY5Y cells.
• FIG. 15A shows NADPH-diaphorase activity in cell lysates. The absorbance at 585 nm was normalized for total protein.
• FIGs. 16A-B show the effects of 7-NI and nNOS silencing on SH-SY5Y cell proliferation (the clonogenic growth assay).
• FIG. 16A presents representative images of plates with SH-SY5Y cells non-treated and treated with 7-NI, si-nNOS RNA (silenced nNOS), and vehicle (negative control, NC).
• FIGs. 17A-D present data obtained in Western blot analysis of the levels of 3-nitrotyrosine, components of the mTOR signaling pathway, and synaptophysin.
• FIG. 17A presents a representative WB of protein prepared from cell lysate of SH-SY5Y (1), SH-SY5Y+7- NI (2), and SH-SY5Y+si-nNOS (3).
• FIG. 17B is a bar graph showing the relative abundance of 3-Ntyr in the 3 groups of cells.
• FIG. 17C presents a representative Western blotting (WB) of proteins (p-mTOR, mTOR, TSC2, pAKT, AKT, pRPS6, RPS6, and Syp) prepared from the cell lysate of the 3 groups.
• FIG. 17D are bar graphs showing the relative abundance of p-mTOR, mTOR, TSC2, pAKT, AKT, pRPS6, RPS6, and Syp. The data were normalized for b-actin and presented as mean ⁇ SEM. A one-way ANOVA followed by Fisher's LSD multiple comparison post hoc test was conducted. * P ⁇ 0.05, ** P ⁇ 0.01.
• FIGs. 18A-C show immunofluorescence of synaptophysin and 3-nitrotyrosine in SH- SY5Y cells with inhibited nNOS activity.
• Cells (with or without treatment) were postfixed in 4 % paraformaldehyde and then incubated with the primary rabbit monoclonal Syp (red), and either primary mouse monoclonal NeuN (green), or primary mouse monoclonal 3-Ntyr (green) antibodies, in another group of cells.
• Cells were incubated with their respective secondary antibodies, such as anti-mouse Alexa fluor488, or anti-rabbit Alexa fluor594, and then mounted with DAPI (Blue) in both groups of cells.
• the images were acquired using a confocal microscope.
• FIG. 18A presents representative images of Syp and 3-Ntyr immunofluorescence.
• FIG. 18B-C are bar graphs showing the relative fluorescent intensity of Syp (FIG. 18B) and N-Tyr (FIG. 18C) immunofluorescence in the 3 groups of cells.
• the data are presented as mean ⁇ SEM.
• the scale bar is 100 ⁇ m.
• the present invention in some embodiments thereof, relates to therapy, and, more particularly, but not explicitly, to pharmaceutical compositions and methods for treating neurological conditions associated with abnormal activity of neuronal nitric oxide synthase (nNOS) such as, but not limited to, autistic spectrum disorders (ASDs) and neural-derived cancer.
• nNOS neuronal nitric oxide synthase
• ASDs autistic spectrum disorders
• neural-derived cancer neural-derived cancer
• nitric oxide e.g., free, physiologically available NO
• treatment with nNOS inhibitors leads to reversal in the diseased phenotype, thereby demonstrating a role for inhibition or reduction in nNOS activity in treating neurological conditions that are associated with elevated NO levels.
• the present inventors have designed pharmaceutical compositions that are usable in the inhibiting nNOS activity and in treating neurological conditions that are associated with elevated NO levels and/or aberrant nNOS activity.
• Embodiments of the present invention relate to methods for reducing a level (e.g., amount or concentration) of physiologically available nitric oxide and/or for reducing an activity of nNOS in a subject in need thereof.
• a level e.g., amount or concentration
• Embodiments of the present invention relate to methods method of treating a disease or condition in which a beneficial clinical effect is achieved by reduction in nNOS activity, such as, but not limited to, ASD or cancer of a neural original (neural-derived cancer or neural cancer).
• Embodiments of the present invention further relate to pharmaceutical compositions usable in any of the above methods.
• Some embodiments of the present invention relate to pharmaceutical compositions and/or methods in which an active agent that reduces an activity of nNOS reduces the nNOS activity selectively or preferentially in the CNS of the subject (e.g., the brain).
• compositions that comprises an agent is a selective nNOS inhibitor.
• a method of treating a disease or condition in which a beneficial clinical effect is achieved by reduction in nNOS activity comprising administering to a subject in need thereof an effective amount of a composition comprising an active agent which reduces nNOS activity, thereby treating the disease or condition in which a beneficial clinical effect is achieved by reduction in nNOS activity.
• composition comprising an active agent which reduces nNOS activity, and optionally a pharmaceutically acceptable carrier, for use in treating the disease or condition in which a beneficial clinical effect is achieved by reduction in nNOS activity.
• the methods and uses as described herein are for reducing a level (e.g., an amount) of physiologically available nitric oxide (NO) in a neuronal cells of a subject in need thereof.
• a level e.g., an amount
• the reduction is by at least 20 %, or at least 30 % or at least 40 %, or at least 50 %.
• the methods and uses as described herein are for reducing a level (e.g., an amount) of physiologically available nitric oxide (NO) in the CNS (e.g., the brain) of a subject in need thereof.
• a level e.g., an amount
• the reduction is by at least 20 %, or at least 30 % or at least 40 %, or at least 50 %.
• a method of treating a disease or condition in which a beneficial clinical effect is achieved by reduction in an amount of physiologically available nitric oxide in a diseased tissue comprising administering to a subject in need thereof an effective amount of a composition comprising an active agent which reduces nNOS activity, thereby treating the disease or condition.
• an effective amount of the composition is an amount that results in reducing an amount of the physiologically available nitric oxide by at least 20 %, or at least 30 %, or at least 50 %, or at least 60 %, or at least 70 %.
• the diseased tissue comprise neuronal cell.
• the diseased tissue is in the CNS (e.g., brain) of the subject.
• Reducing an activity of nNOS or reducing an amount of physiologically available nitric oxide can be measured by determining an amount of Ntyr in the plasma of the subject, or by any other methods known in the art, as discussed in further detail hereinafter.
• the methods and uses as described herein are for reducing nNOS activity in the CNS, or in the brain.
• the methods and uses as described herein are for reducing an amount of physiologically available nitric oxide in neuronal cells, for example, in the CNS or in the brain.
• a method of treating a disease or condition in which a beneficial clinical effect is achieved by reduction in nNOS activity in the brain comprising administering to a subject in need thereof an effective amount of a composition comprising an active agent which reduces nNOS activity, wherein reduction in said nNOS activity is selectively or preferentially in the brain of the subject as compared to other tissues, thereby treating the disease or condition in which a beneficial clinical effect is achieved by reduction in nNOS activity in the brain.
• composition comprising an active agent which reduces nNOS activity for use in treating a disease or condition in which a beneficial clinical effect is achieved by reduction in nNOS activity in a brain of a subject in need thereof, wherein the composition is formulated such that a reduction in said nNOS activity is selectively or preferentially in the brain of the subject as compared to other tissues.
• treating and “treatment” include abrogating, substantially inhibiting, slowing or reversing the progression of a condition, substantially ameliorating clinical or aesthetical symptoms of a condition or substantially preventing the appearance of clinical or aesthetical symptoms of a condition.
• treatment can refer to the reduction of the severity or duration of the undesired behaviors, increasing the duration between boosts of undesired behaviors, preventing the behaviors before they occur, improvement in development and improved overall condition .
• the terms “treatment” and “treating” exclude prevention.
• a disease or condition in which a beneficial clinical effect is achieved by reduction in nNOS activity refers to a medical condition in which elevated levels of nitric oxide (NO) are evident, as compared to NO levels in a control subject who doesn’t suffer from the medical disease or condition.
• the control subject belongs to a control population of the same gender, developmental stage and ethnic group, as that of the treated subject.
• a disease or condition in which a beneficial clinical effect is achieved by reduction in nNOS activity in the brain refers to a medical condition in which elevated levels of nitric oxide (NO) are evident in a part of the central nervous system (CNS), as compared to NO levels in a control subject who doesn’t suffer from a medical condition in the CNS.
• the control subject belongs to a control population of the same gender, developmental stage and ethnic group, as that of the treated subject
• nNOS refers to the protein product of the NOS1 gene located on chromosome 12 in human beings, 12q24.22, BRENDA 1.14.13.39. It is also known as NOS1, an enzyme that in humans is encoded by the NOS / gene. The nNOS gene is depicted in humans under accession number P29475.
• Nitric oxide synthases (EC 1.14.13.39) (NOSs) are a family of synthases that catalyze the production of nitric oxide (NO) from L-arginine. NO is a chemical messenger with diverse functions throughout the body depending on its enzymatic source and tissue localization. In the brain and peripheral nervous system, where NOS1 is largely present, NO displays many properties of a neurotransmitter and may be involved in long term potentiation.
• Neuronal NOS (NOS1), Endothelial NOS (NOS3), and Inducible NOS macrophage NOS are distinct isoforms. Both the neuronal and the macrophage forms are unusual among oxidative enzymes in requiring several electron donors (co-factors), including, for example: flavin adenine dinucleotide (FAD), flavin mononucleotide (FMN), NADPH, and tetrahydrobiopterin. All nitric oxide synthase isoforms are calcium-calmodulin controlled. For example, nNOS is activated at calcium concentrations over 100 nM.
• FAD flavin adenine dinucleotide
• FMN flavin mononucleotide
• NADPH tetrahydrobiopterin
• All nitric oxide synthase isoforms are calcium-calmodulin controlled. For example, nNOS is activated at calcium concentrations over 100 nM.
• nNOS activity refers to the production of free (physiologically available) nitric oxide (NO) in neuronal cells or in a nerve tissue (neuronal tissue), including, unless otherwise indicated, the peripheral and/or the central nervous system
• nNOS activity can also be referred to as the production of free (physiologically available) nitric oxide (NO) by nNOS enzyme in a nerve tissue (CNS, e.g., brain) or peripheral organs which comprise neuronal cells that express nNOS.
• CNS nerve tissue
• nNOS enzyme e.g., a nerve tissue
• peripheral organs which comprise neuronal cells that express nNOS.
• the production of NO by NOS is effected by catalyzing a five-electron oxidation of a nitrogen atom of the guanidine group of L-arginine. Oxidation of L-Arg to L-eitrulline occurs via two successive monooxygenation reactions, which produce N ⁇ -hydroxy-L-arginine (NOHLA) as an intermediate. 2 mol of O 2 and 1.5 mol of NADPH are consumed per mole of NO formed.
• NOHLA N ⁇ -hydroxy-L-arginine
• nNOS activity can be effected (increased or reduced) by interfering in the production of free NO, by means of, for example, affecting a level of one or more co-factors that participate in the monooxygenation reactions and/or a level of its substrate (L-arginine) and/or by interfering with a level of its binding to L-arginine, for example, by means of substrate-competitive inhibitors.
• Uncontrolled production of free NO by nNOS may elicit ASD like symptoms in a model animal such as described hereinbelow and in the Examples section which follows.
• Reduction in nNOS activity can be achieved by down-regulating the level of the nNOS protein product, DNA or mRNA encoding the same, or by inhibiting the activity of the enzyme. This can be achieved by interfering with the cellular localization of the enzyme, inhibiting its intrinsic activity or inhibiting an activity of an activator or an effector thereof, wherein each alternative is considered as an individual embodiment of the invention.
• inhibiting nNOS activity can be effected by interfering in the production of free NO, by means of, for example, reducing a level of one or more co-factors that participate in the monooxygenation reactions and/or reducing a level of its substrate (L-arginine) and/or by interfering with a level of its binding to L-arginine, for example, by means of substrate-competitive inhibitors.
• Selective inhibition of nNOS can be effected by interfering with a level of a co-factor that participates in the nNOS-catalyzed NO production but not in the NO production that is catalyzed by other isoforms, and/or by using a substrate-competitive inhibitor that has an affinity to nNOS that is higher compared to its affinity to the other NOS isoforms.
• a selective nNOS inhibitor has an affinity to nNOS, determined by the dissociation constant (Ki) for nNOS that is higher by at least 10-folds or at least 100-folds or at least 1,000-folds than its dissociation constant (Ki) for eNOS or iNOS.
• Nitric oxide synthase activity assays are commercially available. These include, for example, the NOS activity assay kit by Abeam e.g., ab211083.
• An activity parameter may be Tyrosine nitration, NO 2 , NO 3 , and others.
• nNOS levels can be determined at the protein or mRNA levels.
• nNOS protein levels can be determined using an immunological assay, e.g., Western blotting, ELISA, such as for example, by using an ELISA assay kit such as that available from Cosmo Bio USA or LSBio e.g., LS-F4243.
• a disease or condition in which a beneficial clinical effect is achieved by reduction in nNOS activity refers to a medical condition which onset or progression is dependent on overproduction (as compared to its level in a normal/healthy CNS tissue) of nitric oxide (NO) in neuronal cells. This is typically achieved by dysregulated (increased) activity in nNOS as compared to a healthy nerve tissue (of the peripheral or central nervous system).
• a disease or condition in which a beneficial clinical effect is achieved by reduction in nNOS activity refers to a medical condition which onset or progression is dependent on over production (as compared to its level in a normal/healthy CNS tissue) of nitric oxide (NO) in the CNS (e.g., brain). This is typically achieved by dysregulated (increased) activity in nNOS as compared to a healthy CNS.
• nitric oxide e.g., brain
• a beneficial effect relates to a decrease in at least one pathological symptom.
• decrease in at least one symptom associated with the disease or condition refers to a statistically significant decrease, e.g., at least 10 %, 20 %, 30 %, 40 %, 50 %, 60 %, 70 %, 80 %, 90 % or even complete disappearance of the symptom.
• reduction/decrease in nNOS activity is optimally to its level or a level of NO in a normal/healthy tissue of the CNS or to the level that improves the medical condition of the patient.
• Exemplary diseases or conditions according to the present embodiments include, but are not limited to, Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, Multiple sclerosis, Schizophrenia, addiction, ALS, Epilepsy, bipolar disease, migraine and in addition all kinds of neurodevelopmental disorders as well as neurodegenerative diseases associated with unbalanced NO levels.
• Additional examples include, but are not limited to, depression, ADD, ADHD, as well as hypoxic and ischemic conditions of the CNS such as trauma, hypoxic-ischemic encephalopathy of a newborn, during or after surgery; metabolic diseases involving the central nervous system such as Sphingolipid metabolism diseases (i.e., GM1 -gangliosidosis , GM2-gangliosidoses, Tay- Sachs disease, Sandhoff disease, AB-variant of GM2-gangliosidosis, Fabry disease, Gaucher disease, Metachromatic leukodystrophy, Krabbe disease, Niemann-Pick disease, type A, B, C or Farber disease). See Tripathi MK, Kartawy M and Amal H. The role of nitric oxide in brain disorders: Autism spectrum disorder and other psychiatric, neurological, and neurodegenerative disorders. Redox Biol. 2020: 101567, which is incorporated by reference as if fully set forth herein.
• the present inventors have shown an alleviation in ASD-like symptoms in mouse models treated with a nNOS inhibitor as shown the Examples section which follows.
• the disease or condition is a brain disorder.
• the disease or condition is a memory or mood disorder.
• the disease or condition is a neuropsychiatric disorder.
• the disease or condition is an autism spectrum disorder
• autism spectrum disorder refers to conditions previously diagnosed as autism (autistic disorder), including high- functioning autism, Asperger syndrome, pervasive developmental disorder not otherwise specified (PDD- NOS), and childhood disintegrative disorder.
• ASD autism spectrum disorder
• ASD symptoms e.g., impaired communication and social interaction
• ADD e.g., ADHD
• ADNP Helsmoortel- Van Der Aa
• NAP Nevunetide
• treatment of ASD refers to improvement in at least one undesired parameter, characterization, behavior associated with ASD including: problems with social communication and social interaction, the presence of restricted, repetitive patterns of behavior, interests, or activities, Self- injurious behavior (SIB), abnormal responses to sensations including sights, sounds, touch, and smell, problems keeping a consistent speech rhythm, developmental problems manifested in perceptual disturbances, disturbances of development rate, relating, speech and language, and motility, and including also memory deficiency and other cognitive malfunctions.
• SIB Self- injurious behavior
• the ASD is defined according to DSM-5, as provided infra.
• Severity is based on social communication impairments and restricted repetitive patterns of behavior. (See Table 1 below.)
• Stereotyped or repetitive motor movements, use of objects, or speech e.g., simple motor stereotypies, lining up toys or flipping objects, echolalia, idiosyncratic phrases).
• Severity is based on social communication impairments and restricted, repetitive patterns of behavior. (See Table A below.)
• Table A Severity levels for autism spectrum disorder
• the condition is Social (Pragmatic) Communication Disorder. Diagnostic criteria according to DSM-5 are summarized infra.
• Impairment of the ability to change communication to match context or the needs of the listener such as speaking differently in a classroom than on the playground, talking differently to a child than to an adult, and avoiding use of overly formal language.
• the symptoms are not attributable to another medical or neurological condition or to low abilities in the domains or word structure and grammar, and are not better explained by autism spectrum disorder, intellectual disability (intellectual developmental disorder), global developmental delay, or another mental disorder.
• ASD and SCD are contemplated herein as co-morbidities or alternative embodiments.
• autism Autism disorders. About 10-15% of autism cases have an identifiable Mendelian (single- gene) condition, chromosome abnormality, or other genetic syndrome, and ASD is associated with several genetic disorders [Zafeiriou DI, Ververi A, Vargiami E (2007). "Childhood autism and associated comorbidities”. Brain Dev. 29 (5): 257-272. doi: 10.1016/j.braindev.2006.09.003].
• ADHD Attention deficit hyperactivity disorder
• ADD Attention deficit disorder
• Sleep problems affect about two-thirds of individuals with ASD at some point in childhood. These most commonly include symptoms of insomnia such as difficulty in falling asleep, frequent nocturnal awakenings, and early morning awakenings.
• the disease or condition is selected from the group consisting of Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, multiple sclerosis, schizophrenia, addiction, amyotrophic lateral sclerosis (ALS), epilepsy, bipolar disease and migraine.
• the disease or condition is a neurodevelopmental disorder, a psychiatric disorder or a neurodegenerative disease.
• NO takes part in the development of cancers.
• the present inventors have shown that inhibition of NO production in neuroblastoma (NB) cells, either by pharmacological intervention, using the selective nNOS inhibitor 7-NI, or by genetic ablation, using a specific gene silencing tool for silencing expression of nNOS, is able to suppress NB malignancy.
• This effect was manifested by reduced proliferation, significantly reduced levels of the marker of NB Syp (MIETTINEN and RAPOLA, 1987), and nitrosative stress, seen by the reduced levels of 3-Ntyr.
• the present inventor has further shown, for the first time, that the pro-cancer effect of nNOS is mediated by the activation of the mTOR signaling pathway and that the selective nNOS inhibitor 7-NI is able to inhibit significantly both the activation of the mTOR signaling and malignancy of the human NB cells.
• the disease or condition is a cancer of a neural origin or a neuroectodermal origin, which is also referred to herein as neural cancer or as neural-derived cancer.
• the cancer is selected from the group consisting of neuroblastoma, glioma, ganglioglioma, central neurocytoma, ganglioneuroblastoma, medulloblastoma and a primitive neuroectodermal tumor (PNET).
• the cancer is neuroblastoma.
• the neuroblastoma comprises a mutation in ALK.
• ALK tyrosine kinase receptor anaplastic lymphoma kinase
• the tumor is a primary tumor.
• the tumor is a metastatic tumor.
• the tumor is a tumor metastasis.
• the tumor is a recurrent tumor.
• the tumor is resistant to a first-line (e.g., chemotherapy) treatment.
• a first-line e.g., chemotherapy
• embodiments of the invention relate to administration of an effective amount of a composition comprising an active agent which reduces nNOS activity, as defined herein.
• the active agent reduces an amount of physiologically available NO in neuronal cells, as described herein.
• the reduction in the nNOS activity is selectively or preferentially in neuronal cells or a nerve tissue of the subject as compared to other tissues.
• the reduction in the nNOS activity is selectively or preferentially in a peripheral and/or central nervous system of the subject as compared to other tissues.
• the reduction in the nNOS activity is selectively or preferentially in a brain of the subject as compared to other tissues.
• compositions comprising an active agent which reduces nNOS activity and a pharmaceutically acceptable carrier, wherein the composition and the active agent are such that upon administration to a subject, reduction in the nNOS activity is effected selectively or preferentially in a nerve tissue of the subject as compared to other tissues, as described herein.
• nNOS-reducing composition Such a composition is also referred to herein as “nNOS-reducing composition”, or, alternatively, as “NO-reducing composition”.
• an active agent which reduces nNOS activity refers to a substance or a physical condition which reduces the activity of nNOS, by any one of: affecting its inherent catalytic activity, ability to interact with other cellular proteins or factors, affecting its cellular localization and/or affecting its level or level of NO within the cell.
• the agent which is also referred to as an “nNOS inhibitor” or a “neuronal NO reducing composition” is acting such that the reduction in nNOS activity is selectively or preferentially achieved in neuronal cells or a nerve tissue to be treated, for example, the CNS (e.g., brain) of the subject, as compared to other tissues.
• nNOS is expressed in various tissues, for example, brain, retina, frontal cortex, heart, colon, colon muscle, rectum, prostate and pancreas.
• the agent is active on nNOS and does not affect the activity of other NOS enzymes such as NOS2 and/or NOS3, as described hereinabove with respect to nNOS selectivity.
• any of these embodiments individually or combined, ensure activity of the agent only in the affected site (or predisposed site), without acting on other NOS (e.g., iNOS) enzymes or in other tissues in which nNOS is expressed.
• NOS e.g., iNOS
• the agent decreases nNOS expression.
• the agent decreases nNOS translation.
• the agent inhibits nNOS enzymatic activity.
• the agent affects nNOS interaction with other proteins or its dimerization.
• the protein acts as a homodimer. It interacts with DLG4; the interaction possibly being prevented by the association between NOS1 and CAPON. Forms a ternary complex with CAPON and RASDl. Forms a ternary complex with CAPON and SYN1. Interacts with ZDHHC23. Interacts with NOSIP; which may impair its synaptic location (By similarity). Interacts with HTR4. Interacts with VAC14 (By similarity). Interacts with SLC6A4 (By similarity). Interacts (via N-terminal domain) withDLG4 (viaN-terminal tandem pair of PDZ domains).
• the active agent in the composition may be a small molecule, an amino acid based molecule (peptide, protein, antibody or RNA encoding same), or a nucleic acid based molecule (e.g., RNA including antisense and inhibitor RNA; DNA) or a combination of several types of molecules.
• RNA encoding the claimed proteinaceous agent when RNA encoding the claimed proteinaceous agent is used, measures are taken to improve its stability and bioavailability as described for instance in U.S. 20150030576.
• the reduction in the amount of free NO may be by one of the following mechanism
• nNOS nNOS decrease in expression of the nNOS from its gene (in the transcription or translation level), or at the DNA level such as achieved by genome editing. 2. Inhibition of nNOS activity in the enzymatic level (by small molecule, competing peptide, antibody, antibody fragment)
• the phrase “decreases expression or activity” or “downregulates expression or activity” refers to downregulating the expression of a protein (e.g. nNOS) at the genomic (e.g. homologous recombination and site specific endonucleases) and/or the transcript level using a variety of molecules which interfere with transcription and/or translation (e.g., RNA silencing agents) or on the protein level (e.g., aptamers, small molecules and inhibitory peptides, antagonists, enzymes that cleave the polypeptide, antibodies and the like).
• a protein e.g. nNOS
• genomic e.g. homologous recombination and site specific endonucleases
• transcript level e.g., RNA silencing agents
• the nNOS gene is depicted under accession number P29475. According to an embodiment of the invention the expression o from the gene may be selectively reduced at the transcription or translation level
• control For the same culture conditions the expression or activity is generally expressed in comparison to the expression or activity in a cell of the same species but not contacted with the agent or contacted with a vehicle control, also referred to as control.
• Down regulation of expression may be either transient or permanent.
• down regulating expression refers to the absence of mRNA and/or protein, as detected by RT-PCR or Western blot, respectively.
• down regulating expression refers to a decrease in the level of mRNA and/or protein, as detected by RT-PCR or Western blot, respectively.
• the reduction may be by at least a 10 %, at least 20 %, at least 30 %, at least 40 %, at least 50 %, at least 60 %, at least 70 %, at least 80 %, at least 90 %, at least 95 % or at least 99 % reduction.
• Down-regulation at the nucleic acid level is typically effected using a nucleic acid agent, having a nucleic acid backbone, DNA, RNA, mimetics thereof or a combination of same.
• the nucleic acid agent may be encoded from a DNA molecule or provided to the cell per se.
• the downregulating agent is a polynucleotide.
• the downregulating agent is a polynucleotide capable of hybridizing to a gene or mRNA encoding nNOS.
• the downregulating agent directly interacts with nNOS.
• the agent directly binds nNOS.
• the agent indirectly binds nNOS (e.g. binds an effector of nNOS). More specifically, a nNOS inhibitor (e.g., 7-NI) leads to de-nitrosylation of TSC2 which leads to a reduction in mTOR signaling.
• nNOS inhibitor e.g., 7-NI
• the downregulating agent is an RNA silencing agent or a genome editing agent.
• RNA silencing refers to a group of regulatory mechanisms [e.g. RNA interference (RNAi), transcriptional gene silencing (TGS), post-transcriptional gene silencing (PTGS), quelling, co- suppression, and translational repression] mediated by RNA molecules which result in the inhibition or "silencing" of the expression of a corresponding protein- coding gene.
• RNA silencing has been observed in many types of organisms, including plants, animals, and fungi.
• RNA silencing agent refers to an RNA which is capable of specifically inhibiting or “silencing" the expression of a target gene.
• the RNA silencing agent is capable of preventing complete processing (e.g., the full translation and/or expression) of an mRNA molecule through a post-transcriptional silencing mechanism
• RNA silencing agents include non-coding RNA molecules, for example RNA duplexes comprising paired strands, as well as precursor RNAs from which such small non-coding RNAs can be generated.
• Exemplary RNA silencing agents include dsRNAs such as siRNAs, miRNAs and shRNAs.
• the RNA silencing agent is capable of inducing RNA interference.
• the RNA silencing agent is capable of mediating translational repression.
• the RNA silencing agent is specific to the target RNA (e.g., nNOS) and does not cross inhibit or silence other targets (e.g., (iNOS or eNOS) or a splice variant which exhibits 99% or less global homology to the target gene, e.g., less than 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, 90%, 89%, 88%, 87%, 86%, 85%, 84%, 83%, 82%, 81% global homology to the target gene; as determined by PCR, Western blot, Immunohistochemistry and/or flow cytometry.
• targets e.g., iNOS or eNOS
• a splice variant which exhibits 99% or less global homology to the target gene, e.g., less than 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, 90%, 89%, 88%, 87%, 86%,
• RNA interference refers to the process of sequence- specific post-transcriptional gene silencing in animals mediated by short interfering RNAs (siRNAs).
• RNA silencing agents that can be used according to specific embodiments of the present invention.
• DsRNA, siRNA and shRNA - The presence of long dsRNAs in cells stimulates the activity of a ribonuclease PI enzyme referred to as dicer.
• Dicer is involved in the processing of the dsRNA into short pieces of dsRNA known as short interfering RNAs (siRNAs).
• Short interfering RNAs derived from dicer activity are typically about 21 to about 23 nucleotides in length and comprise about 19 base pair duplexes.
• the RNAi response also features an endonuclease complex, commonly referred to as an RNA-induced silencing complex (RISC), which mediates cleavage of single- stranded RNA having sequence complementary to the antisense strand of the siRNA duplex. Cleavage of the target RNA takes place in the middle of the region complementary to the antisense strand of the siRNA duplex.
• RISC RNA-induced silencing complex
• some embodiments of the invention contemplate use of dsRNA to downregulate protein expression from mRNA.
• dsRNA longer than 30 bp are used.
• dsRNA is provided in cells where the interferon pathway is not activated, see for example Billy et al., PNAS 2001, Vol 98, pages 14428- 14433. and Diallo et al, Oligonucleotides, October 1, 2003, 13(5): 381-392. doi: 10.1089/154545703322617069.
• the long dsRNA are specifically designed not to induce the interferon and PKR pathways for down-regulating gene expression.
• Shinagwa and Ishii [Genes & Dev. 17 (11): 1340-1345, 2003] have developed a vector, named pDECAP, to express long double-strand RNA from an RNA polymerase P (Pol P) promoter.
• pDECAP RNA polymerase P
• the transcripts from pDECAP lack both the 5'-cap structure and the 3'-poly(A) tail that facilitate ds-RNA export to the cytoplasm, long ds-RNA from pDECAP does not induce the interferon response.
• siRNAs small inhibitory RNAs
• siRNA refers to small inhibitory RNA duplexes (generally between 18-30 base pairs) that induce the RNA interference (RNAi) pathway.
• RNAi RNA interference
• siRNAs are chemically synthesized as 21mers with a central 19 bp duplex region and symmetric 2-base 3'-overhangs on the termini, although it has been recently described that chemically synthesized RNA duplexes of 25-30 base length can have as much as a 100-fold increase in potency compared with 21mers at the same location.
• siRNA duplex into RISC The observed increased potency obtained using longer RNAs in triggering RNAi is suggested to result from providing Dicer with a substrate (27mer) instead of a product (21mer) and that this improves the rate or efficiency of entry of the siRNA duplex into RISC.
• Exemplary siRNAs which can be used in accordance with the present teachings are provided in the Examples section which follows and in SEQ ID NOs: 3-8.
• RNA silencing agent of some embodiments of the invention may also be a short hairpin RNA (shRNA).
• siRNAs which can be used in accordance with the present teachings are provided in the Examples section which follows and in SEQ ID NOs: 9-14.
• RNA agent refers to an RNA agent having a stem-loop structure, comprising a first and second region of complementary sequence, the degree of complementarity and orientation of the regions being sufficient such that base pairing occurs between the regions, the first and second regions being joined by a loop region, the loop resulting from a lack of base pairing between nucleotides (or nucleotide analogs) within the loop region.
• the number of nucleotides in the loop is a number between and including 3 to 23, or 5 to 15, or 7 to 13, or 4 to 9, or 9 to 11. Some of the nucleotides in the loop can be involved in base-pair interactions with other nucleotides in the loop.
• RNA silencing agents suitable for use with some embodiments of the invention can be effected as follows. First, the nNOS mRNA sequence is scanned downstream of the AUG start codon for AA dinucleotide sequences. Occurrence of each AA and the 3’ adjacent 19 nucleotides is recorded as potential siRNA target sites. Preferably, siRNA target sites are selected from the open reading frame, as untranslated regions (UTRs) are richer in regulatory protein binding sites. UTR-binding proteins and/or translation initiation complexes may interfere with binding of the siRNA endonuclease complex [Tuschl ChemBiochem 2:239-245].
• UTRs untranslated regions
• siRNAs directed at untranslated regions may also be effective, as demonstrated for GAPDH wherein siRNA directed at the 5’ UTR mediated about 90 % decrease in cellular GAPDH mRNA and completely abolished protein level (www(dot)ambion(dot)com/techlib/tn/91/912.html).
• potential target sites are compared to an appropriate genomic database (e.g., human, mouse, rat etc.) using any sequence alignment software, such as the BLAST software available from the NCBI server (www(dot)ncbi(dot)nlm(dot)nih(dot)gov/BLAST/). Putative target sites which exhibit significant homology to other coding sequences are filtered out.
• sequence alignment software such as the BLAST software available from the NCBI server (www(dot)ncbi(dot)nlm(dot)nih(dot)gov/BLAST/).
• Qualifying target sequences are selected as template for siRNA synthesis.
• Preferred sequences are those including low G/C content as these have proven to be more effective in mediating gene silencing as compared to those with G/C content higher than 55 %.
• Several target sites are preferably selected along the length of the target gene for evaluation.
• a negative control is preferably used in conjunction.
• Negative control siRNA preferably include the same nucleotide composition as the siRNAs but lack significant homology to the genome.
• a scrambled nucleotide sequence of the siRNA is preferably used, provided it does not display any significant homology to any other gene.
• RNA silencing agent of some embodiments of the invention need not be limited to those molecules containing only RNA, but further encompasses chemically-modified nucleotides and non- nucleotides. miRNA and miRNA mimics - According to another embodiment the RNA silencing agent may be a miRNA.
• the miRNA is miR-146a or synthetic version thereof .
• Other contemplated miRS include, but are not limited to, hsa-miR-146a-5p (MIRT735124), hsa- miR-1273f (MIRT783312), hsa-miR-143-3p (MIRT783811), hsa-miR-147a (MIRT783856), hsa-miR-3622a-5p (MIRT784976), hsa-miR-3911 (MIRT785428), hsa-miR-4269 (MIRT785560), hsa-miR-4708-5p (MIRT786482), hsa-miR-4710 (MIRT786499), hsa-miR-4770 (MIRT786696), hsa-miR-4792 (MIRT786788), hsa-miR-574-5p (MIRT735124),
• miRNA refers to a collection of non-coding single- stranded RNA molecules of about 19-28 nucleotides in length, which regulate gene expression. miRNAs are found in a wide range of organisms (viruses. fwdarw. humans) and have been shown to play a role in development, homeostasis, and disease etiology.
• the pri-miRNA is typically part of a polycistronic RNA comprising multiple pri-miRNAs.
• the pri-miRNA may form a hairpin with a stem and loop.
• the stem may comprise mismatched bases.
• the hairpin structure of the pri-miRNA is recognized by Drosha, which is an RNase III endonuclease. Drosha typically recognizes terminal loops in the pri-miRNA and cleaves approximately two helical turns into the stem to produce a 60-70 nucleotide precursor known as the pre-miRNA. Drosha cleaves the pri-miRNA with a staggered cut typical of RNase III endonucleases yielding a pre-miRNA stem loop with a 5' phosphate and ⁇ 2 nucleotide 3' overhang. It is estimated that approximately one helical turn of stem ( ⁇ 10 nucleotides) extending beyond the Drosha cleavage site is essential for efficient processing. The pre-miRNA is then actively transported from the nucleus to the cytoplasm by Ran-GTP and the export receptor Ex-portin-5.
• the double- stranded stem of the pre-miRNA is then recognized by Dicer, which is also an RNase PI endonuclease. Dicer may also recognize the 5' phosphate and 3' overhang at the base of the stem loop. Dicer then cleaves off the terminal loop two helical turns away from the base of the stem loop leaving an additional 5' phosphate and ⁇ 2 nucleotide 3' overhang.
• the resulting siRNA-like duplex which may comprise mismatches, comprises the mature miRNA and a similar- sized fragment known as the miRNA*.
• the miRNA and miRNA* may be derived from opposing arms of the pri-miRNA and pre-miRNA. miRNA* sequences may be found in libraries of cloned miRNAs but typically at lower frequency than the miRNAs.
• RISC RNA-induced silencing complex
• the miRNA strand of the miRNA:miRNA* duplex When the miRNA strand of the miRNA:miRNA* duplex is loaded into the RISC, the miRNA* is removed and degraded.
• the strand of the miRNA:miRNA* duplex that is loaded into the RISC is the strand whose 5' end is less tightly paired. In cases where both ends of the miRNA:miRNA* have roughly equivalent 5' pairing, both miRNA and miRNA* may have gene silencing activity.
• the RISC identifies target nucleic acids based on high levels of complementarity between the miRNA and the mRNA, especially by nucleotides 2-7 of the miRNA.
• the target sites in the mRNA may be in the 5' UTR, the 3' UTR or in the coding region.
• multiple miRNAs may regulate the same mRNA target by recognizing the same or multiple sites.
• the presence of multiple miRNA binding sites inmost genetically identified targets may indicate that the cooperative action of multiple RISCs provides the most efficient translational inhibition.
• miRNAs may direct the RISC to downregulate gene expression by either of two mechanisms: mRNA cleavage or translational repression.
• the miRNA may specify cleavage of the mRNA if the mRNA has a certain degree of complementarity to the miRNA. When a miRNA guides cleavage, the cut is typically between the nucleotides pairing to residues 10 and 11 of the miRNA.
• the miRNA may repress translation if the miRNA does not have the requisite degree of complementarity to the miRNA. Translational repression may be more prevalent in animals since animals may have a lower degree of complementarity between the miRNA
• any pair of miRNA and miRNA* there may be variability in the 5’ and 3’ ends of any pair of miRNA and miRNA*. This variability may be due to variability in the enzymatic processing of Drosha and Dicer with respect to the site of cleavage. Variability at the 5’ and 3’ ends of miRNA and miRNA* may also be due to mismatches in the stem structures of the pri-miRNA and pre-miRNA. The mismatches of the stem strands may lead to a population of different hairpin structures. Variability in the stem structures may also lead to variability in the products of cleavage by Drosha and Dicer.
• miRNA mimic refers to synthetic non-coding RNAs that are capable of entering the RNAi pathway and regulating gene expression. miRNA mimics imitate the function of endogenous miRNAs and can be designed as mature, double stranded molecules or mimic precursors (e.g., or pre-miRNAs). miRNA mimics can be comprised of modified or unmodified RNA, DNA, RNA-DNA hybrids, or alternative nucleic acid chemistries (e.g., LNAs or 2'-O,4'-C-ethylene-bridged nucleic acids (ENA)).
• nucleic acid chemistries e.g., LNAs or 2'-O,4'-C-ethylene-bridged nucleic acids (ENA)
• the length of the duplex region can vary between 13-33, 18-24 or 21-23 nucleotides.
• the miRNA may also comprise a total of at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39 or 40 nucleotides.
• the sequence of the miRNA may be the first 13-33 nucleotides of the pre-miRNA.
• the sequence of the miRNA may also be the last 13-33 nucleotides of the pre-miRNA.
• Preparation of miRNAs mimics can be effected by any method known in the art such as chemical synthesis or recombinant methods.
• contacting cells with a miRNA may be effected by transfecting the cells with e.g. the mature double stranded miRNA, the pre-miRNA or the pri-miRNA.
• the pre-miRNA sequence may comprise from 45-90, 60-80 or 60-70 nucleotides.
• the pri-miRNA sequence may comprise from 45-30,000, 50-25,000, 100-20,000, 1,000- 1,500 or 80-100 nucleotides.
• Antisense - Antisense is a single stranded RNA designed to prevent or inhibit expression of a gene by specifically hybridizing to its mRNA. Downregulation of a nNOS can be effected using an antisense polynucleotide capable of specifically hybridizing with an mRNA transcript encoding nNOS.
• the first aspect is delivery of the oligonucleotide into the cytoplasm of the appropriate cells
• the second aspect is design of an oligonucleotide which specifically binds the designated mRNA within cells in a way which inhibits translation thereof.
• the prior art teaches of a number of delivery strategies which can be used to efficiently deliver oligonucleotides into a wide variety of cell types [see, for example, Jaaskelainen et al. Cell Mol Biol Lett. (2002) 7(2):236-7; Gait, Cell Mol Life Sci.
• nNOS mRNA which is coding for the nNOS protein
• Nucleic acid agents can also operate at the DNA level as summarized infra.
• Downregulation of nNOS can also be achieved by inactivating the gene (e.g., NOS1) via introducing targeted mutations involving loss-of function alterations (e.g. point mutations, deletions and insertions) in the gene structure.
• NOS1 inactivating the gene
• targeted mutations involving loss-of function alterations e.g. point mutations, deletions and insertions
• loss-of-function alterations refers to any mutation in the DNA sequence of a gene (e.g., NOS1) which results in downregulation of the expression level and/or activity of the expressed product, i.e., the mRNA transcript and/or the translated protein.
• Non- limiting examples of such loss-of-function alterations include amissense mutation, i.e., a mutation which changes an amino acid residue in the protein with another amino acid residue and thereby abolishes the enzymatic activity of the protein; a nonsense mutation, i.e., a mutation which introduces a stop codon in a protein, e.g., an early stop codon which results in a shorter protein devoid of the enzymatic activity; a frame- shift mutation, i.e., a mutation, usually, deletion or insertion of nucleic acid(s) which changes the reading frame of the protein, and may result in an early termination by introducing a stop codon into a reading frame (e.g., a truncated protein, devoid of the enzymatic activity), or in a longer amino acid sequence (e.g., a readthrough protein) which affects the secondary or tertiary structure of the protein and results in a non-functional protein, devoid of the enzymatic activity
• loss-of-function alteration of a gene may comprise at least one allele of the gene.
• allele refers to any of one or more alternative forms of a gene locus, all of which alleles relate to a trait or characteristic. In a diploid cell or organism, the two alleles of a given gene occupy corresponding loci on a pair of homologous chromosomes.
• loss-of-function alteration of a gene comprises both alleles of the gene.
• the e.g. NOS1 may be in a homozygous form or in a heterozygous form.
• homozygosity is a condition where both alleles at the e.g. NOS1 locus are characterized by the same nucleotide sequence.
• Heterozygosity refers to different conditions of the gene at the e.g. NOS1 locus.
• Genome Editing using engineered endonucleases - this approach refers to a reverse genetics method using artificially engineered nucleases to cut and create specific double- stranded breaks at a desired location(s) in the genome, which are then repaired by cellular endogenous processes such as, homology directed repair (HDR) and non-homologous end-joining (NFfEJ).
• HDR homology directed repair
• NFfEJ non-homologous end-joining
• HDR utilizes a homologous sequence as a template for regenerating the missing DNA sequence at the break point.
• a DNA repair template containing the desired sequence must be present during HDR.
• Genome editing cannot be performed using traditional restriction endonucleases since most restriction enzymes recognize a few base pairs on the DNA as their target and the probability is very high that the recognized base pair combination will be found in many locations across the genome resulting in multiple cuts not limited to a desired location.
• restriction enzymes recognize a few base pairs on the DNA as their target and the probability is very high that the recognized base pair combination will be found in many locations across the genome resulting in multiple cuts not limited to a desired location.
• ZFNs Zinc finger nucleases
• TALENs transcription- activator like effector nucleases
• CRISPR/Cas system CRISPR/Cas system
• Meganucleases are commonly grouped into four families: the LAGLIDADG family, the GIY-YIG family, the His-Cys box family and the HNH family. These families are characterized by structural motifs, which affect catalytic activity and recognition sequence. For instance, members of the LAGLIDADG family are characterized by having either one or two copies of the conserved LAGLIDADG motif. The four families of meganucleases are widely separated from one another with respect to conserved structural elements and, consequently, DNA recognition sequence specificity and catalytic activity. Meganucleases are found commonly in microbial species and have the unique property of having very long recognition sequences (>14bp) thus making them naturally very specific for cutting at a desired location.
• Meganucleases can be designed using the methods described in e.g., Certo, MT et al. Nature Methods (2012) 9:073-975; U.S. Patent Nos. 8,304,222; 8,021,867; 8, 119,381; 8, 124,369; 8, 129,134; 8,133,697; 8,143,015; 8,143,016; 8, 148,098; or 8, 163,514, the contents of each are incorporated herein by reference in their entirety.
• meganucleases with site specific cutting characteristics can be obtained using commercially available technologies e.g., Precision Biosciences' Directed Nuclease EditorTM genome editing technology.
• ZFNs and TALENs Two distinct classes of engineered nucleases, zinc-finger nucleases (ZFNs) and transcription activator-like effector nucleases (TALENs), have both proven to be effective at producing targeted double- stranded breaks (Christian et al., 2010; Kim etal., 1996; Li etal., 2011; Mahfouz etal., 2011; Miller et al., 2010).
• ZFNs and TALENs restriction endonuclease technology utilizes a non-specific DNA cutting enzyme which is linked to a specific DNA binding domain (either a series of zinc finger domains or TALE repeats, respectively).
• a restriction enzyme whose DNA recognition site and cleaving site are separate from each other is selected. The cleaving portion is separated and then linked to a DNA binding domain, thereby yielding an endonuclease with very high specificity for a desired sequence.
• An exemplary restriction enzyme with such properties is Fokl. Additionally Fold has the advantage of requiring dimerization to have nuclease activity and this means the specificity increases dramatically as each nuclease partner recognizes a unique DNA sequence.
• Fold nucleases have been engineered that can only function as heterodimers and have increased catalytic activity.
• the heterodimer functioning nucleases avoid the possibility of unwanted homodimer activity and thus increase specificity of the double- stranded break.
• ZFNs and TALENs are constructed as nuclease pairs, with each member of the pair designed to bind adjacent sequences at the targeted site.
• the nucleases bind to their target sites and the Fokl domains heterodimerize to create a double- stranded break. Repair of these double- stranded breaks through the nonhomologous end-joining (NHEJ) pathway most often results in small deletions or small sequence insertions. Since each repair made by NHEJ is unique, the use of a single nuclease pair can produce an allelic series with a range of different deletions at the target site.
• NHEJ nonhomologous end-joining
• deletions typically range anywhere from a few base pairs to a few hundred base pairs in length, but larger deletions have successfully been generated in cell culture by using two pairs of nucleases simultaneously (Carlson et al., 2012; Lee et al., 2010).
• the double- stranded break can be repaired via homology directed repair to generate specific modifications (Li etal., 2011; Miller et al., 2010; Urnov etal., 2005).
• ZFNs rely on Cys2- His2 zinc fingers and TALENs on TALEs. Both of these DNA recognizing peptide domains have the characteristic that they are naturally found in combinations in their proteins. Cys2-His2 Zinc fingers typically found in repeats that are 3 bp apart and are found in diverse combinations in a variety of nucleic acid interacting proteins. TALEs on the other hand are found in repeats with a one-to-one recognition ratio between the amino acids and the recognized nucleotide pairs.
• Zinc fingers correlated with a triplet sequence are attached in a row to cover the required sequence
• OPEN low- stringency selection of peptide domains vs. triplet nucleotides followed by high- stringency selections of peptide combination vs. the final target in bacterial systems
• ZFNs can also be designed and obtained commercially from e.g., Sangamo BiosciencesTM (Richmond, CA).
• TALEN Method for designing and obtaining TALENs are described in e.g. Reyon et al. Nature Biotechnology 2012 May;30(5):460-5; Miller et al. Nat Biotechnol. (2011) 29: 143-148; Cermak et al. Nucleic Acids Research (2011) 39 (12): e82 and Zhang et al. Nature Biotechnology (2011) 29 (2): 149-53.
• a recently developed web-based program named Mojo Hand was introduced by Mayo Clinic for designing TAL and TALEN constructs for genome editing applications (can be accessed through www(dot)talendesign(dot)org).
• TALEN can also be designed and obtained commercially from e.g., Sangamo BiosciencesTM (Richmond, CA).
• ZFIN commercializes (among other vendors) nNOS specific Talen editing tools (ZDB- TALEN-181 1 14-1 ).
• CRISPR-Cas system Many bacteria and archea contain endogenous RNA-based adaptive immune systems that can degrade nucleic acids of invading phages and plasmids. These systems consist of clustered regularly interspaced short palindromic repeat (CRISPR) genes that produce RNA components and CRISPR associated (Cas) genes that encode protein components.
• CRISPR clustered regularly interspaced short palindromic repeat
• Cas CRISPR associated genes that encode protein components.
• the CRISPR RNAs (crRNAs) contain short stretches of homology to specific viruses and plasmids and act as guides to direct Cas nucleases to degrade the complementary nucleic acids of the corresponding pathogen.
• RNA/protein complex RNA/protein complex and together are sufficient for sequence- specific nuclease activity: the Cas9 nuclease, a crRNA containing 20 base pairs of homology to the target sequence, and a trans-activating crRNA (tracrRNA) (Jinek et al. Science (2012) 337: 816-821.). It was further demonstrated that a synthetic chimeric guide RNA (gRNA) composed of a fusion between crRNA and tracrRNA could direct Cas9 to cleave DNA targets that are complementary to the crRNA in vitro.
• gRNA synthetic chimeric guide RNA
• transient expression of Cas9 in conjunction with synthetic gRNAs can be used to produce targeted double- stranded brakes in a variety of different species (Cho etal., 2013; Cong et al., 2013; DiCarlo et al., 2013; Hwang et al., 2013a, b; Jinek et al., 2013; Mali et al., 2013).
• the CRIPSR/Cas system for genome editing contains two distinct components: a gRNA and an endonuclease e.g. Cas9.
• the gRNA is typically a 20 nucleotide sequence encoding a combination of the target homologous sequence (crRNA) and the endogenous bacterial RNA that links the crRNA to the Cas9 nuclease (tracrRNA) in a single chimeric transcript.
• the gRNA/Cas9 complex is recruited to the target sequence by the base-pairing between the gRNA sequence and the complement genomic DNA.
• the genomic target sequence must also contain the correct Protospacer Adjacent Motif (PAM) sequence immediately following the target sequence.
• PAM Protospacer Adjacent Motif
• the binding of the gRNA/Cas9 complex localizes the Cas9 to the genomic target sequence so that the Cas9 can cut both strands of the DNA causing a double-strand break.
• the double- stranded brakes produced by CRISPR/Cas can undergo homologous recombination or NHEJ.
• the Cas9 nuclease has two functional domains: RuvC and HNH, each cutting a different DNA strand. When both of these domains are active, the Cas9 causes double strand breaks in the genomic DNA.
• CRISPR/Cas A significant advantage of CRISPR/Cas is that the high efficiency of this system coupled with the ability to easily create synthetic gRNAs enables multiple genes to be targeted simultaneously. In addition, the majority of cells carrying the mutation present biallelic mutations in the targeted genes.
• nickases Modified versions of the Cas9 enzyme containing a single inactive catalytic domain, either RuvC- or HNH-, are called ‘nickases’. With only one active nuclease domain, the Cas9 nickase cuts only one strand of the target DNA, creating a single- strand break or 'nick'. A single- strand break, or nick, is normally quickly repaired through the HDR pathway, using the intact complementary DNA strand as the template.
• a Cas9 nickase two proximal, opposite strand nicks introduced by a Cas9 nickase are treated as a double- strand break, in what is often referred to as a 'double nick' CRISPR system
• a double-nick can be repaired by either NHEJ or HDR depending on the desired effect on the gene target.
• using the Cas9 nickase to create a double-nick by designing two gRNAs with target sequences in close proximity and on opposite strands of the genomic DNA would decrease off- target effect as either gRNA alone will result in nicks that will not change the genomic DNA.
• dCas9 Modified versions of the Cas9 enzyme containing two inactive catalytic domains
• dCas9 can be utilized as a platform for DNA transcriptional regulators to activate or repress gene expression by fusing the inactive enzyme to known regulatory domains.
• the binding of dCas9 alone to a target sequence in genomic DNA can interfere with gene transcription.
• NOS1 CRISPR sgRNA+Cas9 as ready-to-use knockout vector or virus:
• Cas9 Proteins Cas9 Nuclease Vector/Virus, Cas9-Expressing Cell Fines also available.
• Synthego CRISPR Products for NOS1 DIY CRISPR Kits: Gene Knockout Kit, Synthetic sgRNA, Cas9 / Engineered Cells: Immortalized KO Pools, KO Clones, iPSC KO, iPSC KI / Free Bioinformatics Tools: CRISPR Knockout Design Tool, CRISPR Analysis Tool VectorBuilder CRISPR vectors for NOS 1 (ie. knockout, knockin, CRISPRa, CRISPRi) VectorBuilder Virus packaging for NOS1 CRISPR vectors (ie. lentivirus, AAV, adenovirus)
• NOS1 ZCRISPR plasmid (h) for the human target is available from Santa-Cruz as well as from other vendors
• both gRNA and Cas9 should be expressed in a target cell.
• the insertion vector can contain both cassettes on a single plasmid or the cassettes are expressed from two separate plasmids.
• CRISPR plasmids are commercially available such as the px330 plasmid from Addgene.
• “Hit and run” or “in-out” - involves a two-step recombination procedure.
• an insertion-type vector containing a dual positive/negative selectable marker cassette is used to introduce the desired sequence alteration.
• the insertion vector contains a single continuous region of homology to the targeted locus and is modified to carry the mutation of interest.
• This targeting construct is linearized with a restriction enzyme at a one site within the region of homology, electroporated into the cells, and positive selection is performed to isolate homologous recombinants. These homologous recombinants contain a local duplication that is separated by intervening vector sequence, including the selection cassette.
• targeted clones are subjected to negative selection to identify cells that have lost the selection cassette via intrachromosomal recombination between the duplicated sequences.
• the local recombination event removes the duplication and, depending on the site of recombination, the allele either retains the introduced mutation or reverts to wild type. The end result is the introduction of the desired modification without the retention of any exogenous sequences.
• the “double-replacement” or “tag and exchange” strategy - involves a two-step selection procedure similar to the hit and run approach, but requires the use of two different targeting constructs.
• a standard targeting vector with 3' and 5' homology arms is used to insert a dual positive/negative selectable cassette near the location where the mutation is to be introduced.
• homologously targeted clones are identified.
• a second targeting vector that contains a region of homology with the desired mutation is electroporated into targeted clones, and negative selection is applied to remove the selection cassette and introduce the mutation.
• the final allele contains the desired mutation while eliminating unwanted exogenous sequences.
• Site-Specific Recombinases The Cre recombinase derived from the PI bacteriophage and Flp recombinase derived from the yeast Saccharomyces cerevisiae are site-specific DNA recombinases each recognizing a unique 34 base pair DNA sequence (termed “Lox” and “FRT”, respectively) and sequences that are flanked with either Lox sites or FRT sites can be readily removed via site- specific recombination upon expression of Cre or Flp recombinase, respectively.
• the Lox sequence is composed of an asymmetric eight base pair spacer region flanked by 13 base pair inverted repeats.
• Cre recombines the 34 base pair lox DNA sequence by binding to the 13 base pair inverted repeats and catalyzing strand cleavage and religation within the spacer region.
• the staggered DNA cuts made by Cre in the spacer region are separated by 6 base pairs to give an overlap region that acts as a homology sensor to ensure that only recombination sites having the same overlap region recombine.
• the site specific recombinase system offers means for the removal of selection cassettes after homologous recombination. This system also allows for the generation of conditional altered alleles that can be inactivated or activated in a temporal or tissue- specific manner.
• the Cre and Flp recombinases leave behind a Lox or FRT “scar” of 34 base pairs. The Lox or FRT sites that remain are typically left behind in an intron or 3' UTR of the modified locus, and current evidence suggests that these sites usually do not interfere significantly with gene function.
• Cre/Lox and Flp/FRT recombination involves introduction of a targeting vector with 3' and 5' homology arms containing the mutation of interest, two Lox or FRT sequences and typically a selectable cassette placed between the two Lox or FRT sequences. Positive selection is applied and homologous recombinants that contain targeted mutation are identified. Transient expression of Cre or Flp in conjunction with negative selection results in the excision of the selection cassette and selects for cells where the cassette has been lost. The final targeted allele contains the Lox or FRT scar of exogenous sequences.
• Transposases refers to an enzyme that binds to the ends of a transposon and catalyzes the movement of the transposon to another part of the genome.
• transposon refers to a mobile genetic element comprising a nucleotide sequence which can move around to different positions within the genome of a single cell. In the process the transposon can cause mutations and/or change the amount of a DNA in the genome of the cell.
• transposon systems that are able to also transpose in cells e.g. vertebrates have been isolated or designed, such as Sleeping Beauty [Izsvak and Ivies Molecular Therapy (2004) 9, 147-156] , piggyBac [Wilson et al. Molecular Therapy (2007) 15, 139-145], Tol2 [Kawakami et al. PNAS (2000) 97 (21): 11403-11408] or Frog Prince [Miskey et al. Nucleic Acids Res. Dec 1, (2003) 31(23): 6873-6881].
• DNA transposons translocate from one DNA site to another in a simple, cut-and-paste manner.
• PB is a 2.5 kb insect transposon originally isolated from the cabbage looper moth, Trichoplusia ni.
• the PB transposon consists of asymmetric terminal repeat sequences that flank a transposase, PBase.
• PBase recognizes the terminal repeats and induces transposition via a “cut- and-paste” based mechanism, and preferentially transposes into the host genome at the tetranucleotide sequence TTAA.
• the TTAA target site is duplicated such that the PB transposon is flanked by this tetranucleotide sequence.
• PB When mobilized, PB typically excises itself precisely to reestablish a single TTAA site, thereby restoring the host sequence to its pretransposon state. After excision, PB can transpose into a new location or be permanently lost from the genome.
• the transposase system offers an alternative means for the removal of selection cassettes after homologous recombination quit similar to the use Cre/Lox or Flp/FRT.
• the PB transposase system involves introduction of a targeting vector with 3' and 5' homology arms containing the mutation of interest, two PB terminal repeat sequences at the site of an endogenous TTAA sequence and a selection cassette placed between PB terminal repeat sequences. Positive selection is applied and homologous recombinants that contain targeted mutation are identified.
• Transient expression of PBase removes in conjunction with negative selection results in the excision of the selection cassette and selects for cells where the cassette has been lost.
• the final targeted allele contains the introduced mutation with no exogenous sequences.
• Genome editing using recombinant adeno- associated virus (rAAV) platform is based on rAAV vectors which enable insertion, deletion or substitution of DNA sequences in the genomes of live mammalian cells.
• the rAAV genome is a single- stranded deoxyribonucleic acid (ssDNA) molecule, either positive- or negative- sensed, which is about 4.7 kb long.
• ssDNA deoxyribonucleic acid
• These single- stranded DNA viral vectors have high transduction rates and have a unique property of stimulating endogenous homologous recombination in the absence of double-strand DNA breaks in the genome.
• rAAV genome editing has the advantage in that it targets a single allele and does not result in any off- target genomic alterations.
• rAAV genome editing technology is commercially available, for example, the rAAV GENESISTM system from HorizonTM (Cambridge, UK).
• the agent can be a mutagen that causes random mutations and the cells exhibiting downregulation of the expression level and/or activity of nNOS may be selected.
• the mutagens may be, but are not limited to, genetic, chemical or radiation agents.
• the mutagen may be ionizing radiation, such as, but not limited to, ultraviolet light, gamma rays or alpha particles.
• Other mutagens may include, but not be limited to, base analogs, which can cause copying errors; deaminating agents, such as nitrous acid; intercalating agents, such as ethidium bromide; alkylating agents, such as bromouracil; transposons; natural and synthetic alkaloids; bromine and derivatives thereof; sodium azide; psoralen (for example, combined with ultraviolet radiation).
• the mutagen may be a chemical mutagen such as, but not limited to, ICR191, 1,2,7,8-diepoxy-octane (DEO), 5-azaC, N-methyl-N-nitrosoguanidine (MNNG) or ethyl methane sulfonate (EMS).
• DEO 1,2,7,8-diepoxy-octane
• MNNG N-methyl-N-nitrosoguanidine
• EMS ethyl methane sulfonate
• Methods for qualifying efficacy and detecting sequence alteration include, but not limited to, DNA sequencing, electrophoresis, an enzyme-based mismatch detection assay and a hybridization assay such as PCR, RT-PCR, RNase protection, in-situ hybridization, primer extension, Southern blot, Northern Blot and dot blot analysis.
• Sequence alterations in a specific gene can also be determined at the protein level using e.g. chromatography, electrophoretic methods, immunodetection assays such as ELISA and western blot analysis and immunohistochemistry.
• knock-in/knock-out construct including positive and/or negative selection markers for efficiently selecting transformed cells that underwent a homologous recombination event with the construct.
• Positive selection provides a means to enrich the population of clones that have taken up foreign DNA.
• positive markers include glutamine synthetase, dihydrofolate reductase (DHFR), markers that confer antibiotic resistance, such as neomycin, hygromycin, puromycin, and blasticidin S resistance cassettes.
• Negative selection markers are necessary to select against random integrations and/or elimination of a marker sequence (e.g. positive marker).
• Non-limiting examples of such negative markers include the herpes simplex-thymidine kinase (HSV-TK) which converts ganciclovir (GCV) into a cytotoxic nucleoside analog, hypoxanthine phosphoribosyltransferase (HPRT) and adenine phosphoribosytransferase (ARPT).
• HSV-TK herpes simplex-thymidine kinase
• GCV ganciclovir
• HPRT hypoxanthine phosphoribosyltransferase
• ARPT adenine phosphoribosytransferase
• Modified nucleic acids including modified DNA or RNA molecules, may be used in the in place of naturally occurring nucleic acids in the polynucleotides described herein. Modified nucleic acids can improve the half-life, stability, specificity, delivery, solubility, and nuclease resistance of the polynucleotides described herein.
• siRNA agents can be partially or completed composed of nucleotide analogs that confer the beneficial qualities described above.
• synthetic, RNA-like nucleotide analogs e.g., locked nucleic acids (LNA)
• LNA locked nucleic acids
• Modified nucleic acids include molecules in which one or more of the components of the nucleic acid, namely sugars, bases, and phosphate moieties, are different from that which occurs in nature, preferably different from that which occurs in the human body.
• Nucleoside surrogates are molecules in which the ribophosphate backbone is replaced with a non- ribophosphate construct that allows the bases to the presented in the correct spatial relationship such that hybridization is substantially similar to what is seen with a ribophosphate backbone, e.g., non-charged mimics of the ribophosphate backbone.
• Modifications can be incorporated into any double- stranded RNA (e.g., any RNAi agent (e.g., siRNA, shRNA, dsRNA, or miRNA), RNA-like, DNA, and DNA-like molecules. It may be desirable to modify one or both of the antisense and sense strands of a polynucleotide.
• RNAi agent e.g., siRNA, shRNA, dsRNA, or miRNA
• the modification will occur at all of the subject positions in the nucleic acid but in many, and in fact in most, cases it will not.
• a modification may only occur at a 3' or 5' terminal position, may only occur in a terminal region, e.g., at a position on a terminal nucleotide or in the last 2, 3, 4, 5, or 10 nucleotides of a strand.
• a modification may occur in a double strand region, a single strand region, or in both.
• a phosphorothioate modification at a non-linking O position may only occur at one or both termini, may only occur in terminal regions, e.g., at a position on a terminal nucleotide or in the last 2, 3, 4, 5, or 10 nucleotides of a strand, or may occur in double strand and single strand regions, particularly at termini.
• a modification may occur on the sense strand, antisense strand, or both.
• the sense and antisense strand will have the same modifications or the same class of modifications, but in other cases the sense and antisense strand will have different modifications, e.g., in some cases it may be desirable to modify only one strand, e.g., the sense strand.
• a polynucleotide can include a non-naturally occurring base, such as the bases described in PCT Publication No. WO 2004/094345, hereby incorporated by reference.
• a polynucleotide can include a non-naturally occurring sugar, such as a non-carbohydrate cyclic carrier molecule. Exemplary features of non-naturally occurring sugars for use in the polynucleotides described herein are described in PCT Publication No. WO 2004/094595, hereby incorporated by reference.
• any of the polynucleotides described herein can include an internucleotide linkage (e.g., the chiral phosphorothioate linkage) useful for increasing nuclease resistance.
• a polynucleotide can include a ribose mimic for increased nuclease resistance.
• Exemplary internucleotide linkages and ribose mimics for increased nuclease resistance are described in U.S. Patent Application Publication No. 2005/0164235.
• Any polynucleotide described herein can include ligand-conjugated monomer subunits and monomers for oligonucleotide synthesis. Exemplary monomers are described in U.S. Patent Application Publication No. 2005/0107325.
• Any polynucleotide can have a ZXY structure, such as is described in U.S. Patent Application Publication No. 2005/0164235.
• Any polynucleotide can be complexed with an amphipathic moiety.
• amphipathic moieties for use with RNAi agents are described in U.S. Patent Application Publication No. 2005/0164235.
• the DNA sequence coding for the antisense or iRNA under a suitable control element (promoter) promotor is delivered to the subject.
• the expression control element is it is a universal promotor, such as CMV and UlsnRNA.
• the expression regulatory element is a neuron specific promoter so that expression takes place only in neurons giving the sequence expresses (antisense) selectivity to neurons.
• neuron-specific promotors are: synapsin I promoter Camkn, MeCP2, NSE and Hb9.
• the sequences can be delivered to the CNS by delivery to the brain (see below) and preferably by use of viral delivery system.
• a preferred embodiment is by adeno- associated virus (AAV) and in particular by adeno- associated virus of serotype 9 (AAV9) delivery that has become a preferred vector for CNS delivery, due to its increased ability to cross the blood- brain barrier compared to other AAV serotypes.
• Additional viral delivery systems are Lentivirus and herpes simplex viruses.
• the agent capable of downregulating nNOS is an antibody or antibody fragment capable of specifically binding nNOS.
• the antibody specifically binds at least one epitope of nNOS.
• epitope refers to any antigenic determinant on an antigen to which the paratope of an antibody binds.
• Epitopic determinants usually consist of chemically active surface groupings of molecules such as amino acids or carbohydrate side chains and usually have specific three-dimensional structural characteristics, as well as specific charge characteristics.
• an antibody or antibody fragment capable of specifically binding nNOS is typically an intracellular antibody.
• Intracellular antibodies which may also be called intrabodies, are antibodies that are produced in the cell, and bind an antigen within the same cell.
• the full-length antibody is not functional in the cytosol, prior to secretion, due to its reducing conditions, which affect protein folding and the intramolecular disulfide bonds that are required to maintain the antibody’s conformation and stability.
• the complementarity- determining regions that endow an antibody with its exceptional target specificity are located in the variable regions of both the heavy and light chains. Therefore, it is possible to use antibody fragments incorporating the specificity-providing regions within a single-chain variable fragment (scFv), which can be further engineered for cytosolic stability, to target intracellular antigens (in this case nNOS).
• scFv is a single polypeptide, which is a favorable characteristic for in vivo expression, and it has been studied as a therapeutic for viral infections and cancer, among other diseases.
• variable (V) region domain can be used by itself to form a domain antibody or Dab.
• Dab domain antibody
• These can be engineered from conventional human Igs, or also from those from camelids (camel or llama) and cartilaginous fish (carpet or nurse sharks), whose immune systems were found to have evolved high-affinity V-like domains fused to a conserved framework that is reflective of the constant Fc region found inhuman Ig. It has been reported that single heavy chain V regions or light chain V regions can be expressed inside cells. These are referred to as intracellular domain antibodies, which do not require intramolecular disulfide bonds for stability, hence representing the smallest format of the antibody that retains target specificity while minimizing size - a crucial factor for intracellular targeting.
• the intrabody comprises a signal for ER targeting to cause degradation of the target protein, antibody-antigen interaction- dependent apoptosis that is used to induce programmed cell death through the activation of caspases, and suicide intrabody technology that causes proteolysis of the target protein.
• nNOS specific antibodies are well known in the art. These can be used to prepare antibody fragments and intrabodies for acting in the brain cells (e.g., neurons).
• Examples of such antibodies include, but are not limited to 37-2800 by Thermo Lisher, EP1855Y and EPR 24351-6 by abeam.
• aptamer refers to double stranded or single stranded RNA molecule that binds to specific molecular target, such as a protein.
• Various methods are known in the art which can be used to design protein specific aptamers. The skilled artisan can employ SELEX (Systematic Evolution of Ligands by Exponential Enrichment) for efficient selection as described in Stoltenburg R, Reinemann C, and Strehlitz B (Biomolecular engineering (2007) 24(4):381-403).
• SELEX Systematic Evolution of Ligands by Exponential Enrichment
• Another contemplated agent which can be used to downregulate any of the above described proteins includes a proteolysis-targeting chimaera (PROTAC).
• PROTAC proteolysis-targeting chimaera
• Such agents are heterobifunctional, comprising a ligand which binds to a ubiquitin ligase (such as E3 ubiquitin ligase) and a ligand to one of the above described proteins (nNOS) and optionally a linker connecting the two ligands. Binding of the PROTAC to the target protein leads to the ubiquitination of an exposed lysine on the target protein, followed by ubiquitin proteasome system (UPS)-mediated protein degradation.
• UPS ubiquitin proteasome system
• nNOS non-functional analogue of at least a catalytic or binding portion of nNOS can be also used as an agent which downregulates nNOS because it acts as a homodimer.
• the agent is an amino acid-based agent also referred to as an amino acid based inhibitor.
• the agent is PIN or nitric oxide synthase interacting protein (NOSIP).
• nNOS N-terminus of nNOS could bind to a protein termed PIN which can inhibit nNOS activity. It is found that PIN destabilizes nNOS dimers and inhibits nNOS activity. Recently, it has been demonstrated that PIN inhibits production of NO and 02, not nNOS dimerization.
• NOSIP nitric oxide synthase interacting protein
• small molecule or peptides can be used which interfere with nNOS protein function (e.g., catalytic or interaction).
• Another agent which can be used along with some embodiments of the invention to downregulate nNOS is a molecule which prevents nNOS activation or substrate binding.
• the agent binds to an active site of nNOS and blocks substrate binding.
• Various amino acids define the active site of nNOS. These include, for example, Phenylalanine 589, Tryptophan 592, Tyrosine 593, Glutamate 597, Aspartate 602, Arginine 601, Methionine 341, Histidine 342,
• small molecules that are inhibitors of the neuronal NO synthase can be used as the active agents.
• a non-limiting example is /V“-Nitroargininc, which is well known to be a potent competitive inhibitor of nNOS that binds to the active site of the enzyme and blocks substrate binding, but it shows little selectivity over eNOS.
• Arginine analogs for instance can be used as nNOS competitive inhibitors.
• nNOS inhibitors that can be used in accordance with the invention include, but are not limited to, 7-nitro-indazole (7-NI), L- N G - Methyl- L- arginine (L-NMMA), L-N & Propyl-L- arginine (N-PLA), L-N G -Nitroarginine (L-NNA), L-N G -Nitroarginine methyl ester (L-NAME), L- Thiocitrulline, S-Methyl-L-Thiocitrulline, S-Methyl-L- Thiocitrulline, Ethyl-L-NIO, Vinyl-L- NIO, 7-NI-Br (3-Bromo-7-nitroindazole), and Methylene blue.
• 7-NI 7-nitro-indazole
• L-NMMA Methyl- L- argin
• Inhibitors available from ApexBio as well as other vendors include, but are not limited to (S)-Methylisothiourea sulfate, 1400W dihydrochloride, 2,4-Diamino-6-hydroxypyrimidine, 2- Iminopiperidine hydrochloride and 3-Bromo-7-nitroindazole.
• the agent (or selective nNOS inhibitor) is JI-8 (cis-N'-[4-6- amino-(4-methylpyridin-2-yl methyl)pyrrolidin-3-yl] -N 2 - [2-(3 ’ ’ -fluorophenyl) ethyl]ethane- 1 ,2- diamine) and structural analogs thereof such as described, for example, in Yu et al., Dev Neurosci. 2011 Oct; 33(3-4): 312-319; Ji et al .,Ann Neurol. 2009b;65:209-217; and Ji et al, J Am Chem Soc. 2008;130:3900-3914, which are incorporated by reference as if fully set forth herein.
• the agent is N ⁇ -Nitroargininc.
• the agent reduces a level of an NO precursor.
• the agent increases a level of GSNO reductase level, thereby reducing the level of the NO precursor.
• U.S. 20200222714 discloses a phototherapy for the inhibition of nNOS activity.
• the nNOS inhibitor (the agent) is 7-NI, including structural analogs thereof.
• R 1 is selected from hydrogen, alkyl and cycloalkyl and is preferably hydrogen; and R 2 -R 5 are each independently selected from hydrogen, alkyl, cycloalkyl, aryl, heteroalicyclic, heteroaryl, halo, haloalkyl, hydroxy, alkoxy, aryloxy, thiol, amine, carboxylate, thiocarboxylate, a poly(alkylene glycol moiety), a monosaccharide, a disaccharide, and an oligosaccharide.
• one of R 2 -R 5 is halo, including fluoro, chloro, bromo, and iodo, and is preferably bromo.
• R2 is halo, preferably bromo.
• Such a compound is known as Br-7-NI.
• each of R 2 -R 5 is hydrogen.
• Such a compound is known and is referred to herein as 7-nitro-indazole (7-NI).
• compounds represented by Formula I act as nNOS inhibitors, preferably as selective nNOS inhibitors, as defined herein.
• compounds represented by Formula I are in a form of pharmaceutically acceptable salts thereof.
• the phrase “pharmaceutically acceptable salt” refers to a charged species of the parent compound and its counter-ion, which is typically used to modify the solubility characteristics of the parent compound and/or to reduce any significant irritation to an organism by the parent compound, while not abrogating the biological activity and properties of the administered compound.
• a pharmaceutically acceptable salt of a compound as described herein can alternatively be formed during the synthesis of the compound, e.g., in the course of isolating the compound from a reaction mixture or re-crystallizing the compound.
• a pharmaceutically acceptable salt of the compounds described herein may optionally be an acid addition salt and/or a base addition salt.
• An acid addition salt comprises at least one basic (e.g., amine and/or guanidinyl) group of the compound which is in a positively charged form (e.g., wherein the basic group is protonated), in combination with at least one counter-ion, derived from the selected acid, that forms a pharmaceutically acceptable salt.
• the acid addition salts of the compounds described herein may therefore be complexes formed between one or more basic groups of the compound and one or more equivalents of an acid.
• a base addition salt comprises at least one acidic group of the compound which is in a negatively charged form (e.g., wherein the acidic group is deprotonated), in combination with at least one counter-ion, derived from the selected base, that forms a pharmaceutically acceptable salt.
• the base addition salts of the compounds described herein may therefore be complexes formed between one or more acidic groups of the compound and one or more equivalents of a base.
• the acid additions salts and/or base addition salts can be either mono-addition salts or poly- addition salts.
• addition salt refers to a salt in which the stoichiometric ratio between the counter-ion and charged form of the compound is 1:1, such that the addition salt includes one molar equivalent of the counter-ion per one molar equivalent of the compound.
• poly- addition salt refers to a salt in which the stoichiometric ratio between the counter-ion and the charged form of the compound is greater than 1:1 and is, for example, 2: 1, 3: 1, 4: 1 and so on, such that the addition salt includes two or more molar equivalents of the counter-ion per one molar equivalent of the compound.
• a pharmaceutically acceptable salt would be an ammonium cation and an acid addition salt thereof, which is also referred to herein as an anionic salt, and/or a deprotonated amine and a base addition salt thereof, which is also referred to herein as a cationic salt.
• the base addition salts may include a cation counter-ion such as sodium, potassium, ammonium, calcium, magnesium and the like, that forms a pharmaceutically acceptable salt.
• a cation counter-ion such as sodium, potassium, ammonium, calcium, magnesium and the like.
• Exemplary such cationic salts are described in further detail hereinunder and in the Examples section that follows.
• the acid addition salts may include a variety of organic and inorganic acids, such as, but not limited to, hydrochloric acid which affords a hydrochloric acid addition salt, hydrobromic acid which affords a hydrobromic acid addition salt, acetic acid which affords an acetic acid addition salt, ascorbic acid which affords an ascorbic acid addition salt, benzenesulfonic acid which affords a besylate addition salt, camphorsulfonic acid which affords a camphorsulfonic acid addition salt, citric acid which affords a citric acid addition salt, maleic acid which affords a maleic acid addition salt, malic acid which affords a malic acid addition salt, methanesulfonic acid which affords a methanesulfonic acid (mesylate) addition salt, naphthalenesulfonic acid which affords a naphthalenesulfonic acid addition salt, oxalic acid which affords an oxalic acid addition salt,
• agent e.g., nNOS inhibitor
• nNOS inhibitor as described herein in any of the respective embodiments can be administered to an organism per se, or in a pharmaceutical composition where it is mixed with suitable carriers or excipients.
• a "pharmaceutical composition” refers to a preparation of one or more of the active ingredients described herein with other chemical components such as physiologically suitable carriers and excipients.
• the purpose of a pharmaceutical composition is to facilitate administration of a compound to an organism.
• active ingredient refers to the agent accountable for the biological effect.
• active ingredient active ingredient
• active agent therapeutically active agent
• physiologically acceptable carrier and “pharmaceutically acceptable carrier” which may be interchangeably used refer to a carrier or a diluent that does not cause significant irritation to an organism and does not abrogate the biological activity and properties of the administered compound.
• An adjuvant is included under these phrases.
• excipient refers to an inert substance added to a pharmaceutical composition to further facilitate administration of an active ingredient.
• excipients include calcium carbonate, calcium phosphate, various sugars and types of starch, cellulose derivatives, gelatin, vegetable oils and polyethylene glycols. Techniques for formulation and administration of drugs may be found in “Remington’ s Pharmaceutical Sciences,” Mack Publishing Co., Easton, PA, latest edition, which is incorporated herein by reference.
• Suitable routes of administration may, for example, include oral, rectal, transmucosal, especially transnasal, intestinal or parenteral delivery, including intramuscular, subcutaneous and intramedullary injections as well as intrathecal, direct intraventricular, intracardiac, e.g., into the right or left ventricular cavity, into the common coronary artery, intravenous, intraperitoneal, intranasal, or intraocular injections.
• neurosurgical strategies e.g., intracerebral injection or intracerebroventricular infusion
• molecular manipulation of the agent e.g., production of a chimeric fusion protein that comprises a transport peptide that has an affinity for an endothelial cell surface molecule in combination with an agent that is itself incapable of crossing the BBB
• pharmacological strategies designed to increase the lipid solubility of an agent (e.g., conjugation of water-soluble agents to lipid or cholesterol carriers)
• the transitory disruption of the integrity of the BBB by hyperosmotic disruption resulting from the infusion of a mannitol solution into the carotid artery or the use of a biologically active agent such as an angiotensin peptide).
• each of these strategies has limitations, such as the inherent risks associated with an invasive surgical procedure, a size limitation imposed by a limitation inherent in the endogenous transport systems, potentially undesirable biological side effects associated with the systemic administration of a chimeric molecule comprised of a carrier motif that could be active outside of the CNS, and the possible risk of brain damage within regions of the brain where the BBB is disrupted, which renders it a suboptimal delivery method.
• tissue refers to part of an organism consisting of cells designed to perform a function or functions. Examples include, but are not limited to, brain tissue.
• compositions of some embodiments of the invention may be manufactured by processes well known in the art, e.g., by means of conventional mixing, dissolving, granulating, dragee- making, levigating, emulsifying, encapsulating, entrapping or lyophilizing processes.
• compositions for use in accordance with some embodiments of the invention thus may be formulated in conventional manner using one or more physiologically acceptable carriers comprising excipients and auxiliaries, which facilitate processing of the active ingredients into preparations which, can be used pharmaceutically. Proper formulation is dependent upon the route of administration chosen.
• the present teachings also contemplate the use of delivery vehicles dependent on the chemical structure of the active agent (i.e., nNOS inhibitor).
• Delivery vehicles i.e., carriers such as liposomes, nanocapsules, microparticles, microspheres, lipid particles, vesicles, and the like can be used to deliver the nucleic acid molecules described herein.
• liposomes The formation and use of liposomes is generally known to those of skill in the art. Recently, liposomes were developed with improved serum stability and circulation half-times (U.S. Pat. No. 5,741,516). Further, various methods of liposome and liposome like preparations as potential drug carriers have been described (U.S. Pat. Nos. 5,567,434; 5,552,157; 5,565,213; 5,738,868; and 5,795,587).
• Liposomes have been used successfully with a number of cell types that are normally resistant to transfection by other procedures. In addition, liposomes are free of the DNA length constraints that are typical of viral-based delivery systems. Liposomes have been used effectively to introduce genes, drugs, radiotherapeutic agents, viruses, transcription factors and allosteric effectors into a variety of cultured cell lines and animals. In addition, several successful clinical trials examining the effectiveness of liposome-mediated drug delivery have been completed.
• Liposomes are formed from phospholipids that are dispersed in an aqueous medium and spontaneously form multilamellar concentric bilayer vesicles (also termed multilamellar vesicles (MLVs).
• MLVs generally have diameters of from 25 nm to 4 urn. Sonication of MLVs results in the formation of small unilamellar vesicles (SUVs) with diameters in the range of 200 to 500 ANG, containing an aqueous solution in the core.
• SUVs small unilamellar vesicles
• Nanocapsule or nanoparticle formulations may be used.
• Nanocapsules can generally entrap substances in a stable and reproducible way. Nanoparticles can be used to transport drugs through the BBB when administered intravenously as well as the factors that influence its transportation.
• NPs are colloidal carriers that can have a natural or synthetic origin and can vary from 1 to 1000 nm in size.
• Synthetic NPs may be prepared from polymeric materials such as poly(ethylenimine) (PEI), poly(alkylcyanoacrylates), poly(amidoamine) dendrimers (PAMAM), poly( ⁇ -caprolactone) (PCL), poly(lactic-co-glycolic acid) (PLGA), polyesters (poly(lactic acid) (PLA), or from inorganic materials such as gold, silicon dioxide (silica), among others.
• PPI poly(ethylenimine)
• PAMAM poly(alkylcyanoacrylates)
• PAMAM poly(amidoamine) dendrimers
• PCL poly( ⁇ -caprolactone)
• PCL poly(lactic-co-glycolic acid)
• PLA poly(lactic acid)
• PLA poly(lactic acid)
• inorganic materials such as gold, silicon dioxide (silica), among others.
• Natural NPs are produced from natural polymers, such as polysaccharides (chitosan and alginate), amino acids (poly(lysine), poly(aspartic acid) (PASA)), or proteins (gelatin and albumin). Natural NPs have the advantage of providing biological signals to interact with specific receptors/transporters expressed by endothelial cells.
• ligands have been conjugated to NPs to facilitate BBB penetration.
• Such molecules can be grouped into four different types: (i) ligands that mediate the adsorption of proteins from the bloodstream that interact directly with BBB receptors or transporters; (ii) ligands that have direct interaction per se with BBB receptors or transporters; (iii) ligands that increase charge and hydrophobicity; and (iv) ligands that improve blood circulation time (e.g. PEG).
• Another method includes the use of retrograde tracers based on axonal transport from the periphery such as disclosed in Filler et al. 2010 BMC Neuroscience volume 11, Article number: 8 ”Tri-partite complex for axonal transport drug delivery achieves pharmacological effect”.
• the tripartite molecular construction concept involves an axonal transport facilitator molecule, a polymer linker, and a retrograde tracer.
• axonal transport can be afforded by neuronal tracers, also referred to as histochemical tracers, which are compounds typically used to reveal the location of cells and track neuronal projections.
• a retrograde tracer is taken up in the terminal or along the axon or other neuronal processes and transported to the cell body, whereas an anterograde tracer moves away from the cell body of the neuron.
• the term “retrograde tracer” refers to a molecule that is characterized by the capacity to effect axonal transport from the periphery to the DRG.
• retrograde tracers are provided in, for example, Xiangmin Xu.
• retrograde tracers include horseradish peroxidase (HRP), dextran, isolectin, isolectin B4 (IB4), cholera toxin subunit B, wheat germ agglutinin (WGA), hydroxystilbamidine (a fluorescent dye), viral based tracers such as RABV, and any known axonal retrograde transport agent or tracer.
• HRP horseradish peroxidase
• dextran isolectin
• IB4 isolectin B4
• cholera toxin subunit B wheat germ agglutinin
• WGA wheat germ agglutinin
• hydroxystilbamidine a fluorescent dye
• viral based tracers such as RABV, and any known axonal retrograde transport agent or tracer.
• the term “retrograde tracer residue” or “a residue of a retrograde tracer” interchangeably refer to the part of the conjugate that confers or allows axonal transport of the conjugate from the locus of administration of the conjugate to the perikaryon.
• Mammalian virus vectors that can be used to deliver RNA include oncoretroviral vectors, adenovirus vectors, Herpes simplex virus vectors, and lentiviruses.
• HSV vectors are tropic for the central nervous system (CNS) and can establish lifelong latent infections in neurons.
• the AAVs may be delivered to a subject in compositions according to any appropriate methods known in the art.
• the AAV preferably suspended in a physiologically compatible carrier (e.g., in a composition)
• a subject e.g., a human, mouse, rat, cat, dog, sheep, rabbit, horse, cow, goat, pig, guinea pig, hamster, chicken, turkey, or a non-human primate.
• compositions may comprise an AAV alone, or in combination with one or more other viruses (e.g., a second AAV encoding having one or more different trans genes).
• Suitable carriers may be readily selected by one of skill in the art in view of the indication for which the AAV is directed.
• one suitable carrier includes saline, which may be formulated with a variety of buffering solutions (e.g., phosphate buffered saline).
• Other exemplary carriers include sterile saline, lactose, sucrose, calcium phosphate, gelatin, dextran, agar, pectin, peanut oil, sesame oil, and water.
• the selection of the carrier is not a limitation of the present invention.
• compositions of the invention may contain, in addition to the AAV and carrier(s), other conventional pharmaceutical ingredients, such as preservatives, or chemical stabilizers.
• suitable exemplary preservatives include chlorobutanol, potassium sorbate, sorbic acid, sulfur dioxide, propyl gallate, the parabens, ethyl vanillin, glycerin, phenol, and parachlorophenol.
• Suitable chemical stabilizers include gelatin and albumin.
• the dose of AAV virions required to achieve a desired effect or "therapeutic effect,” e.g., the units of dose in vector genomes/per kilogram of body weight (vg/kg), will vary based on several factors including, but not limited to: the route of AAV administration, the level of gene or RNA expression required to achieve a therapeutic effect, the specific disease or disorder being treated, and the stability of the gene or RNA product.
• a desired effect or "therapeutic effect e.g., the units of dose in vector genomes/per kilogram of body weight (vg/kg)
• An effective amount of the AAV is generally in the range of from about 10 ul to about 100 ml of solution containing from about 10 9 to 10 16 genome copies per subject.
• Other volumes of solution may be used. The volume used will typically depend, among other things, on the size of the subject, the dose of the AAV, and the route of administration.
• a volume in range of 1 ul to 10 ul or 10 ul to 100 ul may be used.
• intravenous administration a volume in range of 10 ul to 100 ul, 100 ul to 1 ml, 1 ml to 10 ml, or more may be used. In some cases, a dosage between about 10 10 to 10 12 AAV genome copies per subject is appropriate.
• 10 12 AAV genome copies per subject is effective to target CNS tissues.
• the AAV is administered at a dose of 10 10 , 10 11 , 10 12 , 10 13 , 10 14 , or 10 15 genome copies per subject.
• the AAV is administered at a dose of 10 10 , 10 11 , 10 12 , 10 13 , or 10 14 genome copies per kg.
• AAV compositions are formulated to reduce aggregation of AAV particles in the composition, particularly where high AAV concentrations are present (e.g., about 1013 GC/ml or more).
• Methods for reducing aggregation of AAVs are well known in the art and, include, for example, addition of surfactants, pH adjustment, salt concentration adjustment, etc. (See, e.g., Wright et al. (2005) Molecular Therapy 12:171-178.)
• Formulation of pharmaceutically-acceptable excipients and carrier solutions is well-known to those of skill in the art, as is the development of suitable dosing and treatment regimens for using the particular compositions described herein in a variety of treatment regimens.
• these formulations may contain at least about 0.1% of the active ingredient or more, although the percentage of the active ingredient(s) may, of course, be varied and may conveniently be between about 1 or 2% and about 70% or 80% or more of the weight or volume of the total formulation.
• the amount of active ingredient in each therapeutically-useful composition may be prepared is such a way that a suitable dosage will be obtained in any given unit dose of the compound.
• the pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions.
• Dispersions may also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms. In many cases the form is sterile and fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms, such as bacteria and fungi.
• the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g., glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and/or vegetable oils.
• polyol e.g., glycerol, propylene glycol, and liquid polyethylene glycol, and the like
• suitable mixtures thereof e.g., vegetable oils
• vegetable oils e.g., glycerol, propylene glycol, and liquid polyethylene glycol, and the like
• suitable mixtures thereof e.g., glycerol, propylene glycol, and liquid polyethylene glycol, and the like
• vegetable oils e.g., glycerol, propylene glycol, and liquid polyethylene glycol, and the like
• Proper fluidity may be maintained, for example, by the use of a coating, such as lecithin, by the maintenance of the required particle size in the case of dispersion
• isotonic agents for example, sugars or sodium chloride.
• Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.
• the solution may be suitably buffered, if necessary, and the liquid diluent first rendered isotonic with sufficient saline or glucose.
• a sterile aqueous medium that can be employed will be known to those of skill in the art.
• one dosage may be dissolved in 1 ml of isotonic NaCl solution and either added to 1000 ml of hypodermoclysis fluid or injected at the proposed site of infusion, (see for example, "Remington's Pharmaceutical Sciences” 15th Edition). Some variation in dosage will necessarily occur depending on the condition of the host. The person responsible for administration will, in any event, determine the appropriate dose for the individual host.
• Sterile injectable solutions are prepared by incorporating the active AAV in the required amount in the appropriate solvent with various of the other ingredients enumerated herein, as required, followed by filtered sterilization.
• dispersions are prepared by incorporating the various sterilized active ingredients into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above.
• the preferred methods of preparation are vacuum-drying and freeze-drying techniques which yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.
• compositions disclosed herein may also be formulated in a neutral or salt form.
• Pharmaceutically-acceptable salts include the acid addition salts (formed with the free amino groups of the protein) and which are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic, oxalic, tartaric, mandelic, and the like. Salts formed with the free carboxyl groups can also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, histidine, procaine and the like.
• solutions Upon formulation, solutions will be administered in a manner compatible with the dosage formulation and in such amount as is therapeutically effective.
• the formulations are easily administered in a variety of dosage forms such as injectable solutions, drug-release capsules, and the like.
• carrier includes any and all solvents, dispersion media, vehicles, coatings, diluents, antibacterial and antifungal agents, isotonic and absorption delaying agents, buffers, carrier solutions, suspensions, colloids, and the like.
• carrier includes any and all solvents, dispersion media, vehicles, coatings, diluents, antibacterial and antifungal agents, isotonic and absorption delaying agents, buffers, carrier solutions, suspensions, colloids, and the like.
• Supplementary active ingredients can also be incorporated into the compositions.
• pharmaceutically-acceptable refers to molecular entities and compositions that do not produce an allergic or similar untoward reaction when administered to a host.
• Delivery vehicles such as liposomes, nanocapsules, microparticles, microspheres, lipid particles, vesicles, and the like, may be used for the introduction of the compositions of the present invention into suitable host cells.
• the vector delivered components may be formulated for delivery either encapsulated in a lipid particle, a liposome, a vesicle, a nanosphere, or a nanoparticle or the like.
• Sonophoresis i.e., ultrasound
• U.S. Pat. No. 5,656,016 has been used and described in U.S. Pat. No. 5,656,016 as a device for enhancing the rate and efficacy of drug permeation into and through the circulatory system
• Other drug delivery alternatives contemplated are intraosseous injection (U.S. Pat. No. 5,779,708), microchip devices (U.S. Pat. No. 5,797,898), ophthalmic formulations, transdermal matrices (U.S. Pat. Nos. 5,770,219 and 5,783,208) and feedback-controlled delivery (U.S. Pat. No. 5,697,899).
• a conjugate, a vector, a lipid, a nanoparticle, a liposome, an adjuvant or a diluent may be further admixed with a pharmaceutically acceptable carrier or excipient.
• a pharmaceutically acceptable carrier or excipient See, e.g., Remington's Pharmaceutical Sciences and U.S. Pharmacopeia: National Formulary, Mack Publishing Company, Easton, Pa. (1984).
• Formulations of therapeutic agents may be prepared by mixing with acceptable carriers, excipients, or stabilizers in the form of, e.g., lyophilized powders, slurries, aqueous solutions or suspensions (see, e.g., Hardman, et al. (2001) Goodman and Gilman's The Pharmacological Basis of Therapeutics, McGraw-Hill, New York, N.Y.; Gennaro (2000) Remington: The Science and Practice of Pharmacy, Lippincott, Williams, and Wilkins, New York, N.Y.; Avis, et al. (eds.) (1993) Pharmaceutical Dosage Forms: Parenteral Medications, Marcel Dekker, NY; Lieberman, et al.
• Toxicity and therapeutic efficacy of the therapeutic compositions, administered alone or in combination with another agent can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD50 (the dose lethal to 50% of the population) and the ED50 (the dose therapeutically effective in 50% of the population).
• the dose ratio between toxic and therapeutic effects is the therapeutic index (LD50/ED50).
• therapeutic compositions exhibiting high therapeutic indices are desirable.
• the data obtained from these cell culture assays and animal studies can be used in formulating a range of dosage for use in human.
• the dosage of such compounds lies preferably within a range of circulating concentrations that include the ED50 with little or no toxicity.
• the dosage may vary within this range depending upon the dosage form employed and the route of administration.
• the mode of administration can vary. Suitable routes of administration include oral, rectal, transmucosal, intestinal, parenteral; intramuscular, subcutaneous, intradermal, intramedullary, intrathecal, direct intraventricular, intravenous, intraperitoneal, intranasal, intraocular, inhalation, insufflation, topical, cutaneous, transdermal, or intra-arterial.
• the composition or therapeutic can be administered by an invasive route such as by injection.
• the composition, therapeutic, or pharmaceutical composition thereof is administered intravenously, subcutaneously, intramuscularly, intraarterially, intra-articularly (e.g. in arthritis joints), intratumorally, or by inhalation, aerosol delivery.
• Administration by non-invasive routes e.g., orally; for example, in a pill, capsule or tablet is also within the scope of the present invention.
• Intrathecal administration is a further preferred form of administration.
• Intrathecal administration involves injection of the drug into the spinal canal, more specifically the subarachnoid space such that it reaches the cerebrospinal fluid. This method is commonly used for spinal anesthesia, chemotherapy, and pain medication.
• Intrathecal administration can be performed by lumbar puncture (bolus injection) or by a port-catheter system (bolus or infusion). The catheter is most commonly inserted between the laminae of the lumbar vertebrae and the tip is threaded up the thecal space to the desired level (generally L3-L4).
• Intrathecal formulations most commonly use water, and saline as excipients but EDTA and lipids have been used as well.
• compositions can be administered with medical devices known in the art.
• a pharmaceutical composition of the invention can be administered by injection with a hypodermic needle, including, e.g., a prefilled syringe or autoinjector.
• the pharmaceutical compositions of the invention may also be administered with a needleless hypodermic injection device; such as the devices disclosed in U.S. Pat. Nos. 6,620,135; 6,096,002; 5,399,163; 5,383,851; 5,312,335; 5,064,413; 4,941,880; 4,790,824 or 4,596,556.
• the liposomes will be targeted to and taken up selectively by the desired tissue.
• the administration regimen depends on several factors, including the serum or tissue turnover rate of the therapeutic composition, the level of symptoms, and the accessibility of the target cells in the biological matrix.
• the administration regimen delivers sufficient therapeutic composition to effect improvement in the target disease state, while simultaneously minimizing undesired side effects.
• the amount of biologic delivered depends in part on the particular therapeutic composition and the severity of the condition being treated.
• Determination of the appropriate dose is made by the clinician, e.g., using parameters or factors known or suspected in the art to affect treatment. Generally, the dose begins with an amount somewhat less than the optimum dose and it is increased by small increments thereafter until the desired or optimum effect is achieved relative to any negative side effects.
• Important diagnostic measures include those of symptoms of, e.g., the inflammation or level of inflammatory cytokines produced. In general, it is desirable that a biologic that will be used is derived from the same species as the animal targeted for treatment, thereby minimizing any immune response to the reagent.
• therapeutically effective amount refers to an amount of the present nucleic acid molecules, mutant proteins/polypeptides, and/or modulators that, when administered alone or in combination with an additional therapeutic agent to a cell, tissue, or subject, is effective to cause a measurable improvement in one or more symptoms of a disease or condition or the progression of such disease or condition.
• a therapeutically effective dose further refers to that amount of the agent sufficient to result in at least partial amelioration of symptoms, e.g., treatment, healing, prevention or amelioration of the relevant medical condition, or an increase in rate of treatment, healing, prevention or amelioration of such conditions.
• a therapeutically effective dose refers to that ingredient alone.
• a therapeutically effective dose refers to combined amounts of the active ingredients that result in the therapeutic effect, whether administered in combination, serially or simultaneously.
• An effective amount of a therapeutic will result in an improvement of a diagnostic measure or parameter by at least 10% ; usually by at least 20% ; preferably at least about 30% ; more preferably at least 40%, and most preferably by at least 50%.
• An effective amount can also result in an improvement in a subjective measure in cases where subjective measures are used to assess disease severity.
• the present agents/compositions may prevent or delay onset or amelioration of symptoms of the condition in a subject or an attainment of a desired biological outcome, such as correction of neuropathology, e.g., cellular pathology associated with a motor neuronal disease.
• the antisense RNA or the iRNA may be delivered as RNA molecules in a suitable carrier that are complementary to a sequence in the nNOS gene, or nNOS mRNA, that can hybridize thereto and reduce its expression.
• the antisense is chemically modified to increase its stability.
• the chemical modification is a modification of a backbone of the oligonucleotide.
• the chemical modification is a modification of a sugar of the oligonucleotide.
• the chemical modification is a modification of a nucleobase of the oligonucleotide.
• the chemical modification increases the intracellular stability of the oligonucleotide.
• the chemical modification increases stability of the oligonucleotide in vivo, for example by increasing resistance to proteases. In some embodiments, the chemical modification increases the oligonucleotide's ability to enter cells. In some embodiments the chemical modification improves the ability to bind target RNA .In some embodiments, the chemical modification increases the half-life of the oligonucleotide or improves another relevant pharmokinetic property. In some embodiments, the chemical modification inhibits polymerase extension from the 3' end of the oligonucleotide. In some embodiments, the chemical modification inhibits recognition of the oligonucleotide by a polymerase. In some embodiments, the chemical modification inhibits double- strand triggered degradation. In some embodiments, the chemical modification inhibits RISC-mediated degradation. In some embodiments, the chemical modification inhibits RISC- mediated degradation or any parallel nucleic acid degradation pathway.
• the consecutive nucleotide bases are linked by a backbone selected from the group consisting of a phosphate-ribose backbone, a phosphate-deoxyribose backbone, a phosphorothioate-deoxyribosebackbone, a 2'-O-methyl-phosphorothioate backbone, a phosphorodiamidate morpholino backbone, a peptide nucleic acid backbone, a 2-methoxyethyl phosphorothioate backbone, an alternating locked nucleic acid backbone, constrained ethyl backbone, and a phosphorothioate backbone, N3 -P5' phosphoroami dates, 2'-deoxy-2'-fluoro- ⁇ -d- arabino nucleic acid, cyclohexene nucleic acid backbone nucleic acid, tricyclo-DNA (tcDNA) nucleic acid backbone, ligand- conjugated antisense
• compositions of some embodiments of the invention may, if desired, be presented in a pack or dispenser device, such as an FDA approved kit, which may contain one or more unit dosage forms containing the active ingredient.
• the pack may, for example, comprise metal or plastic foil, such as a blister pack.
• the pack or dispenser device may be accompanied by instructions for administration.
• the pack or dispenser may also be accommodated by a notice associated with the container in a form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals, which notice is reflective of approval by the agency of the form of the compositions or human or veterinary administration.
• Such notice for example, may be of labeling approved by the U.S. Food and Drug Administration for prescription drugs or of an approved product insert.
• compositions are exemplary compositions:
• the pharmaceutical composition which is also referred to herein as a “formulation”, is composed of a pharmaceutically acceptable carrier and at least one active agent.
• the active agent may be a small molecule, an amino acid based compound (peptide, protein, antibody or antibody fragment) or nucleic acid based compound (RNA, including antisense, and iRNA, and DNA), as described herein in any of the respective embodiments.
• a pharmaceutical composition comprising a therapeutically active agent which reduces nNOS activity, as described herein in any of the respective embodiments and any combination thereof, and a pharmaceutically acceptable carrier, wherein the composition and the therapeutically active agent are selected such that upon administration of the composition to a subject, reduction in the nNOS activity is effected selectively or preferentially as compared to other NOS isoforms.
• a pharmaceutical composition comprising a therapeutically active agent which reduces nNOS activity, as described herein in any of the respective embodiments and any combination thereof, and a pharmaceutically acceptable carrier, wherein the composition and the therapeutically active agent are selected such that upon administration of the composition to a subject, reduction in the nNOS activity is effected selectively or preferentially in neuronal cells or in a nerve tissue of the subject as compared to other tissues.
• a pharmaceutical composition comprising a therapeutically active agent which reduces nNOS activity, as described herein in any of the respective embodiments and any combination thereof, and a pharmaceutically acceptable carrier, wherein the composition and the therapeutically active agent are selected such that upon administration of the composition to a subject, reduction in the nNOS activity is effected selectively or preferentially in the peripheral or central nervous system of the subject as compared to other tissues.
• a pharmaceutical composition comprising a therapeutically active agent which reduces nNOS activity, as described herein in any of the respective embodiments and any combination thereof, and a pharmaceutically acceptable carrier, wherein the composition and the therapeutically active agent are selected such that upon administration of the composition to a subject, reduction in the nNOS activity is effected selectively or preferentially in the CNS (e.g., the brain) of the subject as compared to other tissues.
• a pharmaceutical composition comprising a therapeutically active agent which reduces nNOS activity, as described herein in any of the respective embodiments and any combination thereof, and a pharmaceutically acceptable carrier, wherein the composition and the therapeutically active agent are selected such that upon administration of the composition to a subject, reduction in the nNOS activity is effected selectively or preferentially in the CNS (e.g., the brain) of the subject as compared to other tissues.
• CNS e.g., the brain
• a desired tissue e.g., nerve tissue, the brain, etc.
• an active agent that is selective for reducing NO in the brain and/or an inhibitor of NO synthase that is specific/selective to neuronal NO synthase.
• the neuronal NO synthase inhibitor may be a small molecule specific to that neuronal NO- synthase enzyme, an antisense and iRNA specific to the enzyme’s mRNA, a DNA capable of expressing these antisense and iRNAs, or a combined system for example CRISPR CAS for selectively reducing expression of neuronal NO synthase.
• Such agents are described hereinabove.
• the selectivity of the NO reduction in the nerve tissue may be caused by the properties of the carrier that is delivery selective to the nerve tissue (e.g., CNS), or a delivery system with elements targeted to delivery to the nerve tissue (e.g., CNS) (delivers more to the nerve tissue or CNS than to the body).
• the active agent for example a non-selective NO synthase inhibitor
• the active agent does not have to be neuronal specific as the delivery (and carrier as will be explained below) are those giving nerve tissue (e.g., CNS) selectivity.
• the selectivity to the nerve tissue is denoted by the mode of administration (relevant especially for administration of agents that are nucleic acid based) that it administered locally to the desired tissue (e.g., the brain).
• Brain selectivity in reduction of NO can be done by one of the following mechanisms:
• reducing agents that are not selective of nNOS but are cable of reducing all NOS [general inhibitors of all NOS (eNOS, iNOS, nNOS)] or agents that decrease the expression of the eNOS (NOS3), iNOS (NOS2), nNOs (NOS1) genes delivered by a delivery system (carriers etc.) that are targeted to deliver their cargo selectively to the CNS, such as described herein; and/or
• agents that may not be selective to nNOS but are delivered selectively to the brain by intra-brain administration or by brain-targeted delivery vehicle, such as described herein.
• the composition comprises an active agent which is nNOS specific (nNOS selective).
• the administering mode achieves the reduction of nNOS activity in the CNS.
• composition’s administering mode comprises local administration.
• the agent is a selective nNOS inhibitor.
• a nNOS inhibitor is considered selective when it reduces nNOS activity to an extent that is higher by at least 20 %, or at least 30 %, or at least 40 %, or at least 50 %, compared to other enzymes, particularly other nitric oxide synthase enzymes.
• a nNOS inhibitor is considered selective when its dissociation constant (Ki) for nNOS is lower by at least 10-folds, or by at least 100-folds, or by at least 1,000-folds compared to its Ki for the other NOS isoforms.
• a nNOS inhibitor is considered selective when its IC50 for nNOS is lower by at least 2- folds, or at least 5-folds, or at least 10-folds, compared to its IC50 for the other NOS isoforms.
• the nNOS reducing composition refers to any pharmaceutical composition, comprising one or more active agents in a carrier, that can reduce the amount of physiologically available NO in the brain.
• the “neuronal” specificity may be a property of the agent that reduces specifically nNOS and not substantially any other NOS enzymes, as described herein, or the property of the carrier that carriers a general NO reducer to the neurons (either by the delivery system or the mode of administration explained herein).
• the pharmaceutical composition is such that comprises an active agent as described herein in any of the respective embodiments in an effective amount that reduces an amount of physiologically available nitric oxide in a desired tissue (e.g., a nerve tissue as described herein, for example, the brain), or in neuronal cells, as described herein, preferably in a selective manner, as described herein.
• a desired tissue e.g., a nerve tissue as described herein, for example, the brain
• neuronal cells e.g., a selective manner, as described herein.
• a pharmaceutical composition according to these embodiments can be designed for oral, buccal, sublingual, parenteral, nasal, transdermal, or intratissue administration, particularly for repeated administration or continued, extended or slow release administration, over prolonged periods of time or targeted slow and regulated delivery.
• a pharmaceutical composition according to these embodiments can be designed for providing high systemic bioavailability and optionally extended release.
• a pharmaceutical composition according to these embodiments can be applied for repeated administration or continued slow release administration, which release therapeutically effective concentrations of the active agent over prolonged periods of time or targeted slow and regulated delivery.
• the formulations include stable aqueous solutions, liposomes, emulsions and nano and micro-particulate dispersions for subcutaneous or intramuscular injections.
• Formulations can be in the form of ointments, creams and gels for topical and transdermal delivery of the agent.
• extended or controlled release refers to retaining active levels of the active agents in the blood or in the designated tissue (e.g., nerve tissue as described herein) for at least 48 hours, from an implant or an injection SC, IM or in tissue.
• tissue e.g., nerve tissue as described herein
• extended or controlled release refers to retaining active levels of the active agents in the blood for at least 2 hours after oral or intranasal administration.
• a pharmaceutical composition that comprises an active agent that selectively reduces an activity of nNOS, as described herein in any of the respective embodiments.
• the active agent is JI-8 or a structural analog thereof, as described herein.
• the active agent is 7-NI, or a compound represented by Formula I as described herein in any of the respective embodiments and any combination thereof.
• 7-NI is water insoluble with poor capabilities of crossing biological membranes. Its target sites are receptors in the nerve system, for example, the brain. Thus, it is required to deliver 7-NI to the desired nerve tissue (e.g., brain, peripheral and/or central nervous system). According to some embodiments, this is possible using nanoparticles delivered via IV injection or by nose-to-brain nasal spray.
• formulations described herein can protect 7-NI from early degradation or metabolism while allowing high blood levels over prolonged period of times, depending on the type of delivery system used.
• a pharmaceutical composition as described herein comprises an active agent as described herein in any of the respective embodiments and any combination thereof, preferably a small molecule agent such as a small molecule nNOS inhibitor (e.g., 7-NI or a compound of Formula I as described herein, or JI-8 or a structural analog thereof, as described herein).
• a small molecule agent such as a small molecule nNOS inhibitor (e.g., 7-NI or a compound of Formula I as described herein, or JI-8 or a structural analog thereof, as described herein).
• the active agent is 7-NI or a compound of Formula I as described herein.
• PNL Pre-nanodispersion lipid
• the pharmaceutical composition or formulation comprises a carrier that forms a nanodispersion upon contacting an aqueous solution (a pre- nanodispersion carrier).
• a pre- nanodispersion carrier a carrier that forms a nanodispersion upon contacting an aqueous solution
• the composition or formulation is a pre- nanodispersion lipid (PNL) composition or formulation.
• the composition comprises an aqueous carrier in which nanoparticles formed of the pre-nanodispersion lipid formulations are dispersed.
• Such formulations increase the bioavailability of the active agent (e.g., 7-NI) after oral intake.
• active agent e.g., 7-NI
• a PNL formulation typically includes a carrier that comprises a mixture of at least one lipid, at least one of a surfactant, a water-miscible solvent (e.g., an edible solvent), and optionally further comprise an emulsifier, a dispersing agent and other ingredients.
• a carrier that comprises a mixture of at least one lipid, at least one of a surfactant, a water-miscible solvent (e.g., an edible solvent), and optionally further comprise an emulsifier, a dispersing agent and other ingredients.
• the mixture of surfactants, lipids, and solvent form nanoparticles when contacting an aqueous medium (e.g., a physiological medium) or an aqueous solution.
• the carrier of a PNL formulation comprises components that are considered as GRAS.
• Exemplary lipids that are suitable for use in the context of embodiments that relate to PNL formulations include solid and liquid lipids such as, but are not limited to, one or more of: fatty acids, fatty alcohols, triglycerides, hydrogenated vegetable oil, Migliol, vegetable oil and waxes. Specific examples are listed in the Examples section that follows.
• Exemplary surfactants that are suitable for use in the context of embodiments that relate to PNL formulations include, but are not limited to, hydrophilic or amphiphilic surfactants or dispersing agent such as, but not limited to, one or more of: surfactants of the Tween® family, surfactants of the Span® family, PEG-lipids and PEG-hydrogenated castor oil. Specific examples are listed in the Examples section that follows.
• Exemplary water-immiscible solvents that are suitable for use in the context of embodiments that relate to PNL formulations include, but are not limited to, ethanol, isopropanol, ethyl lactate, ethyl acetate, and propylene glycol. Specific examples are listed in the Examples section that follows.
• the carrier in a PNL formulation is a clear liquid in which the active agent (e.g., 7-NI or a compound of Formula I) is soluble, and which upon contacting an aqueous media, spontaneously disperses into nanoparticles having an average size (e.g., diameter) of, for example, 200 nm or less, preferably below 100 nm, preferable below 50 nm.
• the active agent e.g., 7-NI or a compound of Formula I
• an average size e.g., diameter
• the pro-nanodispersion lipid (PNL) based formulations are suitable for oral administration per se, for example, as a liquid formulation loaded in soft gelatin capsule that upon swallowing, the liquid content interacts with the stomach liquids to form a nanodispersion that allow crossing through the GI tract surface into the blood stream.
• PNL pro-nanodispersion lipid
• the PNL formulation serves as solubilizer of the active agent (e.g., 7-NI of a compound of Formula I as described herein) and the nano-dispersion for crossing biomembranes.
• the active agent e.g., 7-NI of a compound of Formula I as described herein
• compositions for oral administration as described herein, are also contemplated for a PNL formulation.
• the PNL formulation can be in a liquid form, and can be dispersed in a glass of water or soft drinks and taken as a drink.
• the PNL formulation can be comprise an aqueous solution in which the pro- nanodispersion mixture form a nanodispersion (nanoparticles dispersed in the aqueous solution) for injection, oral, nasal administration (e.g., as a nasal spray) or ophthalmic administration (e.g., as eye drops).
• the selection of the inactive ingredients (composing the carrier) should consider the safety of the final formulation for the type of delivery and the administration mode.
• the PNL composition for injection should include ingredients that are approved for subcutaneous (SC), intramuscular (IM) or intravenous (IV) administration and should not provoke local or systemic toxicity or irritation.
• SC subcutaneous
• IM intramuscular
• IV intravenous
• eye drops and nasal spray should consider the sensitivity of these tissue surfaces to certain ingredients.
• the PNL formulations as described herein can be used for oral, ophthalmic, nasal, transdermal, subcutaneous and buccal delivery, that provides an effective dose to the subject to be treated.
• the dispersion in an aqueous medium can be prepared shortly before administration or pre- prepared.
• the PNL composition or formulation as described herein in any of the respective embodiments comprises as an active agent, 7-NI or a compound of Formula I, or a pharmaceutically acceptable salt thereof, as described herein, for example, a 7-NI lipid salt as described herein.
• the pharmaceutical composition or formulation is configured for controlled or extended release of the active agent.
• such formulations are injectable and implantable formulations that increase the bioavailability of the active agent (e.g., 7-NI or a compound of Formula I or a salt thereof as described herein) at a controlled rate to the surrounding tissue for periods of e.g., days to months.
• the active agent e.g., 7-NI or a compound of Formula I or a salt thereof as described herein
• Injectable controlled and extended release formulations may include: polymeric or liquid based nanoparticles, microparticles, inserts, injectable anhydrous pasty formulation, polymeric liquid formulations that gel into the body to form in- situ implants (e.g., depot) that release the active agent (e.g., 7-NI or a compound of Formula I) for a time period of from 1 day to a few weeks or months).
• in- situ implants e.g., depot
• active agent e.g., 7-NI or a compound of Formula I
• such formulations can be prepared from different forms and structures of biodegradable polymers.
• Exemplary biodegradable polymers include those that have already been used in humans, including, but not limited to, polyesters made from lactide, glycolide, caprolactone and ethylene/propylene carbonate, and sebacic acid based polyanhydride.
• Protein and polysaccharide based natural polymer carriers are also contemplated, including, but not limited to, gelatin, collagen
• polymeric implants in the form of a wedge or a rod or fiber, are inserted into the body using a trocar or a 16-21G needle.
• the implant is prepared by either forming a homogeneous melt mix of the polymer and the active agent (e.g., 7-NI or a compound of Formula I as described herein) that is molded into the desired form, suitable for insertion into the body.
• the devices are prepared by compression molding of a polymer- active agent homogeneous powders.
• Polymeric injectable extended release compositions can be configured for, for example, intramuscular or subcutaneous administration. These compositions constantly release the drug over periods from a few days to a few months.
• In situ depot forming systems for parenteral controlled drug delivery can be in the form of aqueous dispersions of microparticles, polymeric liquids or pastes having a wide range of viscosities.
• Such systems usually contain a biodegradable carrier dissolved or dispersed in a solvent/co- solvent system, while the drug is either dispersed or dissolved in the liquid phase of the delivery system Upon Subcutaneous or intramuscular injection, a solid depot is formed at the site of injection. The administration of such a system is far less invasive and costly than the surgical procedures which are often required for implantation.
• extended release formulations are made of ricinoleic acid and castor oil containing polyesters and polyanhydrides, adapted for use as carriers, such as described, for example, in U.S. Patent Application Publication Nos. 2004/0161464, and 2004/0161464 to Domb).
• Biodegradable carriers are synthesized from ricinoleic acid oligoesters and aliphatic molecules having at least one carboxylic acid and at least one hydroxy or carboxylic acid group that are liquids or pastes at temperatures below 37 °C.
• the composition is made of copolymers or ricinoleic acid and sebacic acid at 6:4 to 8:2 w/w ratio that are pasty and injectable at room temperature. These polymers increase their viscosity upon immersion in aqueous medium or injected in tissue.
• Microspheres and nanospheres prepared from PLGA are also contemplated for controlled/extended release.
• Microspheres and nanospheres can be prepared by dissolving the polymer with the active agent (e.g., 7-NI or a compound of Formula I) in an organic solvent such as chloroform, DMSO, etc., and adding an anti-solvent containing surfactants, such that droplets of the polymer-drug solution are formed whereupon solvent evaporation (in case of water as antisolvent) or diffusion out the droplet to the organic antisolvent, microspheres and nanospheres are formed.
• the active agent e.g., 7-NI or a compound of Formula I
• organic solvent such as chloroform, DMSO, etc.
• an anti-solvent containing surfactants such that droplets of the polymer-drug solution are formed whereupon solvent evaporation (in case of water as antisolvent) or diffusion out the droplet to the organic antisolvent, microspheres and nanospheres are formed.
• the size of the particles can be controlled by the concentration of the polymer-drug solution, the anti- solvent ratio, the surfactant content, the solvent evaporation or leach-out and preparation conditions, including: temperature, solvents used, mixing rate and evaporation aids.
• a pharmaceutical composition as described herein is formulated for injection (e.g., by intravenous administration) and comprise a lipid or polymeric nanoparticles or liposomes in which the active agent (7-NI or a compound of Formula I or a slat thereof) is entrapped or encapsulated.
• the active agent is incorporated in a biodegradable polymer or lipid carrier.
• the carrier is in a form of micro- or nano-particles.
• micro- or nano-particles compositions are formulated for administration via oral administration, oral inhalation, nasal spray, IV, IM or SC injection, or transdermal delivery.
• the administration is to the brain using nanoparticles delivered to the olfactory tissue.
• biodegradable polymers suitable for use in the context of these embodiments include, but are not limited to, lactide homo- and copolymers with glycolide or caprolactone, polycaprolactone and its copolymers and other biodegradable polymers in the form of injectable particles dispersed in water, an injectable polymeric pastes or in the form of an insert. Liposomal or a liposphere type of dispersion are also contemplated.
• the encapsulated active agent may feature a hydrodynamic surface, such as PEG chains, which reduce RAS ability to eliminate the active agent from the blood stream
• the active agent is a compound of Formula I in which one or more of R2-R5 is a poly(alkylene glycol) moiety as defined herein.
• Methods for making nanoparticles and microparticles include: precipitation of a solution or dispersion of the active agent (e.g., 7-NI or a compound of Formula I or a salt thereof) in the polymer solution and precipitation is an anti- solvent under controlled conditions to form nano and microparticles that entrap the active agent.
• the active agent e.g., 7-NI or a compound of Formula I or a salt thereof
• a solution of PLGA 75:25 dissolved in dichloromethane is mixed with an active agent (e.g., 7-NI or a compound of Formula I or a salt thereof) solution in ethanol to form a clear solution that contain polymer:7NI at a 100:1 to 65:35 w/w ratio.
• This solution is added dropwise into stirred heptane containing a surfactant as antisolvent to form particles upon precipitation.
• the polymer/active agent solution is added to a stirred aqueous solution containing a surfactant such as polyvinyl alcohol or a mixture of Tween® and/or Span® surfactants that upon slow solvent evaporation, nano and microparticles are formed.
• a surfactant such as polyvinyl alcohol or a mixture of Tween® and/or Span® surfactants that upon slow solvent evaporation, nano and microparticles are formed.
• the size of the particles is controlled and can be tailored by the ratio or solvent: antisolvent, polymer and 7NI concentrations in solution, mixing rate and type of mixing (overhead, stirrer, ultrasound), temperature, etc.
• compositions comprising pharmaceutically acceptable salt of a compound of Formula I (e.g., salts of 7-nitroindazole) are also contemplated.
• 7-Nitroindazole is a water insoluble molecule that need to be taken for a long time period.
• Such compositions can be used in repeated administrations or in continued extended (slow release) administration, over prolonged periods of time or targeted slow and regulated delivery.
• the formulations can increase the bioavailability of 7-Nitroindazole after oral, nasal, short and extended release injectable formulations and transdermal and topical formulations.
• the indazole moiety of 7-Nitroindazole is prone to the formation of a salt by eliminating the proton from the N-H of the azole to form a salt with positively charged moieties, including: divalent and trivalent metal ions, ammonium and phosphonium cationic counterparts.
• the basic amine that is part of the aromatic ring forms a salt with proton containing molecules, including HC1, phosphate, H 2 SO 4 and organic acids.
• These salts possess properties that are different from the non-salt 7-Nitroindazole, which include: solubility, thermal properties and stability, chemical stability ease of formulation, controlled release, crossing biological membranes and biodistribution.
• the salts according to these embodiments can be included in any of the pharmaceutical compositions or formulations as described herein.
• composition for oral or nasal administration is provided.
• the active agent e.g., 7-nitroindazole or a compound of Formula I or a salt thereof
• the active agent can be dissolved or dispersed as nanoparticulate to allow GI absorption.
• an anhydrous pre-concentrate solution of the active agent e.g., 7-nitroindazole or a compound of Formula I or a salt thereof
• an anhydrous pre-concentrate solution of the active agent is formed in a certain mixture of surfactants, lipids and edible solvent, that spontaneously form nanoparticles upon addition to aqueous media, i.e.
• lipid based formulations can be delivered in soft gelatin capsules or absorbed in porous silica or another carrier and incorporated in common tablet composition and compressed into tablets that upon oral intake, release to the GI liquids to form nanoparticles to be absorb through the GI tract to the blood stream
• These lipid based formulations can be delivered nasally, for example, as sprayable formulations.
• a pharmaceutical composition for oral administration such as described herein is formulated in a dosage form that allows at least 25 % bioavailability.
• an orally-administered composition is used at a dose of from 10 to 1000 mg, or from 200 to 1000 mg, or from 200 to 600 mg, including any intermediate values and subranges therebetween, and even up to 2,000 mg per day, which can be in a once- daily, twice-daily, trice-daily, four-times daily or more unit dosage form
• an extended release oral formulations for 1-4 weeks can be designed.
• Low dose is also contemplated nasal spray delivery.
• each dose may contain 1-10 mg, so as to achieve a certain blood level or brain tissue concentration.
• each spray is between 50-200 microliters which may contain 1-10 mg of the active agent. In exemplary embodiments, a daily dose of up to 100 mg is contemplated.
• compositions for injection are:
• Injectable polymeric delivery systems are preferably configured to deliver drugs for periods of weeks to month, depending on the daily dose and the formulation.
• Exemplar injectable formulations are based on poly(lactide-glycolide) copolymers that have been used in the clinic for the extended delivery of drugs such as Risperidone and LHRH analogs.
• Additional exemplary formulations for injection which provide extended release of the active agent include the extended/controlled release compositions or the particulate compositions/formulations as described herein.
• the dose for extended release injectable compositions is typically a function of the daily dose multiplied by the number of days the delivery system intends to deliver the active agent.
• a maintenance dose of the active agent which can be less than a desirable daily dose is also contemplated in the context of these embodiments. This maintenance dose can be combined with an oral dose or nasal dose or transdermal patch, e.g., at a low daily dose as described herein.
• compositions for buccal administration are provided.
• buccal delivery of the active agent can be performed using a PNL formulations as described herein in any of the respective embodiments, absorbed in or on a carrier suitable for buccal delivery, for example, in cross-linked polyacrylic acid, Carbopol 940 or Carbopol 970, or/and in hydroxypropyl cellulose (HPC) or hydroxypropyl methyl cellulose (HPMC).
• a PNL formulations as described herein in any of the respective embodiments, absorbed in or on a carrier suitable for buccal delivery, for example, in cross-linked polyacrylic acid, Carbopol 940 or Carbopol 970, or/and in hydroxypropyl cellulose (HPC) or hydroxypropyl methyl cellulose (HPMC).
• HPC hydroxypropyl cellulose
• HPMC hydroxypropyl methyl cellulose
• the active agent e.g., 7-nitroindazole or a compound of Formula I or a salt thereof
• PNL absorbed solids are mixed at a 10:0 to 6:4 Carbopol to HPC w/w ratio and compressed into tablets of 13 mm in diameter.
• Buccal delivery is typically dose limited by the penetration through the buccal and in some embodiments, administration is of small doses of 1-100 mg per day.
• compositions for transdermal administration are provided.
• Transdermal formulations are usually applied for low dose delivery of an active agent since the skin penetration is low for most molecules, including 7-NI.
• an active agent e.g., 7-nitroindazole or a compound of Formula I or a salt thereof
• a pasty formulation that is applied onto a common transdermal patch.
• enhancers such as azone, PEG and other agents may be added.
• Tolerable doses and formulations are used with the objective to reach the highest dose possible so that the skin surface area to be applied for the delivery of the active agent is adjusted to the desired dose per hour.
• a transdermal patch can be applied to the skin for one week, and, if desired, repeatedly replaced every week.
• a transdermal patch is applied to the skin of the subject on daily basis, or every 2, 3 or 4 days.
• nNOS reducing agents Delivery of a nNOS reducing agents - by a brain- selective delivery system
• nucleic acid-based nNOS inhibitor e.g., (a promotor and/or a gene and/or other nucleic acid-based materials) as described herein in any of the respective embodiments.
• nNOS inhibitors can be done by any delivery system suitable for delivery to the CNS, either by direct delivery or by systemic delivery.
• a non-limiting delivery system or delivery vehicle of such nNOS inhibitors to the CNS are nanoparticles, typically having a size of less than 200 nm. These may include lipid-based nanoparticles, polymer nanoparticles, dendrimers and inorganic nanoparticles, some of which may be tailored to pass through the BBB.
• liposomes that can also pass the BBB.
• the preferred pathway for this approach is receptor (or transporter) -mediated transcytosis by which a cargo (e.g., nanoparticles) transports between the apical and basolateral surface in the brain ECs.
• a cargo e.g., nanoparticles
• low-density lipoproteins undergo transcytosis through the ECs by a receptor-mediated process, bypassing the lysosomal compartment and releasing at the basolateral surface of the brain side.
• exosomes which are small extracellular vesicles secreted by cells.
• the major advantage of exosomes versus other synthetic nanoparticles is their non-immunogenic nature, leading to a long and stable circulation.
• BBB contains transporters to amino acids
• using a BBB naturally present arginine transporter for the delivery may be a simple viable approach for delivery to the brain.
• Another approach is to use compounds or electric stimulation to transiently open the BBB and allow high concentrations of systemically administered sequences to reach the brain.
• An example of such a compound is cereport (a bradykinin analog) or regadenoson (an adenosine receptor agonist).
• Ultrasound has become an attractive technique to facilitate drugs to cross the BBB in recent years.
• Microbubble-enhanced diagnostic ultrasound (MEUS) a non-invasive technique, effectively helped drugs cross the BBTB.
• MUS transcranial magnetic stimulation
• TMS transcranial magnetic stimulation
• Routes of administration of the desired delivery vehicles may be systemic administration without further radiation based manipulations (e.g., using particles, that inherently enter the BBB); systemic administration using compounds in conjunction with various manipulations (e.g., in conjunction with microcrobubble-enhanced diagnostic ultrasound (MEUS), transcranial magnetic stimulation (TMS)) to transiently open the BBB; nasal administration.
• systemic administration without further radiation based manipulations (e.g., using particles, that inherently enter the BBB); systemic administration using compounds in conjunction with various manipulations (e.g., in conjunction with microcrobubble-enhanced diagnostic ultrasound (MEUS), transcranial magnetic stimulation (TMS)) to transiently open the BBB; nasal administration.
• MEUS microcrobubble-enhanced diagnostic ultrasound
• TMS transcranial magnetic stimulation
• Vehicles for a targeted delivery to the CNS can also be utilized as carrier in pharmaceutical compositions that comprise any of the other agents that reduce nNOS activity as described herein in any of the respective embodiments and any combination thereof.
• the administration is by direct injection into the parenchyma or by injection into the cerebrospinal fluid via the intracerebroventricular or intrathecal (cisternal or lumbar) route, as described herein in any of the respective embodiments and any combination thereof.
• Preferred local administration to the brain can be carried out by administration to the cerebrospinal fluid via intracerebroventricular route.
• Another option is delivery to the cisterna magna route of injection has been recently adopted as an alternative method for delivery into cerebrospinal fluid (CSF) which results in wide-spread gene delivery throughout the CNS.
• CSF cerebrospinal fluid
• a pharmaceutical composition as described herein in any of the respective embodiments and any combination therein, which comprises as an agent that reduced nNOS activity a compound of Formula I or a salt thereof, as described herein in any of the respective embodiments.
• the pharmaceutical composition is for use in the treatment of any of the diseases or conditions as described herein.
• diseases or conditions include, but are not limited to, ASD, as defined herein, Alzheimer’s disease, Parkinson’s disease, Huntington’ s disease, Multiple sclerosis, Schizophrenia, addiction, ALS, Epilepsy, bipolar disease, migraine and in addition all kinds of neurodevelopmental disorders as well as neurodegenerative diseases, such as described in Tripathi et al. Redox Biol. 2020: 101567.
• a method of treating an autism spectrum disorder as defined herein in any of the respective embodiments and any combination thereof, in a subject in need thereof, the method comprising administering to the subject an effective amount of a composition comprising an active agent which reduces nNOS activity, as described herein in any of the respective embodiments and any combination thereof.
• reduction in the nNOS activity is selectively or preferentially in neuronal cells or a nerve tissue of the subject (e.g., the CNS or the brain) as compared to other tissues, as described herein.
• the reduction in the nNOS activity is in a nerve tissue (CNS, e.g., brain) or in peripheral organs which comprise neuronal cells that express nNOS, as described herein.
• CNS nerve tissue
• peripheral organs which comprise neuronal cells that express nNOS, as described herein.
• reduction in the nNOS activity is selective compared to other NOS isoforms, as described herein.
• reduction in the nNOS activity is selective such that an amount of physiologically available NO is reduced selectively in neuronal cells of the subject, as described herein. According to some embodiments, reduction in the nNOS activity is selective such that an amount of physiologically available NO is reduced selectively in the CNS or the brain of the subject, as described herein.
• a method of treating an autism spectrum disorder as defined herein in any of the respective embodiments and any combination thereof, in a subject in need thereof, the method comprising administering to the subject an effective amount of a pharmaceutical composition as described herein in any of the respective embodiments and any combination thereof, including the exemplary compositions as described herein.
• compositions as described herein in any of the respective embodiments and any combination thereof including the exemplary compositions as described herein for use in treating an autism spectrum disorder, as described herein in any of the respective embodiments, in a subject in need thereof.
• a method of treating a neural-derived cancer, as defined herein in any of the respective embodiments and any combination thereof, in a subject in need thereof comprising administering to the subject an effective amount of a composition comprising an active agent which reduces nNOS activity, as described herein in any of the respective embodiments and any combination thereof.
• reduction in the nNOS activity is selectively or preferentially in a respective nerve tissue or respective neuronal cells of the subject as compared to other tissues, as described herein.
• reduction in the nNOS activity is selective compared to other NOS isoforms, as described herein.
• reduction in the nNOS activity is selective such that an amount of physiologically available NO is reduced selectively in the respective nerve tissue or respective neuronal cells, as described herein.
• a method of treating a neural-derived cancer, as defined herein in any of the respective embodiments and any combination thereof, in a subject in need thereof comprising administering to the subject an effective amount of a pharmaceutical composition as described herein in any of the respective embodiments and any combination thereof, including the exemplary compositions as described herein.
• the neural-derived cancer is neuroblastoma, as defined herein.
• the pharmaceutical composition is an extended release composition as described herein in any of the respective embodiments and any combination thereof.
• the methods and uses as described herein are effected by repetitively administering the composition (e.g., by injection, or transdermally, as described herein) in a time interval between administrations which is at least one day, preferably at least 2 days, at least 3 days, at least 4 days, at least one week, optionally, at least 2 weeks, at least one month, at least two months, and more.
• this can be effected using a controlled-extended release composition as described herein in any of the respective embodiments.
• the subject is a mammal, for example, a human being.
• the subject is afflicted by a disease or condition as described herein in any of the respective embodiments, for example, a chronic disease or condition such as ASD or neuroblastoma.
• the subject is a neonatal or an infant, for example, is aged from 0 to 10 years.
• the subject is an adolescent, for example, is aged between 10 to 20 10 years.
• the subject is an adult, for example, is aged at least 20 years.
• the present invention is based on a second finding that administration of S-nitroso-N- acetylpenicillamines (SNAP), is an NO donor that increases the NO availability induced ASD-like phenotypes in the C57BL/6 mouse model.
• SNAP S-nitroso-N- acetylpenicillamines
• a method of producing a laboratory animal model for autism spectrum disorder comprising administering to said laboratory animal an effective amount of a composition which increases NO levels in a brain of said animal to produce an ASD- like phenotype.
• an ASD-like phenotype refers to molecular and/or behavioral phenotype.
• molecular markers include, but are not limited to: SYNAPTOPHYSIN, GAD1, PSD- 95 and VGAT.
• Examples of behavioral parameters and methods of testing them include, but are not limited to, motor activity (open field test, which also examines the anxiety-like behavior), social behavior (three-chambered social test), anxiety-like behavior (elevated plus maze), explorative activity, and repetitive and restricted behavior (novel object recognition), and/or restricted behavior (marble burying test).
• the animal model is a mammal.
• the animal is a rodent, e.g., mouse, rat or rabbit.
• the mouse if a juvenile mouse (e.g., 6 weeks old).
• composition which increases NO levels in a brain of said animal refers to any substance or physical condition which increases nNOS activity, prevents degradation thereof, prevents depletion of NO from the neural tissue above a level that is normal in non- ASD animals.
• the composition comprises a nucleic acid sequence for increasing expression of heterologous (exogenous) nNOS or homolog thereof in the brain.
• the nucleic acid agent is for increasing an activity of a regulatory region so as to increase expression of endogenous nNOS.
• Administration of the NO donor may be systemic or directly to the brain as described herein.
• the administering is systemic.
• the administering is directly into said brain of said animal.
• the composition comprises an NO donor.
• the NO donor comprises S-nitroso-N- acetylpenicillamines (SNAP).
• NO donors include, but are not limited to, SNAP, nitrates, nitrites, N- nitroso, C-nitroso, S-nitroso, heterocyclics, metal/NO complexes, diazeniumdiolates; organic nitrates such as nitroglycerin, isosorbide-5-mononitrate, nicorandil, pentaerythritol tetranitrate; sodium nitroprusside (SNP), S-nitrosothiols such as S-nitroso-N-acetylpenicillamine (SNAP) and S-nitrosoglutathione; sydnonimines (e.g., molsidomine, SIN-1); and NONOates (e.g., JS-K, Spermine NONOate, and Proli-NONOate
• Embodiments of the present teachings relate to the use of such animals and cells/tissues derived therefrom in research such as in drug screening and development of diagnostic assays.
• an animal model produced according to the method as described herein.
• compositions, method or structure may include additional ingredients, steps and/or parts, but only if the additional ingredients, steps and/or parts do not materially alter the basic and novel characteristics of the claimed composition, method or structure.
• a compound or “at least one compound” may include a plurality of compounds, including mixtures thereof.
• range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of the invention. Accordingly, the description of a range should be considered to have specifically disclosed all the possible subranges as well as individual numerical values within that range. For example, description of a range such as from 1 to 6 should be considered to have specifically disclosed subranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6 etc., as well as individual numbers within that range, for example, 1, 2, 3, 4, 5, and 6. This applies regardless of the breadth of the range.
• a numerical range is indicated herein, it is meant to include any cited numeral (fractional or integral) within the indicated range.
• the phrases “ranging/ranges between” a first indicate number and a second indicate number and “ranging/ranges from” a first indicate number “to” a second indicate number are used herein interchangeably and are meant to include the first and second indicated numbers and all the fractional and integral numerals therebetween.
• method refers to manners, means, techniques and procedures for accomplishing a given task including, but not limited to, those manners, means, techniques and procedures either known to, or readily developed from known manners, means, techniques and procedures by practitioners of the chemical, pharmacological, biological, biochemical and medical arts.
• sequences that substantially correspond to its complementary sequence as including minor sequence variations, resulting from, e.g., sequencing errors, cloning errors, or other alterations resulting in base substitution, base deletion or base addition, provided that the frequency of such variations is less than 1 in 50 nucleotides, alternatively, less than 1 in 100 nucleotides, alternatively, less than 1 in 200 nucleotides, alternatively, less than 1 in 500 nucleotides, alternatively, less than 1 in 1000 nucleotides, alternatively, less than 1 in 5,000 nucleotides, alternatively, less than 1 in 10,000 nucleotides.
• any Sequence Identification Number can refer to either a DNA sequence or a RNA sequence, depending on the context where that SEQ ID NO is mentioned, even if that SEQ ID NO is expressed only in a DNA sequence format or a RNA sequence format.
• any of the active agents as described herein can be in form of a pharmaceutically acceptable salt, as defined herein, a prodrug, a hydrate or a solvate thereof.
• prodrug refers to a compound which is converted in the body to an active compound.
• a prodrug is typically designed to facilitate administration, e.g., by enhancing absorption.
• a prodrug may comprise, for example, the active compound modified with ester groups, for example, wherein any one or more of the hydroxyl groups of a compound is modified by an acyl group, optionally (C 1-4 )-acyl (e.g., acetyl) group to form an ester group, and/or any one or more of the carboxylic acid groups of the compound is modified by an alkoxy or aryloxy group, optionally (C 1-4 )-alkoxy (e.g., methyl, ethyl) group to form an ester group.
• solvate refers to a complex of variable stoichiometry (e.g., di-, tri-, tetra-, penta-, hexa-, and so on), which is formed by a solute (the heterocyclic compounds described herein) and a solvent, whereby the solvent does not interfere with the biological activity of the solute.
• hydrate refers to a solvate, as defined hereinabove, where the solvent is water.
• the active agents as described herein can be used as polymorphs and the present embodiments further encompass any isomorph of the active agent and any combination thereof.
• the compounds and structures described herein encompass any stereoisomer, including enantiomers and diastereomers, of the compounds described herein, unless a particular stereoisomer is specifically indicated.
• enantiomer refers to a stereoisomer of a compound that is superposable with respect to its counterpart only by a complete inversion/reflection (mirror image) of each other. Enantiomers are said to have “handedness” since they refer to each other like the right and left hand. Enantiomers have identical chemical and physical properties except when present in an environment which by itself has handedness, such as all living systems.
• a compound may exhibit one or more chiral centers, each of which exhibiting an (R) or an (S) configuration and any combination, and compounds according to some embodiments of the present invention, can have any their chiral centers exhibit an (R) or an (S) configuration.
• diastereomers refers to stereoisomers that are not enantiomers to one another. Diastereomerism occurs when two or more stereoisomers of a compound have different configurations at one or more, but not all of the equivalent (related) stereocenters and are not mirror images of each other. When two diastereoisomers differ from each other at only one stereocenter they are epimers. Each stereo-center (chiral center) gives rise to two different configurations and thus to two different stereoisomers.
• embodiments of the present invention encompass compounds with multiple chiral centers that occur in any combination of stereo-configuration, namely any diastereomer.
• alkyl refers to any saturated aliphatic hydrocarbon including straight chain and branched chain groups.
• the alkyl group has 1 to 20 carbon atoms. Whenever a numerical range; e.g., “1 to 20”, is stated herein, it implies that the group, in this case the hydrocarbon, may contain 1 carbon atom, 2 carbon atoms, 3 carbon atoms, etc., up to and including 20 carbon atoms. More preferably, the alkyl is a medium size alkyl having 1 to 10 carbon atoms. Most preferably, unless otherwise indicated, the alkyl is a lower alkyl having 1 to 4 carbon atoms. The alkyl group may be substituted or non-substituted.
• the substituent group can be, for example, cycloalkyl, aryl, heteroaryl, heteroalicyclic, halo, hydroxy, alkoxy, aryloxy, thiohydroxy, thioalkoxy, thioaryloxy, sulfinyl, sulfonyl, sulfonate, sulfate, cyano, nitro, azide, phosphonyl, phosphinyl, oxo, imine, oxime, hydrazone, carbonyl, thiocarbonyl, a urea group, a thiourea group, O-carbamyl, N-carbamyl, O-thiocarbamyl, N-thiocarbamyl, S- thiocarbamyl, C-amido, N-amido, C-carboxy, O-carboxy, sulfonamido, guanyl, guanidinyl, hydra
• alkenyl describes an unsaturated aliphatic hydrocarbon comprise at least one carbon-carbon double bond, including straight chain and branched chain groups.
• the alkenyl group has 2 to 20 carbon atoms. More preferably, the alkenyl is a medium size alkenyl having 2 to 10 carbon atoms. Most preferably, unless otherwise indicated, the alkenyl is a lower alkenyl having 2 to 4 carbon atoms.
• the alkenyl group may be substituted or non-substituted.
• Substituted alkenyl may have one or more substituents, whereby each substituent group can independently be, for example, alkynyl, cycloalkyl, alkynyl, aryl, heteroaryl, heteroalicyclic, halo, hydroxy, alkoxy, aryloxy, thiohydroxy, thioalkoxy, thioaryloxy, sulfinyl, sulfonyl, sulfonate, sulfate, cyano, nitro, azide, phosphonyl, phosphinyl, oxo, imine, oxime, hydrazone, carbonyl, thiocarbonyl, a urea group, a thiourea group, O-carbamyl, N-carbamyl, O-thiocarbamyl, N- thiocarbamyl, S-thiocarbamyl, C-amido, N-amido, C-carboxy,
• alkynyl describes an unsaturated aliphatic hydrocarbon comprise at least one carbon-carbon triple bond, including straight chain and branched chain groups.
• the alkynyl group has 2 to 20 carbon atoms. More preferably, the alkynyl is a medium size alkynyl having 2 to 10 carbon atoms. Most preferably, unless otherwise indicated, the alkynyl is a lower alkynyl having 2 to 4 carbon atoms.
• the alkynyl group may be substituted or non- substituted.
• Substituted alkynyl may have one or more substituents, whereby each substituent group can independently be, for example, cycloalkyl, alkenyl, aryl, heteroaryl, heteroalicyclic, halo, hydroxy, alkoxy, aryloxy, thiohydroxy, thioalkoxy, thioaryloxy, sulfinyl, sulfonyl, sulfonate, sulfate, cyano, nitro, azide, phosphonyl, phosphinyl, oxo, imine, oxime, hydrazone, carbonyl, thiocarbonyl, a urea group, a thiourea group, O-carbamyl, N-carbamyl, O-thiocarbamyl, N- thiocarbamyl, S-thiocarbamyl, C-amido, N-amido, C-carboxy, O-carboxy,
• a “cycloalkyl” group refers to a saturated on unsaturated all-carbon monocyclic or fused ring (i.e., rings which share an adjacent pair of carbon atoms) group wherein one of more of the rings does not have a completely conjugated pi-electron system.
• Examples, without limitation, of cycloalkyl groups are cyclopropane, cyclobutane, cyclopentane, cyclopentene, cyclohexane, cyclohexadiene, cycloheptane, cycloheptatriene, and adamantane.
• a cycloalkyl group may be substituted or non- substituted.
• the substituent group can be, for example, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heteroalicyclic, halo, hydroxy, alkoxy, aryloxy, thiohydroxy, thioalkoxy, thioaryloxy, sulfinyl, sulfonyl, sulfonate, sulfate, cyano, nitro, azide, phosphonyl, phosphinyl, oxo, imine, oxime, hydrazone, carbonyl, thiocarbonyl, a urea group, a thiourea group, O-carbamyl, N-carbamyl, O-thiocarbamyl, N-thiocarbamyl, S-thiocarbamyl, C- amido, N-amido, C-carboxy, O-carboxy, sulfonamido, gu
• aryl group refers to an all-carbon monocyclic or fused-ring polycyclic (i.e., rings which share adjacent pairs of carbon atoms) having a completely conjugated pi-electron system. Examples, without limitation, of aryl groups are phenyl, naphthalenyl and anthracenyl. The aryl group may be substituted or non-substituted.
• the substituent group can be, for example, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heteroalicyclic, halo, hydroxy, alkoxy, aryloxy, thiohydroxy, thioalkoxy, thioaryloxy, sulfinyl, sulfonyl, sulfonate, sulfate, cyano, nitro, azide, phosphonyl, phosphinyl, oxo, imine, oxime, hydrazone, carbonyl, thiocarbonyl, a urea group, a thiourea group, O-carbamyl, N-carbamyl, O-thiocarbamyl, N-thiocarbamyl, S- thiocarbamyl, C-amido, N-amido, C-carboxy, O-carboxy, sulfonamido,
• heteroaryl group refers to a monocyclic or fused ring (i.e., rings which share an adjacent pair of atoms) having in the ring(s) one or more atoms, such as, for example, nitrogen, oxygen and sulfur and, in addition, having a completely conjugated pi-electron system.
• heteroaryl groups include pyrrole, furan, thiophene, imidazole, oxazole, thiazole, pyrazole, pyridine, pyrimidine, quinoline, isoquinoline and purine.
• the heteroaryl group may be substituted or non-substituted.
• the substituent group can be, for example, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heteroalicyclic, halo, hydroxy, alkoxy, aryloxy, thiohydroxy, thioalkoxy, thioaryloxy, sulfinyl, sulfonyl, sulfonate, sulfate, cyano, nitro, azide, phosphonyl, phosphinyl, oxo, imine, oxime, hydrazone, carbonyl, thiocarbonyl, a urea group, a thiourea group, O-carbamyl, N-carbamyl, O-thiocarbamyl, N-thiocarbamyl, S- thiocarbamyl, C-amido, N-amido, C-carboxy, O-carboxy, sulfonamido,
• a “heteroalicyclic” group refers to a monocyclic or fused ring group having in the ring(s) one or more atoms such as nitrogen, oxygen and sulfur.
• the rings may also have one or more double bonds. However, the rings do not have a completely conjugated pi-electron system.
• the heteroalicyclic may be substituted or non-substituted.
• the substituted group can be, for example, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heteroalicyclic, halo, hydroxy, alkoxy, aryloxy, thiohydroxy, thioalkoxy, thioaryloxy, sulfinyl, sulfonyl, sulfonate, sulfate, cyano, nitro, azide, phosphonyl, phosphinyl, oxo, imine, oxime, hydrazone, carbonyl, thiocarbonyl, a urea group, a thiourea group, O-carbamyl, N-carbamyl, O-thiocarbamyl, N- thiocarbamyl, S-thiocarbamyl, C-amido, N-amido, C-carboxy, O-carboxy, sulfonamido,
• amine each refer to either a -NR’R” group or a - N + R’R”R’” group, whereinR’, R” and R’” are each hydrogen or a substituted or non-substituted alkyl, alkenyl, alkynyl, cycloalkyl, heteroalicyclic (linked to amine nitrogen via a ring carbon thereof), aryl, or heteroaryl (linked to amine nitrogen via a ring carbon thereof), as defined herein.
• R’, R” and R’ are hydrogen or alkyl comprising 1 to 4 carbon atoms.
• R’ and R” (and R’”, if present) are hydrogen.
• R’, R” or R” ’ hydrocarbon moiety which is bound to the nitrogen atom of the amine is not substituted by oxo (unless explicitly indicated otherwise), such that R’, R” and R’” are not (for example) carbonyl, C-carboxy or amide, as these groups are defined herein.
• alkoxy group refers to any of an -O-alkyl, -O-alkenyl, -O-alkynyl, -O-cycloalkyl, and -O-heteroalicyclic group, as defined herein.
• aryloxy refers to both an -O-aryl and an -O-heteroaryl group, as defined herein.
• a “hydroxy” group refers to a -OH group.
• a “thiohydroxy” or “thiol” group refers to a -SH group.
• a “thioalkoxy” group refers to any of an -S-alkyl, -S-alkenyl, -S-alkynyl, -S-cycloalkyl, and -S-heteroalicyclic group, as defined herein.
• a “thioaryloxy” group refers to both an -S-aryl and an -S-heteroaryl group, as defined herein.
• halo refers to fluorine, chlorine, bromine or iodine.
• a “sulfonamide” or “sulfonamido” group encompasses both S-sulfonamido and N- sulfonamido groups, as defined herein.
• amide or “amido” group encompasses C-amido and N-amido groups, as defined herein.
• a “nitro” group refers to an -NO 2 group.
• a “cyano” group refers to a -C ⁇ N group.
• phosphinyl describes a -PR’R” group, with each of R’ and R” as defined hereinabove.
• hydrozine describes a -NR’-NR”R”’ group, with R’, R”, and R’” as defined herein.
• alkylene glycol describes a -O-[(CR’R”) z -O] y -R”’ end group or a -O-[(CR’R”) z -O] y - linking group, with R’, R” and R’” being as defined herein, and with z being an integer of from 1 to 10, preferably, from 2 to 6, more preferably 2 or 3, and y being an integer of 1 or more.
• R’ and R” are both hydrogen.
• z is 2 and y is 1, this group is ethylene glycol.
• z is 3 and y is 1, this group is propylene glycol.
• y 2-4, the alkylene glycol is referred to herein as oligo(alkylene glycol).
• the alkylene glycol is referred to herein as poly( alkylene glycol).
• a poly( alkylene glycol) group or moiety can have from 10 to 200 repeating alkylene glycol units, such that z is 10 to 200, preferably 10-100, more preferably 10-50.
• saccharide as used herein encompasses monosaccharides, disaccharides and oligosaccharides.
• monosaccharides include glucose (dextrose), fructose, galactose, and ribose.
• Monosaccharides can be classified according to the number of carbon atoms of the carbohydrate, i.e., triose, having 3 carbon atoms such as glyceraldehyde and dihydroxyacetone; tetrose, having 4 carbon atoms such as erythrose, threose and erythrulose; pentose, having 5 carbon atoms such as arabinose, lyxose, ribose, xylose, ribulose and xylulose; hexose, having 6 carbon atoms such as allose, altrose, galactose, glucose, gulose, idose, mannose, talose, fructose, psicose, sorbose and tagatose; heptose, having 7 carbon atoms such as
• SHANK3 and CNTNAP2 mutant mice were obtained from Jackson Laboratory and used for studying behavioral and synaptic abnormalities associated with autism spectrum disorder. Unless otherwise indicated, WT and mutant mice are 6-weeks old.
• SHANK3 mutation leads to an increase of in nitric oxide (NO) levels and to changes in the S-nitroso-proteome in SHANKS mice.
• NO nitric oxide
• the present inventors have showed that this mutation leads to S-nitrosylation of key proteins involved in vesicle release and synaptic function which could result in autistic-like behaviors (Amal et al. Molecular Psychiatry 2018, w w w(dot)doi(dot)org/ 10(dot) 1038/s41380-018-0113-6).
• S-nitroso-N-acetylpenicillamines was obtained from Tzamal D-Chem WT or mutated Mice were treated with SNAP intraperitoneally. Each mouse was given the dose of 20 mg/ kg body weight on each day of the experiment. Behavioral testing started after 2 hours of treatment. SNAP was first solubilized in DMSO (solubility is 20 mg/ml) and further volume was made up with 0.9% saline. Control animals were treated with vehicle (0.9 % saline and DMSO). All animals were sacrificed after 24 hours of last treatment [1].
• Open field test Mice were tested in an open field (45 X 45 cm) virtually divided into central and peripheral regions. Animal activity was recorded by video tracking (Noldus Ethovision). Each mouse was allowed to explore the apparatus for 5 minutes. The distance traveled, the number of rears and revolutions, the number of grooming bouts and cumulative grooming time, the number of head shaking or twitches, the number of entries in the center, and the time spent in the central and peripheral regions were recorded. Measures were recorded in 5- minute intervals.
• Novel object recognition takes place in a white open field arena (45 X 45 cm).
• the test involves a set of two unique novel objects, each about the size of a mouse, constructed from two different materials and non- uniform in shape[4].
• the test consisted of one 10-minute habituation session, a 5-minute familiarization session and a 5-minute recognition test, each video tracked (Noldus Ethovision). During the habituation, animals were allowed to freely explore an empty open field. At the end of the session, they were shifted from the open field to a place in a temporary clean holding cage for about 2 minutes.
• Familiarization and recognition sessions were scored for total time spent investigating each object, the number of object interactions and the latency of the first object interaction.
• Time spent in each side during habituation and familiarization and time spent sniffing two identical objects during the familiarization phase were used to examine an innate side bias.
• Total time spent sniffing both objects was used as a measure of general exploration.
• FIG. 4B Three-chambered sociability test (see, FIG. 4B): Sociability and preference for social novelty and social recognition were tested in a three-chambered apparatus. The subjected mouse was first placed in the central, neutral chamber and allowed to explore for 10 minutes with all the doors closed. Next, doors were opened and the mouse was allowed to freely explore the other two empty chambers (1 and 2) for an additional 10 minutes. Lack of side preference was confirmed during this habituation.
• Elevated plus maze test (see, FIG. 4C): The elevated plus-maze consisted of four arms (30 X 5 cm), two open, and the other two closed. The platform was made of white plexiglass. The apparatus was elevated 45 cm above the floor. The test, described in, was initiated by placing the mouse on the central platform of the maze, facing one of the open arms, and letting it move freely. Each session lasted 5 min. The time spent in the close and open arms was recorded.
• marble Burying test ( see, FIG. 4D): The marble-burying assay is a tool for assessing either anxiety-like and/or repetitive- like behaviors in mice. Subjects were tested in a regular clean cage (28 cm long X 18 cm wide X 12 cm high) with 3 cm of fresh bedding. The subject was first placed in the empty cage for a 5-min habituation. It was then temporary placed in an empty clean cage while 20 dark blue glass marbles (15 mm in diameter) were positioned over the bedding equidistant in a 4 X 5 arrangement to cover the whole cage surface. The subject was then returned in the test cage and allowed to explore and bury the marbles during a 15-min session that was videotaped. At the end of the session the subject was removed and the number of marbles buried (50% marble covered by bedding material) was recorded.
• 3-Nitrotyrosine is a post-translational modification in proteins occurring through the action of a nitrating agent resulting in the addition of a N(3 ⁇ 4 group (at the ortho position to the phenolic hydroxyl group), leading to protein tyrosine nitration (PTN).
• PTN protein tyrosine nitration
• An essential feature of PTN is that it is a stable post-translational modification and does not occur at random.
• 3-Ntyr represents a reliable marker of nitrosative stress.
• WB analysis of cortex tissues prepared from wild-type mice (C57BL/6 mice) and two ASD mouse models - SHANK3 mouse model (Ml) and CNTNAP2 mouse model (M2) showed higher levels of Ntyr in both ASD mouse models compared to the wild-type (FIG. 1C), as is also demonstrated in the respective qualitative analyses presented in FIGs. ID and IE.. *P ⁇ 0.05.
• SNAP administration induces ASD-like phenotypes in a C57BL/6 mouse model
• S-nitroso-N-acetylpenicillamines is an NO donor that increases the NO availability, subsequently leading to nitrosative stress and aberrant SNO signaling.
• Wild-type mice were treated with SNAP intraparentaly (IP), 20 mg/kg/day for 7 days.
• IP intraparentaly
• NOR novel object recognition test
• sociability test See, FIGs. 4A-B, and the obtained data are presented in FIGs. 2A-B, respectively.
• the NOR test showed that SNAP-treated mice failed to display a preference for the novel object, whereas the control group spent significantly more time exploring the novel object.
• the sociability test showed that the control group spent more time interacting with the stranger cage, indicating high sociability. Conversely, the SNAP-treated mice did not exhibit any preference to engage in social interaction.
• 7-nitroindazole (7-NI) is a selective inhibitor of neuronal nitric oxide synthase.
• IP 7-NI interparentally
• NOR object recognition test
• sociability test See, FIGs. 4A-B, and the obtained data are presented in FIGs. 3A-B, respectively.
• the NOR test showed that the 7-NI-treated mice exhibited a significant preference for the novel object over the familiar object, while vehicle-treated mice spent significantly less time exploring the novel object compared to the 7-NI treated mice.
• the sociability test showed that 7-NI-treated mice spent significantly more time interacting with the stranger cage, while the vehicle-treated mice did not exhibit any preference for social interaction.
• 3-nitrotyrosine levels in were also evaluated by confocal microscopy of the cortical region in neurons of the tested mice, and the obtained data is presented in FIGs. 3G and 3H. As can be seen, 7-NI treatment reduced 3-nitrotyrosine levels in the neurons by about 50 %, compared to neurons of untreated mice.
• NOR novel object recognition test
• This test is based on the spontaneous tendency of the mice to spend a prolonged time exploring a novel object than a familiar one (see, FIG. 4A).
• FIG. 5 A the NOR test showed that the WT mice spent significantly more time exploring the novel object than the familiar object, whereas the SNAP-treated mice failed to display a preference for the novel object, indicating a lack of interest and reduced novelty seeking among the SNAP- treated group.
• a three- chamber sociability test was conducted as in Example 2 (see also FIG. 4B), to evaluate the interest of the mice to engage in social interaction with a stranger mouse.
• mice prefer to spend more time with another mouse (sociability), and the mice have the tendency to investigate a novel intruder more than a familiar one (social novelty).
• This test occurs in two different sessions: in the first one (see, upper illustration in FIG. 4B) the mice encounter a stranger mouse (Stranger) and an empty cage, and this session determines the sociability, while in the second session (see, lower image in FIG. 4B) the mice encounter the first intruder (SI) and a novel intruder (S2), and this session determines the social novelty .
• FIG. 4C An elevated plus maze test (see, FIG. 4C) was performed to evaluate the anxiety-like behaviors among the mice, typically the anxiety quantified as the time spent in the closed arms. As shown in FIG. 5C, the analysis showed that the SNAP-treated mice spent significantly more time in the closed arms compared to WT group, reflecting a likelihood of anxious behaviors among the mice that were treated with SNAP.
• a marble burying test (as shown in FIG. 4D) was utilized as an indication for repetitive behaviors and restricted interests. As shown in FIG. 5D, the analysis showed that the SNAP treated mice buried significantly less marbles compared to their WT counterparts. These results indicate a lack of interest to explore novel objects in the SNAP-treated mice.
• mice were divided into three testing groups: WT mice, SHANK3 knockout mice (Ml) and SHANK3 knockout mice that were administered with 7-NI (M1+7NI) (chronical IP injections , 80 mg/kg/day for 10 days, 3 days before starting the behavioral test).
• FIG. 6A The data obtained in the novel object recognition test is presented in FIG. 6A, and show that the WT mice spent significantly more time exploring the novel object than the familiar one, whereas the Ml mice did not exhibit any significant preference for the novel object, reflecting a reduced novelty seeking and restricted interests. Following treatment with the 7-NI the Ml mice exhibited a significant preference for the novel object over the familiar one.
• the Novel Object Recognition Test (see, FIG. 4A) was conducted with aged (10 months) WT mice, SHANK3 knockout mice (Ml) and SHANK3 knockout mice that were administered with 7-NI (M1+7NI) (chronical IP injections , 80 mg/kg/day for 10 days, 3 days before starting the behavioral test).
• FIGs. 6B and 6C show that also the aged autism mice lost their memory, which was restored by the 7-NI treatment.
• mice were divided into three testing groups: WT mice, CNTNAP2-/- mutant mice (M2), and mutant mice that were administered with 7-NI (M2+7NI).
• WT mice WT mice
• M2 CNTNAP2-/- mutant mice
• M2+7NI 7-NI mice
• a three-chamber sociability test was conducted (See, FIG. 4B) and the data is presented in FIG. 7A. The analysis showed that the mutant mice (M2) spent significantly less time interacting with the stranger mouse compared to their WT littermates, indicating a lack of sociability among the mutant mice.
• the 7-NI treated mice (M2+7NI) spent significantly prolonged time interacting with the stranger mouse compared to their untreated counterparts - M2.
• An elevated plus maze test (see, FIG. 4C) was also conducted and the obtained data is presented in FIG. 7B.
• the analysis showed that the mutant mice (M2) spent significantly more time in the closed arms compared to the WT mice, conceivably, indicating increased anxiety among the mutant mice.
• the mice exhibited less anxiety like behaviors compared to the untreated mutant mice.
• mice A dose dependent study was conducted to determine the optimal dose that may produce the greatest effect on mice behavior.
• mice that were treated with 80 mg/kg spent significantly more time interacting with the stranger mouse compared to the mice that were administered with 20 mg/kg of 7-NI. Comparing to the 50 mg/kg, although statistically the difference is not significant, the 80 mg/kg - treated group spent more time interacting with the stranger mouse.
• the second session of the test showed that the mice that were treated with 80 mg/kg 7-NI spent more time interacting with the novel mouse (S2) compared to their counterparts that were treated with lower doses of 7-NI.
• siRNA silencing of nN OS in the background of silenced SHANK3 alleviates ASD phenotype as determined by the synaptophysin marker
• a cell culture model for ASD was developed by silencing SHANK3 with an siRNA (5-3 RNA)- CGA UGA UAA GCA GUU UGC AAA GCU U (SEQ ID NO: 3) in the neuronal ceil line SHSY-5Y cells, followed by silencing with of nNOS using the following RNA (5-3) CCU UGU CCA ACA UGC UCC UAG AGA U (SEQ ID NO: 4).
• SHSY-5Y Cells (with or without treatment) were fixed post treatment in 4 % paraformaldehyde, incubated with the Primary rabbit MAP2+ primary mouse monoclonal 3- nitrotyrosine (FIGs. 9A-B) and with Primary rabbit monoclonal synaptophysin+ primary mouse Map2 (FIGs. 9C-D). Thereafter, cells were incubated with anti-mouse secondary Alexa fluor488 (green)/594(red), and anti-rabbit secondary Alexa fluor 488 (green)/594(red), conjugated secondary antibodies. After washing, cells were mounted with DAPI (Blue). The images were acquired using a confocal microscope. Each group contained nine independent sets of experiments (initial cell seed number - about lO 6 ).
• siRNA to nNQS on primary cultures of SHSY-5Y Cells.
• Silencing nNOS in the SHANKS si-RNA group shows the reduction in nitrotyrosine production (FIGs. 9A-B).
• Synaptophysin which is a reliable marker (Kathuria et al. Mol Psychiatry, 2018 Mar;23(3):735-746) of synaptogenesis and ASD was found to be downregulated in SHSY-5Y cells after treatment with SHANK3 si-RNA (FIGs. 9C-D).
• SHANK3 si-RNA double knockdown
• a recovery in synaptophysin protein expression was observed (FIGs. 9C-D).
• 7-nitroindazole (7-NI) inhibits nitric oxide synthase (NOS) and has been used extensively as a selective inhibitor of neuronal NOS (J. Neurol. Sci. 1998, 160, 9-15). Compared to the other drugs that are currently available, 7-NI evidences a 10-fold selectivity for neuronal NOS ( Pharm Res., 2001, 18, 1607-1612). Despite of the high selectivity for the NOS, 7-NI has a short half-life that does not exceed 2 hours even in very high doses ( Biopharm . Drug Dispos. 2000, 21, 221- 228).
• 7-NI is further limited by a very low solubility in aqueous medium, and hence it is commonly administered by IP injection upon dissolving it in oils (e.g., peanut oil or corn oil).
• oils e.g., peanut oil or corn oil.
• Blank PNL formulation is generally prepared by mixing common surfactants/dispersing agents, particles-forming lipids, and an edible solvent.
• Table 1 below presents an exemplary PNL formulation according to some embodiments of the present invention. The components listed in Table 1 and the amount/concentration thereof should not be regarded as limiting as each of the recited components can be replaced by an alternative component that exhibits the same functionality and is considered as safe, and the relative amount of each component can be altered or adjusted to improve solubility and/or stability.
• the formulation can be prepared by mixing the components at room or elevated temperature to form a clear liquid which 7-nitroindazole is soluble in at about 20 % w/v.
• the formulation is a liquid or semi- solid at room temperature and can optionally be loaded in soft gelatin capsules for oral swallowing, or formulated as tablets for oral administration, or mixed with water to form a nano-dispersion for administration by nasal spray, inhalation, eye drops or injection, as described herein.
• tablets containing 7-nitroindazole- PNL were prepared using the formulation described in Table 1.
• a porcelain mortar to which 300 mg of silica powder, Neusilin US2, was added along with 200 microliters of PNL formulation containing 40 mg 7-NI .
• the mixture was thoroughly blended with a mortar and a pestle until a homogenous mixture was obtained.
• 100 mg HPMC and a tableting aid Syloid 244 FT (5 mg) were added in a geometric mixing until a homogenous mixture was obtained.
• the powdery mixture was fed manually into the die of an instrumented single punch tableting machine to produce tablets using a 1.3 cm flat faced punch. Tablets were prepared by direct compressing. The compression force was set at 3 ton for 10 seconds.
• An exemplary PNL formulation for oral delivery of 7-NI was prepared using MCT, Tween®80; KolliporRH 40; KolliporHS 15; Propylene glycol; Labrasol®; and 7-Nitroinidazole (7-NI), as follows:
• MCT Medium chain triglycerides
• the name refers to the way the carbon atoms are arranged in their chemical structure.
• MCTs are generally made by processing coconut and palm kernel oils in the laboratory.
• Usual dietary fats, by comparison, are long-chain triglycerides.
• MCTs are also used as medicines. MCTs are taken by mouth or given with a needle alone or along with usual medications for involuntary weight loss in people who are very ill (cachexia or wasting syndrome).
• MCTs are also used for obesity, seizures, athletic performance, and other conditions, but there is no good scientific evidence to support these other uses.
• Tween®80 Polysorbate 80 is a nonionic surfactant and emulsifier often used in foods and cosmetics. This synthetic compound is a viscous, water-soluble yellow liquid.
• Labrasol® is a PEG derivative of medium chain fatty acid triglyceride of capric and caprylic acid (Caprylocaproyl Polyoxyl-8 glycerides). It consists of a small fraction of mono- , di- and triglycerides and mainly PEG-8 (MW 400) monoester and diester of caprylic (C8) and capric (CIO) acids. It is widely used in PNL formulations due to its good solubilizing power and spontaneous self-emulsification ability.
• Kolliphor® RH 40 is a nonionic solubilizer and emulsifying agent obtained by reacting 40 moles of ethylene oxide with 1 mole of hydrogenated castor oil.
• the main constituent of Kolliphor®RH 40 is glycerol polyethylene glycol oxystearate, which, together with fatty' acid glycerol polyglycol esters, forms the hydrophobic part of the product.
• the hydrophilic part consists of polyethylene glycols and glycerol ethoxylate.
• Kolliphor®RH 40 is a white to yellowish paste at 20 °C.
• Kol liphor ⁇ RH 40 is widely used and approved solubilizer, is chemically stable and practically tasteless, making it a good component for oral applications, particularly suited for aqueous solutions of fat-soluble vitamins, Suitable for preparing dispersions and emulsions as it is less digestible in the gastrointestinal tract as compared to other unsaturated ethoxylated surfactants.
• Kolliphor® HS 15 is a nonionic solubilizer and emulsifying agent obtained by reacting 15 moles of ethylene oxide with 1 mole of 12-hydroxy stearic acid.
• Kolliphor® HS 15 was designed to provide a low immunogenicity during parenteral administration.
• Propylene glycol is a synthetic food additive that belongs to the same chemical group as alcohol. It is a colorless, odorless, slightly syrupy liquid that is a bit thicker than water. It has practically no taste. Table 2 below presents the components that make-up the exemplary PNL blank formulation.
• Table 2 All the materials were weighed in the glass vial and heated at 70 °C for 20 minutes until a clear transparent liquid was obtained. The mixture was stirred timely to assure complete mixing and homogeneity. Thereafter, the mixture was cooled to room temperature for 2 hours.
• 7-NI loaded PNL formulation was prepared by adding the drug at a selected weight % to the PNL mixture at 70 °C and stirring for 30 minutes. The drug dissolved in the PNL mixture. The mixture thereafter was cooled to room temperature for 1 hour.
• FIG. 10A presents photographs of the obtains PNL solution, without and with 7-NI, showing that both formulations are transparent at room temperatures.
• the stability of the PNL was tested by keeping it at room temperature for 3 days. No phase separation was observed.
• Dynamic light scattering was used to check the size of the obtained nanoparticle aqueous dispersions. 100 ⁇ L of the freshly prepared PNL was dispersed in 10 mL DDW, and 100 ⁇ L of the dispersion was diluted with 1 mL DDW and analyzed.
• DLS Dynamic light Scattering
• the z- average of the NPs was calculated using the auto-correlation function of the intensity of light scattered from the particles, assumed to be in the spherical form by the instrument software.
• the dispersibility of the PNL formulations upon storage at room temperature for 3 days was also tested. After 3 days storage, 100 ⁇ L of the PNL formulation was dispersed in 10 mL DDW and checked for aggregation. The obtained data is presented in Table 4, demonstrating no aggregation in both PNL formulations.
• Table 4 The obtained data demonstrate that the designed 2% w/w 7-NI-containing PNL formulation is a stable formulation and does not show aggregation upon dispersion in DDW.
• the PNL nano-dispersion is easily prepared by shaking in water and the size of the particles in the dispersion is smaller than 20 nm.
• the designed 7-NI-loaded PNL formulation is suitable for the oral drug delivery of 7-NI as well as for eye drops or nose-to-brain nasal spray for direct delivery to the brain.
• Particles loaded with about 20 % w/w 7-nitroindazole are obtained with an average particle size of about 35 microns.
• the in vitro release is determined in physiologic phosphate buffer at 37 °C where the release media is replaced at certain time points and analyzed by UV or HPLC for 7-nitroindazole concentration. A constant release for more than 20 days is obtained.
• the indazole moiety of 7-Nitroindazole is prone to the formation of a salt by: (i) eliminating the proton from the N-H of the azole to thereby obtain a negatively- charged indazole that forms a salt with a positively charged moiety (e.g., cation), including, for example, divalent and trivalent metal ions, ammonium ions and phosphonium ions, referred to herein as cationic salts of 7-NI; or (ii) protonating the basic amine that is part of the aromatic ring using proton containing molecules, such as, for example, HC1, phosphoric acid, phosphonic acid, sulfuric acid, sulfonic acid, and organic acids, referred to herein as anionic salts of 7-NI.
• Such salts may confer different or improved properties compared to 7-NI, including, for example, solubility, thermal properties and stability, chemical stability, ease of formulation, controlled release, crossing biological membranes and bio-distribution
• the salts can be formulated in, for example, aqueous or lipidic solutions for injection, oral administration, or nasal-spray administration.
• salts that are formed by abstraction of the N-H proton of the Indazole to form Indazole anion that form a salt with cationic counterparts can be prepared using various cation-forming materials that provide a desirable solubility.
• solubility can be tuned by the selecting the type of salt.
• lipidic cation such as phosphatidyl choline will form a lipid-soluble 7-NI.
• PEG terminated with triethylammonium forms a salt with indazole anions, the hydrophilic PEG chain will make the molecule hydrophilic.
• Salts with cations counterpart are prepared by reacting a corresponding base with 7- nitroindazole.
• the salt is analyzed by FTIR, DSC/TGA thermal analysis, elemental analysis and/or NMR.
• Potassium/Sodium salts of 7-Nitroindazole (FIG. 11A): Potassium/Sodium salts of 7- nitroindazole are synthesized using the synthetic procedure for potassium salt of indazole or triazole or pyrazole [7-9].
• a mole equivalent of 7-nitroindazole dissolved in water and 2- propanol (1:1) mixture a mole equivalent of 1 M aqueous potassium/sodium hydroxide is added and stirred for 15 minutes. The solution is evaporated to dryness under vacuum at 80 °C and then further dried in a vacuum oven for 4 hours at 110 °C.
• Calcium/Magnesium salts of 7 -Nitroindazole (FIG. 11B): Calcium/Magnesium salts of 7-nitroindazole are synthesized using 7-nitroindazole and calcium/magnesium hydride. To a solution of 7-Nitroindazole (2 mol equivalents, at least) dissolved in dry THF, CaH 2 MgH 2 is added and the obtained reaction mixture stirred overnight. The solution is thereafter evaporated to dryness under vacuum
• Zinc salt of 7- Nitroindazole (FIG. 11C): Zinc salts of 7-nitroindazole are synthesized using the synthetic procedure for zinc salt of pyrazole [10]. To a solution of Zn(OAc) 2 (1 mol equivalent) in H 2 O , a solution of 7-nitroindazole (2 mol equivalents, at least) in MeOH is added under stirring. The obtained suspension (e.g., 1:1 H 2 O:MeOH mixture) is stirred for 48 hours and thereafter filtered. The obtained solid salt is washed with water and dried under vacuum
• Iron/Cobalt salt of 7- Nitroindazole Iron(III) or Cobalt(m) salt of 7- nitroindazole is synthesized using the synthetic procedure for Fe(m) or Co(m) salt of pyrazole [11].
• a mixture of Fe(acetylacetonate)3 (Fe(acac)s) (1 mol equivalent) or Co(acac)3 (1 mol equivalent) and excess 7-nitroindazole (e.g., 15 mol equivalents) is heated in a sealed flask under nitrogen for 6 hours at 180 °C without stirring.
• the mixture is allowed to cool, and the precipitated solid is washed with acetone in order to remove excess 7-nitroindazole and then filtered off, giving the Fe(m) / Co(m) salt of 7-nitroindazole.
• the acetone can be evaporated to recover the unreacted 7-nitroindazole.
• Choline salt of 7 -Nitroindazole (FIG. HE): Choline salt of 7-nitroindazole in synthesized using 7-nitroindazole and choline hydroxide. To a mol equivalent of 7-nitroindazole dissolved in methanol, a mol equivalent of choline hydroxide is added and the obtained solution stirred overnight. The solution is thereafter evaporated to dryness in vacuum and then further dried in a lyophilizer.
• Sulfate salt of 7 -Nitroindazole (FIG. 11F ): Sulfate salt of 7-nitroindazole is synthesized using the synthetic procedure for sulfate salt of pyrazole [12-15].
• 7-Nitroindazole (1 or 2 mol equivalent(s)) is dissolved in acetonitrile or another organic non-protic solvent and then concentrated H 2 SO 4 (1 mol equivalent) is added dropwise under cooling conditions. The reaction mixture is stirred for 24 hours and refluxed in the presence of a flow of nitrogen gas. The obtained solid is washed with diethyl ether three times and dried in a vacuum oven overnight.
• Phosphate and mesylate salts of 7-NI are prepared similarly.
• the phosphate counter ion can be replaced with an organic carboxylate, including, for example, acetic, fumaric, and hexanoic acid.
• the present inventors have designed biodegradable-polymer based formulations that, once administered, provides a constant release of 7-NI in biological medium for 10 days or more.
• An exemplary formulation is based on a polymeric gel carrier that comprises poly(sebacic- co-ricinoleic) acid (PSARA) gel.
• PSARA poly(sebacic- co-ricinoleic) acid
• PSA:RA pasty injectable polymer of a 9200 molecular weight was prepared as previously prepared [Journal of Controlled Release, 2017, 257, 156-162].
• the formulation of PSA:RA with 7-NI was prepared with the drug at room temperature by gravimetric mixing, where 7-NI fine powder is gradually added to the polymer paste and mixed well to form a uniform fine paste. The paste is loaded into syringes for treatment.
• the final composition of 7-NI in the PSA:RA formulation was 5 % w/w.
• the formulation is injectable through 19G or 21G needle.
• Quantification of the 7-NI was done in methanol by detecting the absorbance wavelength at 355 nm A standard curve of 7-NI in methanol at a concentration range of 1-20 ⁇ g/mL, as shown in FIG. 12A, was generated.
• the release of 7-NI was monitored in 10 mM phosphate buffer at pH 7.2 and 37 °C under constant shaking at 75 rpm
• the solubility of the 7-NI in the PBS was found to be 0.14 mg/mL, which is consistent with the literature reported solubility (see, for example, Biopharm. Drug Dispos. 2000, 21, 221-228).
• the release medium was diluted suitably with methanol and absorbance was recorded.
• FIG. 12B presents the release profile of the 7-NI from the polymeric gel formulation. As can be seen, the release of 7-NI lasted for 7 days in PBS.
• PSARA Poly (sebacic-co-ricinoleic)acid
• 7-NI loaded PSA RA injectable formulations for extended releaseofthe high concentration of 7-NI were prepared as described in Example 12 hereinabove.
• FIG. 13A in an open field test performed on day 4 after injection, there was no significant change in motor activity between treated mutant mice and the respective control groups.
• FIGs. 13B-C in the three-chamber sociability test (day 9+10), both in the first and second days the treated mice spent more time around the cage of a novel animal/object compared to the untreated ones, indicating that 7-NI has a reversal effect on sociability behavior.
• FIG. 13D in the marble burying test (day 7), it was shown that while the mutant mice didn’t bury marbles which could indicate the loss of interest, the treated ones buried in average 8 out of 10 marbles, indicating that 7-NI treatment enhances the mice interest.
• FIG. 13E the anxious behavior for these mice was determined in an elevated plus maize and the obtained results show that the treated mice spent significantly more time in open arm comparing to the untreated mice.
• Human NB SH-SY5Y cells were obtained from the American Type Culture Collection (ATCC) and maintained in Dulbecco's modified Eagle's medium (DMEM) and Ham's F- 12 (1:1) supplemented with 10 % fetal bovine serum, 2 mM L-glutamine, and 100 U/ml penicillin- G/ 100 mg/ ml streptomycin in a humidified atmosphere (37 °C, 5 % CO 2 ). Cells were plated onto 25 cm 2 and 75 cm 2 plates at a density of 7.0 x 10 5 and 2.1 x 10 6 cells/cm 2 respectively for Western blotting (WB) and 1 x 10 5 for immunofluorescence.
• WB Western blotting
• the SH-SY5Y cells were treated with 100 mM 7- nitroindazole (7-NI) for 24 hours (Fujibayashi et al., 2015). This concentration was confirmed in a dose-response experiment (FIG. 14A) using an MTT viability assay.
• MTT cell viability assay MTT cell viability assay:
• SH-SY5Y cells were plated in 6 well plates, as well as on 22 mm 2 coverslips at a density of 6.0 x 10 4 cells/cm 2 and transfected with 20 nM nNOS siRNA (NOS 1HSS 1072, Invitrogen) for 24 hours, with the use of lipofectamine RNAi MAX (56530, Invitrogen) according to the manufacturer's protocol. Then cells were washed with phosphate-buffered saline (PBS) and harvested for WB and fixed for immunofluorescence (Fujibayashi et al., 2015).
• PBS phosphate-buffered saline
• Cells were seeded into 6-well plates at concentrations of 500/well or 1000/well in triplicates. After 24 hours, 7-NI was added (100 mM for 24 hours), or cells were transiently transfected with siRNA-nNOS, as described above, before changing to serum-containing medium. Cells were incubated for 14 days to form visible colonies. Colonies were stained with crystal violet, washed with PBS, air-dried, and imaged. The colonies were visualized using ImageJ software. Cell colonies of greater than 50 cells were identified and counted (Fopez-Rivera et al., 2014).
• the NADPH-diaphorase activity assay was used to determine the NOS activity based on the NADPH-dependent reduction of nitro-blue tetrazolium salt (NBT) to visible formazan (Amaroli and Chessa, 2012; Seckler etal., 2020).
• NBT nitro-blue tetrazolium salt
• SH-SY5Y cells grown in six-well culture plates were lysed in 50 mM Tris-HCl buffer (pH 7.4), containing 0.1% Triton X- 100, 2 mM EDTA, and a protease inhibitor cocktail (Sigma, St. Louis, MO).
• Cells were lysed in ice-cold RIPA buffer containing 50 mM Tris-HCl, 1 % Nonidet P-40, 0.25 % sodium deoxycholate, 150 mM NaCl, protease-, and phosphatase inhibitor cocktails, pH 7.4. After sonication, the lysates were centrifuged at 17,000 g for 30 minutes at 4 °C, and the supernatant was collected. The protein concentrations were determined with the BCA protein assay.
• Proteins were resolved by SDS-PAGE, transferred to a PVDF membrane, and probed with the following antibodies: anti-pMTOR (rabbit, diluted 1:1000), anti-mTOR (rabbit, diluted 1 : 1000), anti-TSC2 (rabbit, diluted 1 : 1000), anti-nNOS (rabbit, diled 1 : 1000), anti-pAKT (rabbit, diluted 1: 1000), anti- AKT (rabbit, diluted 1: 1000), anti-pRPS6 (rabbit, diluted l:1000), anti-RPS6 (mouse, diluted 1:1000), anti-synaptophysin (mouse, diluted 1:1000), anti- ⁇ -actin (rabbit, diluted 1: 1000), anti-3-Nitrotyrosine (rabbit, diluted 1:5000) from Abeam All primary antibodies, except anti-3-Nitrosine, were purchased from Cell Signaling Technology. The blots were then visualized using an enhanced chemiluminescence (ECL) system (Ch
• the cells were blocked with blocking buffer (PBS containing 1% BSA, 1% goat serum, and 0.1% tritonX-100, pH 7.4) for 30 min at room temperature and then incubated overnight at 4°C with the following antibodies: anti-nNOS (rabbit, diluted 1:200), anti-NeuN (mouse, diluted 1:200), anti-synaptophysin (rabbit, diluted 1:200), anti-3-Nitrotyrosine (mouse, diluted 1:200) from Abeam All primary antibodies, except anti-3-Nitrosine, were purchased from Cell Signaling Technology.
• blocking buffer PBS containing 1% BSA, 1% goat serum, and 0.1% tritonX-100, pH 7.4
• the samples were incubated with Alexa 488- or Alexa 594-conjugated secondary antibodies for 2 hours and then mounted with DAPI-containing mounting media.
• the mounted slides were observed under a confocal microscope (Choi et al., 2018).
• FIGs. 14A-E show an optimal concentration of 7-NI (FIG. 14A), and successful knockdown of nNOS by siRNA (FIGs. 14B-E).
• FIG. 14A presents comparative plots showing the cell viability of SH-SY5Y as measured by MTT (the dose-response curve). The concentration of 7-NI for the cell treatment was 100 mM. Data were presented in percentage of 100.
• FIG. 14B is a representative blot of nNOS. 1, SH-SY5Y; 2, SH-SY5Y+negative control (NC); and 3, SH- SY5Y+si-nNOS.
• FIG. 14C presents representative fluorescence images of nNOS immunofluorescence.
• Blue color represents DAPI (a marker of nucleus), green color shows NeuN (a marker of neuron) and red color represents nNOS.
• FIG. 14D is a bar graph showing the relative abundance of nNOS.
• FIG. 14E is a bar graph showing the relative fluorescence intensity of nNOS.
• EXAMPLE 16 nNOS inhibition/knockdown prevents NO-mediated tumor proliferation
• the clonogenic survival assay showed a decrease in the number of colonies following the nNOS silencing and 7-NI treatment of SH-SY5Y cells (FIGs. 16A-B). This points to the reduced proliferative capacity of the treated cells.
• EXAMPLE 17 nNOS inhibition/knockdown prevents TSC-2 S-nitrosylation and reduces the activity of the mTOR signaling pathway
• SH-SY5Y cells showed a relatively high intensity of 3-Ntyr and Syp immunofluorescence.
• Pharmacological inhibition or knockdown of nNOS significantly decreased the intensity of 3-Ntyr and Syp (FIGs. 18A-C).

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Engineering & Computer Science (AREA)
• Epidemiology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Biomedical Technology (AREA)
• Organic Chemistry (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Neurology (AREA)
• Neurosurgery (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Molecular Biology (AREA)
• Genetics & Genomics (AREA)
• Psychiatry (AREA)
• Zoology (AREA)
• Biochemistry (AREA)
• Psychology (AREA)
• Oil, Petroleum & Natural Gas (AREA)
• Physics & Mathematics (AREA)
• Biophysics (AREA)
• Wood Science & Technology (AREA)
• Pain & Pain Management (AREA)
• General Engineering & Computer Science (AREA)
• Biotechnology (AREA)
• Hospice & Palliative Care (AREA)
• Inorganic Chemistry (AREA)
• Dermatology (AREA)
• Orthopedic Medicine & Surgery (AREA)
• Environmental Sciences (AREA)
• Nanotechnology (AREA)
• Endocrinology (AREA)
• Toxicology (AREA)

Priority Applications (10)

Applications Claiming Priority (2)

Related Child Applications (2)

Publications (1)

Family

ID=81846510

Family Applications (1)

Country Status (10)

Cited By (3)

Citations (40)

• 2022
  • 2022-05-10 JP JP2023568675A patent/JP2024517903A/ja active Pending
  • 2022-05-10 EP EP22725570.0A patent/EP4337197A1/en active Pending
  • 2022-05-10 BR BR112023023486A patent/BR112023023486A2/pt unknown
  • 2022-05-10 US US18/290,220 patent/US20240316006A1/en active Pending
  • 2022-05-10 AU AU2022272489A patent/AU2022272489A1/en active Pending
  • 2022-05-10 IL IL308282A patent/IL308282A/en unknown
  • 2022-05-10 MX MX2023013202A patent/MX2023013202A/es unknown
  • 2022-05-10 KR KR1020237041932A patent/KR20240017813A/ko active Pending
  • 2022-05-10 WO PCT/IL2022/050486 patent/WO2022239001A1/en not_active Ceased
  • 2022-05-10 CA CA3217972A patent/CA3217972A1/en active Pending
• 2025
  • 2025-04-08 US US19/173,097 patent/US20250255850A1/en active Pending

Patent Citations (53)